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Summary 
Major surgical trauma and allogeneic transfusions cause 
immunomodulation, a systemic condition characterised by a reduction in natural 
killer (NK) cell function, macrophage migration, antigen presentation, pro-
inflammatory cytokine synthesis and lymphocyte blastogenesis. Clinically there is 
increased tumour recurrence, increased post-operative infections, delayed 
wound healing, prolonged hospital stay and increased mortality. 
Immunomodulation affects innate immunity as reflected in NK cell function. 
Hence a method was developed to measure the NK cell precursor frequency 
(NKpf) in samples of peripheral blood mononuclear cells (PBMC). The technique 
was based on the principle of limiting dilution analysis and was performed in the 
presence of recombinant interleukin two (rIL-2) and rIL-15. After five day's culture 
lysis of the K562 cell-line was measured and NKpf calculated. NKpf was 
measured before and after joint replacement surgery in 120 orthopaedic patients 
assigned to five groups according to the type of transfused blood they received, 
namely: allogeneic non-Ieukodepleted; allogeneic leukodepleted; autologous 
unwashed blood salvaged post-operatively from the operation site (autologous 
salvaged), and autologous pre-deposit. The fifth group was non-transfused. 
Interferon-gamma (IFNy), IL-10 and IL-4 synthesis were measured in 
supernatants of similar cultures and flow-cytometry was used to measure 
percentage of the CD3 negative cells that were CD56 positive in the five-day 
cultures. 
The results showed all groups had significantly decreased post-operative 
NKpf (p<0.05), and non significant decreased post-operative IFNy and IL-10 
synthesis (p>0.05) except the autologous salvaged group. By contrast, the latter 
showed a significant rise in post-operative NKpf values (p<0.05) and a non 
significant increase in IFNy and IL-10 synthesis (p>0.05). IL-4 and 
immunophenotyping studies were inconclusive. The proportion developing post-
operative infections in those who received allogeneic blood (non-Ieukodepleted 
a 
and leukodepleted) was 15% compared to 80/0 in those who received autologous 
blood (pre-deposit and salvaged) and 12% in the non-transfused group. 
It was concluded that, major surgical trauma could be associated with 
impairment of NK cell potential, decreased IFNy and IL-10 synthesis and that 
allogeneic transfusions add to these effects even after leukodepletion. These 
effects could lead to an increased risk of post-operative infections. By contrast 
autologous salvaged blood reverses these systemic effects perhaps by 
transferring locally synthesised cytokines and chemokines from the operation site 
to the circulation. 
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1.1. Innate immunity 
The immune system provides an effective defence system to meet 
infectious micro-organisms through two distinct pathways, innate immunity and 
adaptive immunity (Klein and Horejsi, 1997; Janeway et aI., 2001) 
Innate immunity provides a fast recognition and response system to most 
pathogens. The anatomical components of innate immunity include skin and 
mucosal surfaces as the first major external barrier protecting the body from 
exposure to pathogens. The cellular components include polymorphonuclear 
(PMN) cells (neutrophils, eosinophils, and basophils), monocytes/macrophages, 
dendritic cells and natural killer (NK) cells. These cells are connected by a wide 
range of soluble mediators including defensins, cathelicidins, chemokines, 
cytokines and complement. Complement and other soluble mediators can 
directly bind to conserved molecular structures on pathogens leading to 
opsonisation by phagocytes and release of soluble mediators that act as chemo-
attractants or activators of leukocytes and mast cells (Klein and Horejsi, 1997; 
Janeway et aI., 2001) 
Innate immunity curbs infection and neoplasia, and is essential to the 
development of primary adaptive immunity. This begins with soluble mediators 
activating dendritic cells and attracting lymphocytes and NK cells to the site of 
infection and inflammation. It also up-regUlates major histocompatibility complex 
(MHC) Class " molecules expression by release of interferon gamma (IFNy) 
thereby amplifying the antigen-presentation pathway that is essential to the 
development of adaptive immunity (Trinchieri and Perussia, 1984). 
1.1.1. Natural Killer (NK) cells 
Natural killer (NK) cells are bone marrow derived mononuclear cells that 
recognise and kill target cells without previous sensitisation. They are also an 
important source of cytokines such as IFNy. In the 1970s, NK cells were 
discovered during studies of natural cell-mediated cytotoxicity to virus-induced 
tumours in rodents and some cancer patients (Nunn et aI., 1976). This new cell 
population capable of lysing certain tumour cells in the absence of prior 
sensitisation was named natural killer cells due to their ability to kill tumour cell 
lines without previous stimulation (Nunn et aI., 1976; Trinchieri, 1989; 
Reyburnetal.,1997). 
Morphologically NK cells are large granular lymphocytes, with a kidney 
shaped nucleus and azurophilic cytoplasmic granules. In the resting state they 
have average diameters of 7-8 Jlm and in the activated state10-12 Jlm. NK cells 
are present in fetal liver and spleen as early as 6- 8 weeks of gestation. They 
make up 5 to 15% of the total lymphocytes circulating in the blood. They 
represent up to 50% of total resident lymphocyte population in liver and around 5-
100/0 of splenic lymphocytes in adults and children. They constitute 2-7% of the 
lymphocyte population in the lymph node and 30% in the lung (Herberman, 1981; 
Hata et aI., 1991; Whiteside and Herberman, 1994). 
T -cells and NK cells are both derived from multipotent haemopoietic stem 
cells, but NK cells do not require recombinase activity genes (RAG) for 
development, whereas T-cells do (Lanier, 2000a). Maturation pathways of 
human NK cells are complex and poorly understood. They develop primarily, but 
not exclusively along non-thymic pathways. Long-term bone marrow cultures 
showed that C03-C056+ NK cells developed from the C034+/HLA-OR-/Lin- bone 
marrow cells in the presence of rIL-3, rIL-2, macrophage inflammatory protein-1 
alpha (MIP-1a) and stem cell factor (SCF is also called c-kit ligand, KL) in the 
presence of stromal cell line (Miller et aI., 1998), the fms-like tyrosine kinase 3 
ligand (flt3L), SCF and IL-7 (Punzel et aI., 1999), IL-2, IL-3, IL-7, SCF and flt3L in 
the presence of the murine stromal cell line (Miller et aI., 1999), IL-15 and SCF 
2 
(Colucci and DLSanto, 2000), flt3L, IL-7, IL-3 and SCF(McKenna et aL, 2000). 
These grown cells in long-term culture express the characteristic CD3-CD56+ 
phenotype of NK cells, but not the T-cell (CD3+ CD5+ TcR), monocyte (CD14+ 
CD15+), nor the B-cell (CD19+) phenotypes. They were cytotoxic against the 
K562 cell line target. Although, qualitative assays have been widely applied, few 
quantitative assays have been developed to measure human NK function. 
In Sato's experiment, fetal thymocytes of 16 to 22 gestational weeks were 
incubated with IL-15, IL-7 and SCF for two weeks. The cell colonies expressed 
CD56 but not CD3. They were also cytotoxic against K562 (Sato et aL, 1999). 
Another investigation demonstrated that the early human haemopoietic 
stem cell phenotype CD34+ CD3- CD8- CD56- yielded NK cell clones in the 
presence of rIL-15, suggesting an important role for this cytokine in development 
and maturation. The distinction between non-T derived NK and NKT-cells that 
have some of the hallmarks of thymus processed cells is unclear, and it has not 
been attempted to distinguish between these subsets in this study. The role of 
thymic NK is still unclear (Mrozek et aL, 1996; Sivakumar et aL, 1998; Yu et aL, 
1998; Punzel et aL, 1999; Liu et aI., 2000a). 
NK cells do not express a functional T-cell receptor (TcR), except natural 
killer T-cells (NKT-cells) (see section-1.1.8), because they do not rearrange the 
alp and y/o TcR genes line. However, NK cells may express limited transcripts of 
p and s proteins of the TcR complex associated with the Fc receptor (FcyRIII). 
FcyR1l1 (CD16) is the receptor for IgG1/1gG3 and stimulates the antibody-
dependent cytotoxicity mediated pathway in NK cells. They also express FcRl1 
(CD32) and FC/-lR that are involved in signal transduction and NK cell function. 
The TcR is not involved in NK cell recognition or cytotoxic activity, and 
recognition is not restricted through the major histocompatibility complex (MHC). 
However, recent studies show that NK cytotoxic function is abrogated when its 
receptors bind to MHC Class I molecules (Lanier et aL, 1992; Bancroft, 1993; 
Warren et aL, 1994). Since NK receptors recognise self-HLA Class I and are 
inhibited, they are called killer inhibitory receptors (KIR). NK cells are sensitive to 
3 
'missing-self ' MHC Class I molecules as they occur in virally infected or 
neoplastic cells. The lack of inhibitory signals via the KI R leads to killing of the 
tumour cell (Lanier, 2000b; Parham, 2000). 
Typically human NK cells do not express CD3 but do express interleukin 2 
receptor (IL-2R), CD16 and CD56, the latter being a major hallmark (Carson et 
aI., 1994; Carayol et aI., 1998). In humans, CD16, the low affinity receptor for 
IgG (FcyRIII), is also expressed on macrophages, mast cells and neutrophils. 
CD16 exists in two isoforms: a 56-60 KDa trans-membrane isoform (FcyRIIIA) 
expressed on the NK cell, monocytes and macrophages; and a 48 KDa isoform 
(FcyRIIIB) expressed exclusively on neutrophils. CD16 may also be expressed 
on CD3+ T -cells in certain individuals. CD56 is expressed on >95% of NK cells, 
NKT- cells and some mature human haematopoietic cells. CD56 is also 
expressed in adult neural, muscle and embryonic tissues. A number of tumour 
cell types are positive for CD56 including some myeloid leukaemia, myelomas, 
neuroblastomas, Wilm's tumour, and small cell carcinomas (Whiteside and 
Herberman, 1994; Schlossman et aI., 1995; Barclay et aI., 1997; Carayol et aI., 
1998; Godfrey et aI., 2000). Activated NK cell express in addition, HLA-DR, 
CD69 (which acts as a signal-transmitting receptor involved in cellular activation), 
CD71 (transferrin receptor) and CD25 (IL-2Ra) (Whiteside and Herberman, 1994; 
Whiteside and Herberman, 1995b). 
Furthermore, NK cells express cellular adhesion molecules (CAM) to bind 
to targets and extra-cellular matrix (ECM) affecting NK migration from the blood 
circulation to infection or tumour sites across the vascular endothelial cells. NK 
cells express ~1 integrins, which are cell surface receptor proteins for a variety of 
ligands especially VLA-4, VLA-5 (fibronectin receptor) and VLA-6 (Iaminin 
receptor). These facilitate NK cell binding to ECM and targets. ~2 integrins are 
involved in signal transduction and NK cell activation (Rabinowich et aI., 1995; 
Whiteside and Herberman, 1995b). 
NK cells are effector cells of the innate immune response and are 
important during the early stages of viral and intra-cellular bacterial infections 
4 
acting without the need for prior immunisation. They are activated by local 
signals upon interaction with other cells or extra cellular components. Functional 
assay systems, other than lysis of the K562 cell line target, have indicated that 
NK cells playa vital role in defence against intra-cellular bacterial infection, virus-
infected and malignant cells (Bancroft, 1993; Biron et aL, 1999). Patients with 
reduced or no NK cell activity have a high frequency of viral infections such as 
HSV, CMV, EBV, varicella and LCMV and malignant cells (Pross and Lotzova, 
1993; Brittenden et aL, 1996). NK cells have a minor role in defence against 
intra-cellular bacterial infections and antibody-dependent cell mediated 
cytotoxicity (ADCC). Other components of innate immunity such as 
monocytes/macrophages, PMN cells, complement and antibodies playa major 
role in defence against bacterial infections through opsonisation and/or 
phagocytosis (Klein and Horejsi, 1997; Janeway et aL, 2001). Normal mice 
infected with lymphocytic choriomeningitis virus (LCMV) show peak NK cell 
activity on day three following infection, whereas, peak CD8+ T cell activity 
occurs on day seven (Su et aL, 1994). Also, NK cells are involved in the defence 
against leukaemia (Silla et aL, 1995). 
NK cells may have a role in the regulation of haemopoiesis by producing 
a spectrum of cytokines such as colony-stimulating factor (CSF) and 
granulocyte/macrophage colony stimulation factor (GM-CSF). NK cells also 
activate PMN cells to kill Candida Albicans (Whiteside and Herberman, 1994; 
Warren et aL, 1995; Biron et aL, 1999). As they differentiate, human NK cells 
secrete inflammatory cytokines such as IFNy, tumour necrosis factor alpha 
(TNFa), IL-3, IL-8, CSF and GM-CSF (Carson et aL, 1995b; Kos, 1998; Biron et 
aL, 1999). Also, they produce chemokines such as MIP-1 a, MIP-P and 
Iymphotactin (Biron et aL, 1999; Lanier, 2000a). 
Figure-1.1 demonstrates the NK cell development and cross talking 
between activated NK cells and macrophages in cytokine synthesis as part of 
innate immunity, as described in the literature. 
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Figure-1.1: Schematic diagram of NK cell development. 
Multipotent haematopoietic stem cell (MHSC) responds to 
different combinations of cytokines as described in the literature 
and differentiates into NKp. The important role of IL-15 in 
development and maturation of NK cells is illustrated, as is the 
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In certain culture conditions, NK cells may produce anti-inflammatory cytokines 
including IL-5, IL-10 and IL-13 (Warren et aL, 1995; Mehrotra et aL, 1998; Peritt 
et aL, 1998; Hoshino et aL, 1999b). In Warren's study (1995), NK cells 
produced IL-5 when stimulated with gamma-irradiated melanoma cells (MM-170) 
or human EBV-transformed B-Iymphoblastoid cells (JY) and rIL-2. The IL-5 
production was increased by IL-4, but inhibited by IL-12. In addition, IL-5 
produced in freshly isolated NK cells in primary culture was higher than re-
stimulated secondary culture. In Mehrotra's experiment (1998), freshly purified 
NK cells proliferated in response to IL-2 stimulation and produced IL-10. Adding 
IL-12 enhanced this phenomenon. But, IL-12 alone induced neither substantial 
proliferation nor detectable IL-10 production by fresh NK cells. Nonetheless IL-10 
mRNA expression and protein syntheses were detected. By contrast in Peritt 
study (1998), NK cells cultured in the presence IL-12 produced IL-10, while these 
grown in IL-4 produced IL-5 and IL-13. In Hoshino's experiment (1999a), the 
production of IL-13 was observed in the presence IL-2. Finally, phorbol myristate 
acetate and ionomycin induce NK cells to produce IL-13 (Hoshino et aL, 1999a; 
Hoshino et aL, 1999b). 
Figure-2.1 demonstrates the anti-inflammatory cytokines synthesis by NK 
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Figure-2.1: Schematic diagram of anti-inflammatory cytokines 
produced by NK cells. NK cells may synthesis IL-5, IL-10 and IL-13 
when cultured under certain conditions. IL-10 
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1.1.2. Human NK cell receptors 
A balance between two different receptors expressed on the NK cell's 
surface regulates the cytotoxic function of human NK cells. 
1.1.2.1. The cytotoxicity receptors 
NCRs. The first group is called natural cytotoxicity receptors (NCR) that 
trigger human NK cell mediated cytotoxic function. It was shown that NCRs are 
responsible for triggering the cytotoxic function of NK cells leading to the lysis of 
MHC Class I negative cells and xenogeneic tumour cells in-vitro. They appear to 
be directly involved in triggering cytotoxic function of NK cells and display a vital 
role in the reaction against most tumour cells. The NCR are expressed on both 
resting and activated NK cells (Moretta et aI., 2000a; Moretta et aI., 2000b; 
Moretta et al., 2000c). 
The ligands of NCRs on target cells are unidentified, however, they are 
thought to be either as a complete set of ligands for all NCRs expressed by a 
given NK cell clone, a limited number of ligands for NCRs or a single ligand 
expressed on target cells for an NCR. It was also shown that the expression of 
the 2B4 ligand (CD48) on target cells triggered NK cell cytotoxicity, suggesting 
that other receptors co-operate with NCRs to induce NK cell cytotoxic function 
triggering (Sivori et aI., 1999; Moretta et aI., 2000a; Moretta et aI., 2000b). Sivori 
showed that the human 2B4 molecule and its ligand (CD48) on target cells 
should cross-link with NCRs to induce and trigger NK cell cytotoxicity. Indeed, 
the 2B4 molecule acts as a co-receptor involved in non-MHC-restricted target cell 
lysis (Sivori et aI., 1999). 
Initiation of cytotoxic function and cytokine release in NK cells occurs 
through different non-rearranged receptors (Lanier, 2000b). Three NK-specific 
NCR molecules have recently been cloned namely NKp46, NKp30 and NKp44. 
NKp46 is involved in the recognition and lysis of HLA-Class I-unprotected 
allogeneic or xenogeneic cells. For example, murine target lysis by human NK 
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cells occurs through NKp46. Furthermore, NKp46 is the most important NCR 
since it plays a vital role in the recognition and lysis of tumour cells in man. 
NKp30 has the same surface pattern expression as NKp46, but some tumour 
cells are directly targeted through NKp30. NKp44 is expressed on IL-2 activated 
but not resting NK cells and it appears NKp44 can be measured as a specific 
marker for activated NK cells (Sivori et aI., 1999; Moretta et aI., 2000a; Moretta et 
al.,2000b). 
It has also been reported that human NK cells recognise cell-surface 
glycosylphosphatidyl-inositol-linked molecules, called UL 16-binding proteins 
(ULBPs). ULBPs ligate the NKG2D molecule that provides a positive signal for 
NK cytotoxic function, and cytokine and chemokine production including IFNy, 
TNFa, GM-CSF, L Ta/TNF~ and MIP-1 ~ (Cosman et aI., 2001). ULBPs are 
expressed on T-cell, B-cell, erythroleukaemia cell lines and some tissues 
including heart, brain, lung, liver, testis, lymph node, thymus, tonsil and bone 
marrow. Moreover, expression of ULBPs on cells that are naturally resistant to 
NK cell cytotoxic function (e.g. Daudi cells, a Burkitt's leukaemia/lymphoma cell 
line, that express MHC Class I molecules) become sensitive to NK killing 
(Cosman et aI., 2001). 
1.1.2.2. The inhibitory receptors 
KIR. The first family of inhibitory receptors on NK cells are termed killer 
inhibitory receptors (KIR). This group of inhibitory receptors is functional in man 
but not rodent. Most people have different KIR genes not all of which appear 
inhibitory. The expression of KIR varies considerably among individuals although 
all KIR genes are present in the genome. It is assumed that when an NK 
precursor (NKp) is educated each NKp makes a random choice of which KIR 
genes it expresses. Ultimately, each NK cell expresses at least one KIR, having 
undergone allelic exclusion until it ends up with a self-HLA-specific KIR that is 
sufficient to prevent cytotoxic reactivity against normal self-cells (Reyburn et aI., 
1997; Ruggeri et aI., 1999). 
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KIRs bind directly to MHC Class I molecules, and inhibit NK cell cytotoxic function 
signalling. However, the expression of MHC Class I molecules is frequently 
impaired in tumour and virus-infected cells that abrogate immunoreceptor 
tyrosine-based inhibition motifs (ITIM) inhibitory signalling and induce NK-
mediated cytotoxicity. ITIM is an amino-acid stretch molecule with a tyrosine on 
its centre that present in the intra-cytoplasmic domain of inhibitory receptors 
(Biery et aI., 2000). 
In man KIRs are a family of immunoglobulin like (Ig-like) molecules 
(Ruggeri et aI., 1999). The inhibitory receptors recognise different HLA Class I 
molecules such as HLA -A, B or C (Selvakumar et aI., 1997). The KIR2D 
recognises certain HLA-C allo-types. KIR2DL 1 recognises Cw1, 3, 7, 8 and 
KIR2DL2 recognises Cw2, 4, 5, 6 allo-types (Ruggeri et aI., 1999). 
KIR3DL 1 recognises an epitope shared by HLA-Bw4 alleles and KIR3DL2 
recognises HLA-A3 and HLA-A11. KIR3DL 1 and KIR3DL2 contain three Ig 
domains (Ruggeri et aI., 1999; Colonna et aI., 2000). 
CD94. The second family of inhibitory receptors includes CD94-NKG2, a 
lectin-like heterodimer identified in both man and rodent. The CD94-NKG2A 
isoform, is the only functional inhibitor and this recognises the monomorphic 
HLA-E molecule. The expression of CD94-NKG2A on NK cells in man is induced 
by IL-15 (Diefenbach and Raulet, 2001). 
Ly-49. The third family of inhibitory receptors is Ly-49 , a multigene family 
that encodes three different groups of inhibitory receptors and enables NK cells 
to distinguish target cells from self. The first inhibitory receptor group, discovered 
in rodent and called Ly49, binds directly to MHC Class I molecules (Karlhofer et 
aI., 1992). Eight of ten different Ly49 homodimer receptors, identified so far in 
rodent, show inhibitory function (McQueen et aI., 1999). In man only one non-
functional molecular homology belonging to the Ly49 multi-gene family has been 
discovered (Westgaard et aI., 1998). 
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Inhibitory receptors transduce signal(s) that inhibits activation signals. This is 
achieved via ITIM in their cytoplasmic tails. The phosphatases activated by ITIM 
inhibit signals derived from homologous activating motifs, called immunoreceptor 
tyrosine-based activation motifs (IT AM) with a high homology with ITIM (Biery et 
aI., 2000). If ITIM are not activated, as in the case of a MHC Class I negative cell 
(e.g. K562), the ITAM signal the NK cell to kill the target. Thus, by the induction 
of inhibitory signals, normal cells are protected against NK-mediated lysis. By 
contrast, NCR induces a signal that triggers cytolytic activity mediated by perforin 
and granzyme release that leads to lysis or apoptosis of the target cell (Pende et 
aI., 1999; Moretta et aI., 2000b). The ontogeny of NK cell is not fully understood. 
This process involve the differential expression of both cytotoxicity and inhibitory 
receptors on individual NK cells (Raulet et aI., 2001). 
Figure 3.1 demonstrate interaction between MHC Class I molecules and 
some receptors (Trowsdale, 2001). Figures 4.1 and 5.1 demonstrate known 
ITIM-bearing molecule and interaction with KIRs (fig-4.1) and oligomeric 
activating receptor complexes expressed on NK cells (fig-5.1) (Biery et aI., 2000). 
Figure 3.1: Schematic diagrams 
of some of the cytotoxicity 
receptors are shown along with 
their chromosomal position and 
Class I ligand . NKG2D is 
functional in rodent and man , and 
KIR2DL4 has not been confirmed 
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Figure 4.1: Schematic diagram of interaction between IT AM and ITIM-bearing receptors 
and their ligands (HLA-8w4 etc) in man. Three families are included: (A) killer inhibitory receptors 
(KIRs)*, (8) monocyte Ig-like receptor, (C) CD94-NKG2. EC: extracytoplasmic domain, TM: 
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1.1.3. The cytotoxicity mechanism of human NK cells 
Human NK cells recognise and kill tumour cells, viral cells or cells with 
intra-cellular bacteria through a variety of different pathways. 
Granule-mediated cell death. Cytotoxicity by human NK cells follows 
adhesion to the target cell via the CD2, CD69, 284, NKG2D-DAP10, LFA-1 
(leukocyte function antigen-associated-1) and NCRs. The expression of CD69 
precedes CD25 expression on NK cells. Trans-membrane signalling through this 
pathway activates phosphatidyl-inositol (PI) metabolism and calcium influx 
leading to secretion of granules responsible for cell death. These granules are 
released into the intra-cellular space between the NK cell and its target. The 
major components of these granules are perforin, a pore-forming protein, and 
granzymes a family of serine proteases. Insertion of perforin into the lipid bilayer 
results in polymerisation of the membrane constituents and the formation of the 
tubular trans-membrane pores causing osmotic damage. Granzymes synergise 
with perforin to trigger a caspase dependent internal disintegration pathway in 
target cells leading to apoptosis (Tschopp and Nabholz, 1990; Smyth and 
Trapani, 1995; Warren and Smyth, 1999). 
NK cells are capable of lysing intra-cellular bacteria-infected cells, 
malignant and/or transformed cells, transplanted cells and virus-infected cells 
through this pathway (Smyth and Trapani, 1995). 
Antibody-dependent cell mediated cytotoxicity (ADCC). Another 
effector pathway of NK cells is via the recognition of antibody (lgG)-coated target 
cells. This antibody-dependent cell cytotoxicity (ADCC) mechanism plays an 
important role in response to viral infection and neoplasia. It involves the CD16 
(Fcy RillA) Fc receptor expressed on NK cells (Sulica et aI., 1996; Warren and 
Smyth, 1999). 
Non-secretory apoptotic cell death. NK cells are capable of killing 
targets through expressing of Fas ligand (FasL) and upon interaction with Fas 
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(C095/APO-1) on target cells, signal the pathway leading to apoptosis. The 
expression of FasL on activated NK cell is remarkably enhanced (Puppo et aI., 
2000; Puppo et aI., 2001). 
Secreted TNFa by NK cells engages the tumour necrosis factor receptor 
(TNFR) on target cells and induce apoptosis cell death (Vujanovic et aI., 1996). 
Pro-inflammatory reaction. Activated NK cells produce IFNy, TNFa, GM-
CSF, IL-3 and IL-8 thereby inducing an inflammatory cascade. IFNy released 
rapidly before adaptive immunity has developed is essential to first line defence 
and plays a pivotal role in suppressing or slowing infection (Scharton and Scott, 
1993; Orange and Biron, 1996; Biron et aI., 1999). Secreted IFNy, IL-2 and IL-15 
are the main regulatory signals for NK cell cytotoxic function (Cousens et aI., 
1997; Lin et aI., 1998) 
Other cytokines involved are TNFa and IL-1 act synergistically with IL-2 to 
activate large granulocyte lymphocytes. IL-12 stimulates IFNy production and 
induces cytotoxicity activation. IFNa augments NK cell function thereby affecting 
the kinetics of cytotoxicity (Cousens et aI., 1997; Lin et aI., 1998). 
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1.1.4. Interleukin-2 and NK cells 
Cytokines are hormone-like glycoproteins produced by a wide variety of 
cells involved in intercellular communication. They affect the activation, 
differentiation and proliferation of cells involved in haemopoiesis, immunity, and 
the inflammatory processes. During differentiation and proliferation of 
haemopoietic stem cells, cytokines affect progenitor cell-cycling and lineage 
specific differentiation (Mosmann et aI., 1997; Annunziato et aI., 1999). 
In-vivo, IL-2 is thought to be only transiently produced by antigen-activated 
T-cells, which in turn express high affinity IL-2 receptor (IL-2R). Activated T-cells 
release IL-2, a 15-kD glycoprotein belonging to the helical-cytokine family. IL-2 is 
able to drive NK and T cells to activation, proliferation and cytokine induction. IL-
2 causes NK cells to become Iymphokine-activated killer (LAK) cells that are 
active against certain NK resistant tumour cells. IL-2 stimulates NK cells through 
the a, p and y sub-units of the IL-2R expressed on the surface of NK cells. IL-2 
binds to a sub-unit with low affinity binding, to the p and y sub-units with 
intermediate affinity binding and to the triplet a, p and y with high affinity. The IL-
2RP (CD122) chain is shared between the IL-2 and IL-15 receptors only, whereas 
the IL-2Ry (CD132) common chain (Yc) is shared by IL-2, IL-4, IL-7, IL-9 and IL-15 
receptors (Voss et aI., 1992; Shi et aI., 1997; Waldmann et aI., 1998). 
IL-2 can drive CD34+/DR- haemopoietic progenitor cells to differentiate 
into NK cells with a characteristic CD3- CD56+ phenotype (Miller et aI., 1998; 
Miller et aI., 1999). 
IL-2 also stimulates a number of other cells, including B-cells in the 
production of opsonising antibodies, proliferation and activation, and monocytes. 
It has been shown that IL-2 is a powerful activator of monocytes, leading them to 
express tumouricidal and microbicidal activity and increasing the synthesis and 
release of hydrogen peroxide and superoxide (Badolato et aI., 1997; Bosco et aI., 
1997). 
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1.1.5. Interlukin-15 and NK cells 
IL-15 is a 14-15-kD glycoprotein that, like IL-2, belongs to a four alpha 
helix bundle family of cytokines. It was recently discovered and cloned in 1994 in 
the culture supernatants from simian kidney epithelial cell lines that activated 
human monocyte/macrophages (Carson et aI., 1994; Carson et aI., 1995b). 
Bone marrow stromal cells, dendritic cells and keratinocytes, all produce IL-15. 
IL-15 mRNA has been detected in the placenta, skeletal muscle, kidney and 
synovial-derived cells in rheumatoid arthritis patients (Blauvelt et aI., 1996; 
Doherty et aI., 1996; Mcinnes et aI., 1996; Jonuleit et aI., 1997). 
Recent reports suggest that IL-15 shares many of the biological properties 
of IL-2, despite the absence of sequence homology. The interlukin-15 receptor 
(IL-15R) has a unique a chain, but shares the p and y chains of the IL-2R. Since 
signals are only transduced via the p and y chains this accounts for the shared 
activity observed between these two cytokines, whereas the IL-15Ra chain is 
only responsible for specific and high-affinity binding of IL-15. Signals received 
by IL-15R cause NK cells to produce IFNy, GM-CSF and TNFa (Gosselin et aI., 
1999; Waldmann and Tagaya, 1999). Mice lacking the IL-2 gene develop NK 
cells, whereas mice and humans lacking the y sub-unit of the IL-2R have no NK 
cells. In addition, mutations in human IL-2Ryc appears responsible for the X 
chromosome-linked immunodeficiency disease (SCIDX) characterised by a 
defect in T-cell differentiation and the lack of NK cells (Noguchi et aI., 1993; 
DiSanto et aI., 1995). It was also reported that IL-15Ra-knockout or IL-2I1L-
15Rp-knockout mice have no NK, NKT- and yeST-cells, which are important in 
innate immunity (Liu et aI., 2000a). Furthermore, in an in-vivo study it has been 
shown that mice treated with the isotope strontium 89 (89Sr) have no NK cells 
because of impairing of IL-15 production within the bone marrow 
microenvironment (Colucci and DLSanto, 2000). IL-15 is required for induction 
of CD56 and CD7 in early human NK cell development (Mrozek et aI., 1996; 
Carayol et aI., 1998). 
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In-vitro, IL-15 as well as IL-2, enhances the cytotoxicity and maturation of 
neonatal NK cells activity against K562 and ADCC function, as well as the 
percentage of CD56+CD16+ cells (Gaddy and Broxmeyer, 1997; Nguyen et aI., 
1998). IL-15 was also shown to stimulate the expansion of HIV-specific cytotoxic 
T-cells and enhance NK cell cytotoxic function through ADCC pathway in AIDS 
patients (Lin et aI., 1998; Nguyen et aI., 1998). 
Table-1.1 shows the cell markers expressed on multi-potent haemopoietic 
stem cell (MHSC), NK precursor (NKp), resting NK and activated NK cells as 
described in the literature. 
Table-1.1: Cell markers expressed during the maturation of NK cell 
Cell markers MHSC NK precursor Resting NK cell Activated NK cell 
CD2 - + + + 
CD3 - - - -
CD4 - - - -
CD5 - - - -
CD? - + + + 
CDB - - - -
CD14 - - - -
-
- -CD15 -
CD16 - -/+ -/+ -/+ 
-
+ CD25 (IL-2Ra) - -
CD32 - + + + 
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CD33 






- + + + 
CD44 
- + + + 
CD45 + + + + 
CD56 
- + + + 
CD57 
- + + + 
CD69 - -
- + 
CD94-NKG2 - + + + 
CD122(IL-2/1 L-15R~) (+)? + + + 
CD132(IL-2/IL-15Ry) (+)? + + + 
IL-15Ra (-)? + + + 
HLA-DR - - - + 
Flt3 + + (+)? (+)? 
c-kit (CD 117) + + (+)? (+)? 
KIRs - (+)? + + 
NKp30 - - - + 
NKp44 - (+)? + + 
NKp46 - (+)? + + 
2B4 - + + + 
VLA-4 - (+)? + + 
VLA-5 - (+)? + + 
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VLA-6 - (+)? + + 
FasL - + + + 
Ly49 - (+)? + + 
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1.1.6. Prostaglandin E2 (PGE2) and NK cells 
Prostaglandin E2 (PGE2) is a major contributor to the production and 
maintenance of immunosuppression after major, haemorrhage and injury, leading 
to increased infectious morbidity and mortality in trauma patients. Deleterious 
effects of PGE2 on NK cytotoxic function and cytokine production, have been 
shown (Menetrier_Caux et aI., 1999; Deichman et aI., 2001). 
Rees and Platts showed that NK cytotoxic function in both whole blood 
and isolated PBMC was significantly decreased in the presence of PGE2 (Rees 
and Platts, 1983). Furthermore, a significant decline in cytotoxic function and 
IFNy production occurred in IL-15-activated (200 ng/ml IL-15 for 2 days) human 
NK cells in the presence of PGE2 (10-200 ng/ml). This suggested that PGE2 
down-regulated surface expression of yc-chain on NK cells leading to suppression 
of IL-15 activation (Joshi et aI., 2001). It was reported that the proliferation of 
Iymphokine-activated killer (LAK) cells induced by IL-2 was inhibited by PGE2 
(Wang et aI., 1997) 
In animals hepatic NK function was inhibited by PGE2, at 10 -20 ng/ml. By 
contrast, there was a significant increase in NK function prostaglandin F2 alpha 
(PGF2 -a) by at 50-100 ng/ml (Liu et aI., 2000b). PGE2 inhibitors, such as 
indomethacin and ibuprofen abrogate the suppressive effects of PGE2 on NK 
cytotoxic and ADCC functions (Lo et aI., 1998; Rhind et aI., 1999). 
The mechanism by which PGE2 inhibits is not fully understood, however, 
binding between activated NK cells and target cells is inhibited by PGE2. 
Another possibility is that cAMP concentration increases leading to suppression 
of cytolytic protein release and NK cell-mediated cytotoxicity (Kim et aI., 1999). 
22 
1.1.7. The Lymphokine-Activated Killer (LAK) cell 
NK cells are able to recognise and killing tumour cells, thereby playing an 
important role in immune defence against malignancy. Incubation of normal 
peripheral blood lymphocytes with IL-2 (1000 U/ml) from patients with neoplasia 
leads to the generation of Iymphokine-activated killer (LAK) cells that in the short-
term can lyse fresh tumour cell targets. Indeed, the in-vitro culture of human 
peripheral blood lymphocytes in high concentrations of IL-2 results in the 
generation of cytotoxic cells that lyse tumour cell targets that are normally 
resistant to NK cell lysis through a mechanism independent of MHC restriction. 
LAK cells have the phenotype CD2+, CD3-, CD11+, CD14- and CD56+. These 
LAK cells are capable of binding to capillary endothelial cells and migrating into 
solid tumour tissue. However, it was reported that treatment with low 
concentration of IL-2 (2x105 U/m2 per day) did not lead to an appreciable clinical 
response against the tumour (Whiteside and Herberman, 1994; Barton et aI., 
1995; Brittenden et aI., 1996). 
Nonetheless, several observations have indicted that in-vitro and in-vivo 
activated NK cells are able to move in to solid tissues, localise to the site of 
metastases and kill tumour cells. Treatment using IL-2 alone, or IL-2 in 
conjunction with LAK cells, has also been shown to mediate disease regression 
in selected patients with advanced cancer and even leukaemic relapse after 
autologous bone marrow transplantation. In-vitro LAK cell activity could be 
enhanced by adding IL-12, IL-7, and IL-15 (Sondel et aI., 1992; Vujanovic et aI., 
1995; Okada et aI., 1996; Tomita et aI., 1998). 
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1.1.8. Human Natural Killer T -cells (NKT -cells) 
In 1978 NKT-cells were characterised by the immunophenotype, CD4-
CD8- or CD4+CD8- low TcR and NK1.1 + cells (Fowlkes et aI., 1978; Budd et aI., 
1987). The term, NKT-cells, was recently given to them (Godfrey et aI., 2000). 
The NKT-cell subset expresses some common characteristics of both T- and NK 
cells by having CD3 and TcR alp, as well as CD56, CD1d and KIR. The 
important characteristics of NKT-cells are expression of TcR, CD1 d and 
production of IFNy and IL-4 (Leite_de_Moraes and Dy, 1997; Godfrey et aI., 
2000). 
They share functional activity with T-cells including secretion of both Th1 
and Th2 cytokines, with particularly high levels of IL-4 and IFNy after stimulation 
through MHC Class I molecules, and the NK1.1 molecule. They are also able to 
lyse target cells that have lost, or express insufficient MHC Class I molecules. 
KIR and NK1.1 expression suggests that NKT-cell populations identify and lyse 
targets in the same way as NK cell (Storkus et aI., 1992; Arase et aI., 1994; 
Leite_De_Moraes et aI., 1998) 
Some NKT -cells develop along extrathymic pathways and are able to 
participate in the innate immune response to tumours whereas other NKT-cells 
are thymus-dependent (Yoshimoto and Paul, 1994; Hammond et aI., 1999). 
NKT-cells may play a key role in the regulation of anti-microbial immunity 
especially against mycobacterium, HIV and salmonella (Jason et aI., 2000). 
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1.2. Adaptive immunity 
Adaptive immunity is an acquired or "educated" response to pathogens or 
other foreign particles during the lifetime of an individual. Its origins coincide with 
the appearance of vertebrates and the acquisition of RAG. RAG allows for 
somatic mutation amongst the genes responsible for immunoglobulin (Ig) and 
TcR specificity. Ig and TcR genes are assembled by rearrangement of antigen 
receptor gene segments during lymphocyte development. Thus vertebrates not 
only have the benefit of innate immunity but also an immune system that can 
adapt to the continuous challenge posed by evolving pathogenic micro-organisms 
(Akamatsu and Oettinger, 1998; Landree et aI., 1999). 
In many cases an adaptive immune response to a pathogen confers life-
long protection. Adaptive immunity has immunologic memory, which 
distinguishes it from innate immunity. It is initiated by antigen-presenting cells 
(APC), lymphocytes and various cytokines. Two major lymphocyte populations 
participate in adaptive immunity, T-cells and B-cells. T-cells express CD3, TcR 
and when activated, IL-2R. T-cells recognise peptides that have been processed 
and presented by APC in the context of self-MHC. T-cells are derived from 
multipotent haemopoietic stem cells in bone marrow but develop exclusively 
along thymic pathways. T-cell subtypes are CD4+ that recognise MHC Class II 
molecules or CD8+ that recognise MHC Class I molecules. Either may express 
ap or y8 TcR. CD4+ T-cells are mostly helper cells that activate other cells such 
as CD8+ T -cells and B-cells, whereas CD8+ T -cells are mostly cytotoxic cells that 
kill intra-cellularly infected or neoplastic cells. I n contrast to T -cells, B-cells 
originate and develop in bone marrow. They recognise the antigens via their B-
cell receptor complex, which consist of an immunoglobulin (Ig) member. Each 
receptor is able to recognise and bind to a unique antigen. After binding, the B-
cell ultimately differentiates into plasma cells that secrete specific antibodies 
(Klein and Horejsi, 1997; Roitt and Rabson, 2000; Janeway et aI., 2001). 
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1.2.1. Pro and anti-inflammatory reactions 
In 1986, Mosmann and his colleagues hypothesised that murine CD4+ 
helper T-cell clones could be characterised in-vitro according to the patterns of 
cytokines they synthesised thereby giving rise to a unifying concept called 'The 
Th1ITh2 Paradigm" (Mosmann et aI., 1986). 
Thus CD4+ T -cells were segregated into two functional subsets: T -helper 
1 (Th1) and T -helper 2 (Th2). Th1 cells secrete pro-inflammatory cytokines such 
as IFNy and IL-2. Th2 cells secrete anti-inflammatory cytokines such as IL-4, IL-
5, IL-10 and IL-13 (Cher and Mosmann, 1987; Coffman et aI., 1987). In 1991 
human Th1 and Th2 were isolated by Romagnani (Romagnani, 1991 a). 
Pro-inflammatory cytokines induce macrophage activation, cell cytotoxicity, 
and cell mediated immunity. They playa vital role in the eradication of infectious 
agents, including intracellular pathogens. Anti-inflammatory cytokines suppress 
phagocyte-dependent inflammation and promote strong antibody responses 
through B-cell activation. The anti-inflammatory cytokines include IL-4, IL-5, IL-6, 
IL-9, IL-10 and IL-13. They are associated with humoral immunity and allergic 
responses. They act on B-cells causing them to activate, proliferate and 
differentiate into antibody producing plasma cells. Type 0 (Tho) cells are a third 
subset of T -cells that may differentiate into both Th1 or Th2 types, and may 
represent a distinct subset of differentiated precursor T -cells. The differentiation 
pathway selected by this subset depends on the cytokines in the 
microenvironment. Another subset is called Th3 . Cells of this subset produce 
high amounts of transforming growth factor (TGF)-P (Mosmann et aI., 1997; 
Lucey, 1999; Romagnani, 2000). 
Several factors influence differentiation along the Th1 and Th2 pathways, 
including the cytokine microenvironment, antigen dose, secondary signalling 
pathways, individual genetic background and antigen-presenting cells (Oriss et 
aI., 1997; Del_Prete, 1998; Annunziato et aI., 1999). Evidence suggests that 
IFNa and IFNy increase IL-12 production by macrophages and maintain 
26 
expression of functional IL-12 receptors on Th cells and as such are the most 
powerful cytokines promoting differentiation of the uncommitted Tho cells along 
the Th1 pathway. The most important cytokine to trigger differentiation of Th2 is 
IL-4 (Mosmann et aI., 1997; Morel and Oriss, 1998; Lucey, 1999). 
Cytokines released by Th1 and Th2 cell subsets are involved in different 
strategies of protection against pathogens, and may also play a role in some 
pathological conditions. Studies in humans and gene-targeted mice have clearly 
shown that Th1-dominated responses are effective in protection against several 
microbes, and usually result in their clearance. However, if the pathogen 
persists, the ongoing Th1 responses may result in inflammatory tissue damage. 
Cytokines other than those produced by Th1 cells, playa role in defence against 
intracellular pathogens for which Th1 responses are not inherently protective like 
the IFNy production during viral infections (De_Vita et aI., 1998; DeLPrete, 1998; 
Romagnani, 2000). 
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1.2.2. Interferon gamma (IFNy) 
The interferon family is divided into two types based on the source of 
secretion. Type one interferon's, including IFNa and IFN~ are secreted by virus-
infected cells and playa vital role as antiviral agents. Envelopes of virus, double-
stranded RNA, bacteria and tumour cells induce their production (Farrar and 
Schreiber, 1993). 
Type two includes IFNy, which is a 35-kDa protein and was identified for 
the first time in 1965 as an antiviral agent in PHA-activated lymphocyte 
supernatants. Human IFNy is secreted by activated Th1, NK, NKT- and dendritic 
cells. IFNy is a strong anti-viral and anti-tumour agent, also acting as an 
immunomodulator during the immune response by switching naive CD4+ T-cells 
to differentiate along the Th1 pathway (Schreiber and Farrar, 1993; Coughlin et 
aI., 1998). 
Human IFNy gene and IFNy receptor (IFNyR) are located on chromosome 
12 and 6 plus 21, respectively. Its receptor has two chains the first of which is a 
90-kDa, a-chain receptor (IFNyR1) encoded on chromosome 6 and responsible 
for ligand binding, ligand trafficking through the cell and signal transduction. The 
second chain is a 62kD, ~-chain encoded by on chromosome 21 and also 
required for signal transduction after ligand binding. Signal transduction via both 
chains is required for activity (Pestka, 1997). 
IFNy is essential for the activation, proliferation, differentiation and 
cytotoxicity of T -, NKT - and NK cells. It stimulates innate cell-mediated immunity 
via NK cells and NKT -cells and adaptive immunity based on the recognition of 
cell surface-bound antigen in association with MHC molecules. IFNy has a 
negative effect on the proliferation and differentiation of Th2 cells and inhibits the 
growth of Th2 clones in-vitro. IFNy production by NK cells is extremely fast and 
provides a reliable source of pro-inflammatory cytokine upon encountering an 
infectious agent or neoplastic cell before clonal expansion of adaptive immunity. 
IFNy indirectly suppresses B-cell proliferation via IL-4 inhibition. By contrast, it 
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induces the expression of IL-2R on the surface of T-cells. IFNy up-regulates 
expression of MHC molecules especially Class \I thereby amplifying the antigen 
presentation pathway (Warren et aI., 1996; Fernandez et aI., 1999; Tanaka et aI., 
2000). 
IFNy IS the most important macrophage-activating factor. Activated 
macrophages kill some of the intra- and extra-cellular parasites, as well as 
malignant cells. IFNy synergises with TNFa and p to inhibit the proliferation of 
various cell types. Also, it induces oxygen and nitrogen anti-microbial effects on 
macrophages by inducing those enzymes that are involved in substrate and 
cofactor synthesis of iNOS (inducible nitric oxide synthase). iNOS promotes the 
production of reactive oxygen intermediates especially nitric oxide (NO) involved 
in killing of targets (Daubener and MacKenzie, 1999; MacKenzie et aI., 1999). 
IFNy secretion by NK cells can be induced by IL-12, IL-15, IL-2, IL-18 
(originally called IGIF or IFNy inducing factor), epidermal growth factor (EGF), IL-
1 a and IL-1 p. The most important cytokine, which stimulates IFNy production by 
NK cells is IL-12 in collaboration with IL-18. Activated macrophages, 
keratinocytes and Kupffer cells secrete IL-18. It is capable of inducing IFNy 
production by NK cells without collaboration with IL-12, whereas with IL-12, IL-18 
induces IFNy production by T-cells (Yoshimoto et aI., 1998; Braun et aI., 2000; 
He et aI., 2000). IFNy production can be inhibited by TGF-p, vitamin 03, 
cyclosporin A (CsA) and IL-10 (Biron et aI., 1999; He et aI., 2000). It has also 
been shown that IFNy inhibits the production of IL-4 by Th2 clones (Hoshino et aI., 
1999b). 
A cultured NK cell line produces IL-13 and IL-5, suggesting that NK cells 
may produce IL-13 and IL-5 in the absence of IFNy (Warren et aI., 1995; Hoshino 
et aI., 1999b). Hoshino and his colleagues suggested that the absence of I FNy 
may favour the differentiation of na·ive Tho cells to Th2 cells that produce anti-
inflammatory cytokines (Hoshino et aI., 1999a; Hoshino et aI., 1999b) 
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1.2.3. Interleukin 10 (IL-10) 
IL-10 is an 18.5-KDa protein containing 160 amino acids, which was first 
described as cytokine synthesis inhibitory factor (CSIF). As with IFNy, IL-10 is an 
acid-sensitive, non-covalent homodimer of two interpenetrating polypeptide 
chains. There are two types of IL-10 receptor. The first is characterised as the 
a-chain (hIL-10Ra) expressed on most haemopoietic cells, T-cells, 
monocytes/macrophages. The second is the p-chain (hIL-10RP) expressed on 
the most cells and tissues. However, the structure and the signalling of IL-10R 
are not fully understood. Human IL-10 is secreted by CD4+ and CD8+ T-cells, 
monocytes/macrophages, B-cells, eosinophils and epithelial cells (Kotenko et aI., 
1997; Ding et aI., 2000b). In mice, IL-10 is produced and released by Tho and 
Th2 cells (de_Waal_Malefyt et aI., 1991a; de_WaaLMalefyt et aI., 1995). 
Human IL-10 acts as an anti-inflammatory cytokine inhibiting the secretion 
of pro-inflammatory cytokines such as IL-1 alp, IL-8, IL-12, IL-18, TNFa, and G-
CSF or GM-CSF by activated monocytes/macrophages. IL-10 is activity 
antagonised by IL-4. It also prevents the release of free oxygen radicals and 
nitric oxide-dependent microbicidal actively of macrophages and neutrophils 
(de_ Waal_Malefyt et aI., 1991 b; Groux et aI., 1998). 
Soluble IL-10 reduces antigen-presenting cell function of 
monocytes/macrophages by down-regulating the expression of Class II MHC. It 
also down-regulates the expression of MHC Classes I and II on tumour cells, 
effectively interfering with HLA associated activation of T-cells. It inhibits T-cell 
proliferation by negatively regulating pro-inflammatory cytokine production by Th1 
cells (de_ Waal_Malefyt et aI., 1991 a). In addition, it down-regulates the 
expression of CD54, CD80, CD86, and the LPS signal-transducing receptors, 
which are important molecules for T-cell activation. In contrast IL-10 increases 
CD16 and CD64 (Fcy RI) expression on monocytes (Groux et aI., 1998). IL-10 is 
a specific chemo-attractant for human T -cells (Matsuda et aI., 1994). IL-10 via 
down-regulates the cyclooxgenase-2 (COX-2) pathway thereby inhibiting PGE2 
production (Moore et aI., 2001). 
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IL-10 activates NK cells through increased sensitivity to IL-2 leading to increased 
cytotoxicity and cytokine release (Mosmann and Sad, 1996; Warren et a\., 1996). 
In 1995, Carson et al showed that overnight incubation of NK cells with IL-10 
significantly increased NK cell cytotoxic function in the presence of IL-2. They 
also showed that IL-10 with IL-2 enhanced the secretion of IFNy, TNFa and GM-
CSF by NK cells. There was no effect of added IL-12. Finally, they confirmed 
that human NK cells express IL-10R message as mRNA (Liu et a\., 1994; Carson 
et a\., 1995a). 
IL-10 may also indirectly suppress IFNy production by NK cells by 
inhibiting its induction by IL-12 (Romagnani, 2000). In an animal experiment by 
Fujii et ai, IL-10 administration given after a booster vaccine enhanced anti-
tumour activity and vaccine efficacy. In a clinical study by Lauw et al it was 
shown that rh1L-10 administration given after LPS significantly increase IFNy 
release and NK activation (Lauw et a\., 2000; FujiLSi et a\., 2001). 
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1.2.4. Interleukin 4 (IL-4) 
Human IL-4 was recognised in the early 1980s as a B-cell growth factor 
(BCGF) (Leanderson et aI., 1982; Muraguchi et aI., 1982). After cloning the 
cDNA of this cytokine in mice and humans in 1986, it was termed IL-4. The 
human IL-4 genes are located on chromosome 5 in man and chromosome 11 in 
mouse. The molecular weight of human IL-4 is between 15 and 19 KDa, and it 
contains 129 amino acids (Mingari et aI., 1986; Yokota et aI., 2000). 
IL-4 induced signal transmission is initiated by two receptors; IL-4R1 
composed of IL-4Ra-chain plus common y-chain, and IL-4R2 composed of IL-
4Ra-chain plus IL-13Ra-chain. However, IL-4 has only a low degree of sequence 
homology with IL-13 (Nelms et aI., 1999). Activated Th2 cells secrete human IL-4. 
Basophils and mast cells also produce IL-4. IL-4 is a multifunctional cytokine that 
regulates proliferation and differentiation of B-cells, T-cells and monocytes. IL-4 
was shown to have negative effects on NK cells by inhibiting genes involved in 
NK cell function. This effect is in contrast to the positive effects of IL-2 and IL-15 
on NK cells. IL-4 inhibits IL-10 production by monocytes (Romagnani, 1991 b; 
Nakamura et aI., 1997). It also down-regulates other monocyte cytokine 
production and function. IL-4 is involved in the development of humoral immunity 
by inducing 8-cell proliferation and induction the production of IgM, IgG4 and IgE 
(DeLPrete, 1998; Romagnani, 2000). 
Human IL-4 is the most potent cytokine directing the development of Th2 
cells, resulting in the release of the anti-inflammatory cytokines IL-5, IL-6, IL-10 
and IL-13. These act as growth/differentiation factors for B-cells, eosinophils and 
mast cells and inhibit some macrophage functions. In the absence of IL-4 
production during the early immune response, na·ive T-cells are obliged to 
differentiate along the Th1 pathway by IL-12 and IFNy (Oriss et aI., 1997; 
Romagnani, 2000). 
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1.3. Major Histocompatibility Complex (MHC) 
The existence of white blood cell antigens independent of red blood cell 
systems was suggested in the 1950s following the detection of the first leukocyte 
antibody in a multi-transfused patient. This antibody reacted with white blood 
cells revealing an antigenic system on white blood cells termed the human 
leukocyte antigen (HLA) system (Van_Rood, 1969; Dausset and Colombani, 
1970). In the early 1970s, an important role of the HLA system in graft rejection 
in humans was demonstrated through investigations in skin grafted and blood 
transfused patients (Ceppellini et aI., 1971; Curtoni et aI., 1972). 
The HLA system codes for cell surface antigens and is located on the 
short arm of chromosome 6 within an estimated 3500-4000 KB of DNA. HLA-
genes are divided into three classes, Class I, Class II, and Class III, based on 
molecular structure. Class I molecules in man include HLA-A, -B, and -C. 
These are synthesised and displayed by most of the cells of the body except cells 
that make up the central nervous system. Class II molecules in man include 
HLA-DR, -DO and -DP. These are constitutively expressed on resting, non-
activated macrophages and B-Iymphocytes but can be up-regulated on most cells 
after IFNy treatment. HLA Class II are involved in processing and presenting 
extra-cellular antigen to T -cells. Class III molecules include the C4, C2 and 
factor B components of the complement system (Trowsdale, 1997; Lehner and 
Trowsdale, 1998; Malcherek et aI., 1998). 
HLA antigens may be determined by serological techniques using 
lymphocytes as target cells, or by DNA techniques. Peripheral blood 
lymphocytes or separated T lymphocytes are used for Class I typing. B-
lymphocytes are used for Class II typing, because DR and DQ antigens are 
constitutively expressed on B-cells, but not on resting T -cells. The antibodies to 
these antigens may be found in the sera of repeatedly transfused patients and in 
multiparious women. HLA antigens recognised as foreign on transplants leads to 
allograft rejection. HLA-Class II allo-types are also associated with autoimmune 
disorders, where the immune system has been abnormally activated to be 
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reactive against structures that it would normally tolerate (Altmann et aI., 1990; 
Kikuti et aI., 1997). 
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1.4. Blood transfusions 
1.4.1. Introduction 
Modern methods of blood collection, preservation, processing and storage 
have resulted in the wide availability of blood and blood components. It cannot 
be confirmed who conceived the idea of transfusing blood, but the earliest 
documented attempt to was during the 1 ih century (Spence et aI., 1993). The 
first major contribution to blood transfusion science was when the A-B-O blood 
groups were discovered early in the last century. The next important step was 
the discovery of the Rh blood factor, in 1940. However, two world wars definitely 
accelerated the development of blood transfusion services (Greenwalt, 1997). 
Blood transfusion is a valuable and vital therapeutic agent for improving 
oxygen supply to the tissues in surgical and non-surgical patients. The majority 
of blood administration in developing countries is in patients who are undergoing 
surgical operations. It is critical to improve haemoglobin levels in patients who 
have undergone surgery thereby decreasing the risk of death (Hebert et aI., 
1997). 
1.4.2. Autologous blood transfusion 
Autologous blood transfusion (ABT) is defined as transfusion of a patient's 
own blood. It is becoming increasingly popular as an alternative for allogeneic 
blood transfusion. The main purpose of autologous transfusion is to avoid the 
risk of infection associated with allogeneic blood such as hepatitis B, C, 
NANBNC, HIV, syphilis, malaria and other transfusion transmitted diseases. The 
safety of the allogeneiC supply has been questioned since the first cases of 
transfusion transmitted human immunodeficiency virus (HIV) were reported in the 
early 1980s. The increasing awareness that allogeneic blood transfusion induces 
an immunomodulatory effect has also encouraged the use of autologous 
transfusion (Fiebig, 1998; Gillon and Thomas, 1999; Greenwalt, 1999). 
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Other reasons to shift from allogeneic to autologous transfusion are: shortfall in 
supply; alloimmunisation to red cells, platelets, leukocytes and plasma proteins; 
the risk of febrile, allergic and haemolytic reactions; graft versus host disease; 
clerical error; and finally cost-effectiveness (Kruskall et aI., 1994; Dalen et aI., 
1996; Duffy and Tolley, 1997). 
1.4.3. Autologous pre-deposit blood 
Patients scheduled for elective surgery needing transfusion can be 
considered for autologous pre-deposit blood transfusion. The patient should be 
well motivated to complete the collection programme and be able to travel to the 
transfusion centre. This usually involves depositing up to four blood units within a 
relatively short interval. Pre-deposit blood is obtained at weekly intervals the last 
unit being collected a minimum of three days before operation. Blood is stored at 
4° C and retransfused when needed during or after surgery. Collected blood can 
be stored for 30-36 days depending on the anticoagulant solution, and it should 
also be labelled and tested in the same way as allogeneic blood. 
Candidates for pre-donation should be in as good health as normal blood 
donors. The criteria for pre-deposit autologous blood donation are: 
a) Age between 17 and 70 
b) Weight more than 50 kg 
c) Good venous access in antecubital fossa 
d) Both men and women should have a haemoglobin level of at least 110 
g/I at referral 
Blood is not to be taken from patients with the following criteria: 
a) Significant cardiovascular disease 
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b) Uncontrolled hypertension (diastolic more than 100 mmHg) 
c) Epilepsy 
d) Haemoglobin level less than 110 g/I 
e) Complicated pregnancy 
f) Autonomic neuropathy 
g) Active bacterial infection of any sort 
h) Patients who are positive for anti HIV 1 and 2; anti-HCV; Hepatitis B 
surface antigen (HBs-Ag) or syphilis 
i) Patients taking ~-blockers (except if taken for anxiety or glaucoma and 
with a pulse rate above 60 beats/min) or other drugs that interfere with 
autonomic regulation 
j) Patients age more than 70 years who have suffered a delayed faint 
after blood donation (Ozik, 1994a; Fiebig, 1998; Courouce et aI., 1999). 
Autologous pre-deposit blood transfusion cannot be used without 
supplementary allogeneic blood if more than five units are required. Pre-deposit 
transfusion can produce some of the same complications as regular allogeneic 
blood transfusion such as bruises at the joints and bacterial contamination (Gillon 
et aI., 1999). 
1.4.4. Autologous post-operatively salvaged blood 
For first time in 1978, Schaff and his colleagues attempted to reinfuse the 
shed blood from mediastinal drainage during and after thoracic surgery. They 
showed a 50% reduction in the need for allogeneic blood (Schaff et aI., 1978a; 
Schaff et aI., 1978b; Schaff et aI., 1979). 
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Patients undergoing total hip or knee replacement operations as well as cardiac 
surgery patients suffer significant blood loss at the site of surgery leading to the 
need to replace shed blood. This closed collection system is widely used for 
surgical procedures, such as cardiac, vascular, orthopaedic, urologic, trauma, 
gynaecologic and transplants surgery. The anticipated blood loss is 20 percent 
or more of the patient's estimated blood volume and there is no contamination of 
the area by bacteria or cancer cells. This procedure is generally not used in 
cancer surgery or surgery of the lower gastrointestinal tract (Clements et aI., 
1992; Elawad and Fredin, 1992; Dalrymple_Hay et aI., 1999). 
1.4.4.1. The method of blood collection in autologous post-operatively 
salvaged blood 
Salvaged blood is collected from the surgical wound via a suction catheter, 
which has two lumens, one to deliver acid citrate dextrose (ACD), to act as both 
anticoagulant and preservative to the site of bleeding, and another to aspirate 
already anticoagulated blood. This is usually performed within the first 24 post-
operative hours. Retrieved blood is collected for six hours and if the volume 
drained is at least 100 ml, reinfusion takes place. Collected blood is reinfused 
as soon as the drained volume reaches 500 ml, on the condition that it occurs 
within six hours after operation. Further reinfusion may be performed within the 
next six hours following the last reinfusion or after a further 500 ml has drained. 
This protocol may be repeated until 12 hours after operation or until a maximum 
of 1500 ml has been reinfused. The collected blood is washed or unwashed and 
re-infused through a 40-micron (Jlm) filter as in a standard blood-giving set 
(Clements et aI., 1992; Elawad et aI., 1992). 
1.4.5. Allogeneic leukodepleted blood 
Cellular blood components contain donor peripheral leukocytes and 
exposure to these may produce a number of transfusion complications. Clinical 
studies indicated that leukocyte-depletion decreased the risk of the transfusion 
complications associated with allogeneic transfusions. Leukodepletion is 
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practised in France, Ireland, Canada, Portugal and was recently introduced in the 
UK (Belardinelli et aL, 1996; Georgeson, 1996; Sirchia and Rebulla, 1997) 
Leukodepletion was officially implemented in the UK on the first of 
November 1998 and two months earlier at the Bristol blood transfusion centre. 
One of the most important reasons for leukodepletion was the presumed risk of 
transmitting new-variant Creutzfeldt-Jakob disease (nvCJD). The United States 
Food and Drug Administration (FDA) recommends withdrawal of components or 
products derived from donations by those at risk of infectivity for nvCJD. 
However, there is no report of any case of confirmed CJD among recipients of 
blood components, not even among recipients who received blood from donors 
who subsequently developed CJD (Heye et aL, 1994; Beckman and Seghatchian, 
1999; Seghatchian, 2000). 
The main goals of universalleukodepletion are: 
a) Prevention of febrile non-haemolytic transfusion reactions (FNHTRs) 
b) Reducing graft rejection after haemopoietic stem cell transplantation, for 
example in multiply transfused, severe aplastic anaemia patients 
c) Prevention of transmission of infectious agents such as cytomegalovirus 
(CMV), Human T-ceilleukaemia/lymphoma virus (HTLV 1/11), Human herpes virus 
8 (HHV-8), Epstein-Barr virus (EBV), Trypanosoma cruzi and nvCJD 
d) Intra-uterine transfusions, for all transfusions to infants below one year 
of age 
e) To avoid transfusion-related acute lung injury causing the adult 
respiratory distress syndrome (ARDS). (Heddle and Blajchman, 1995; Ledent 
and Berlin, 1996; British Committee for Standards in Haematology, 1998; 
Larsson et aL, 1998; Wadhwa et aL, 2000). 
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FNHTRs are thought to occur as a result of several different mechanisms 
including: 1) donor leukocytes recognised by the immune system of recipients via 
leukocyte antibodies as a consequence of HLA allo-immunisation; 2) passive 
transfer of donor inflammatory cytokines produced by leukocytes during the 
period of storage and/or immune destruction of incompatible donor platelets by 
recipient antibodies (Slichter, 1998; Roddie et aI., 2000). 
ARDS is an infrequent but hazardous complication that may occur a few 
hours following blood transfusion. ARDS is characterised by symptoms of 
sudden respiratory distress, severe hypoxemia, fever and hypotention. The 
pathogenesis of transfusion-related acute lung injury causing ARDS is not fully 
understood. This syndrome is thought to be linked to the circulating antibodies 
produced against leukocytes leading to leukocyte aggregation and activation in 
the pulmonary micro-vasculature (Zupa"ska et aI., 1999). 
The current British standard defines that leukocyte-depleted blood 
components must contain less than 5 x 1 06 leukocytes per unit of red cells or per 
adult therapeutic dose of platelets. This should be achieved with at least 99 
percent frequency and at least 95 percent statistical confidence. For achieving 
residual leukocyte counts of less than 5 x 106 per unit, leukocyte-depletion should 
be carried out under controlled conditions, ideally within 48 hours from the 
collection of the donor unit. The preparation of leukocyte-depleted blood 
components should be monitored under quality control guidance (Beckman and 
Seghatchian, 2000; Seghatchian et aI., 2000). 
1.4.5.1. Leukodepletion methods 
Leukocytes can be removed from blood components by centrifugation, 
freeze/thawing and filtration with third generation filters. Filtration has progressed 
in three distinct stages. First-generation filters had the ability to remove large 
clots and particulate debris with a pore size of 170-240~m. Second-generation 
filters had a pore size of 40/-im and were designed to reduce micro aggregates of 
fibrin, platelets and leukocytes by one log10. Third-generation filters remove free 
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leukocytes from blood, down to three log10 to a level less than 5 x 106 per unit 
(Norfolk and Williamson, 1995; Georgeson, 1996; British Committee for 
Standards in Haematology, 1998). 
Leukodepletion can be carried out at the bedside during the transfusion or 
at the blood transfusion centre in the component-processing laboratory. 
Leukodepletion carried out a short time after blood collection has the advantage 
that release of cytokines or fragments of cell membrane is minimised (British 
Committee for Standards in Haematology, 1998; Roddie et aI., 2000). 
1.4.6. Allogeneic non-Ieukodepleted blood 
A local volunteer donor pool provides allogeneic non-leukocyte-depleted 
blood for each blood transfusion centre. For safety the transfusion service 
should recruit and keep safe donors, and do high quality laboratory screening. In 
the United Kingdom, the risk of an infectious unit of blood being transfused is 
estimated at less than 1 in 2 million for HIV, less than 1 in 200,000 for HCV, and 
1 in 50,000-200,000 for HBV. In the USA, this risk is estimated at less than 1 in 
563,000-825,000 for HIV, 1 in 121,000 for HCV and 1 in 66,000 to 200,000 for 
HBV (Gillon and Thomas, 1999; Greenwalt, 1999). 
In developing countries, allogeneic non leukocyte-depleted blood is used 
as packed red cells from which the derived plasma is derived and used for 
fractionation into blood components (Gillon and Thomas, 1999; Greenwalt, 
1999). Allogeneic packed non- leukocyte-depleted blood has been widely used 
as an agent for improving oxygen supply to the tissues, especially in patients 
undergoing elective operations or in massive trauma cases. Some developing 
countries have shifted to implementing or recommending universal 
leukodepletion (Georgeson, 1996). 
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1.4.6.1. The allogeneic blood donation eligibility criteria 
Blood donors with the following characteristics are eligible to donate blood. 
The blood donor must generally be at least 17 years of age, and a maximum of 
75 years of age (although, some states in the USA permit younger people to 
donate with parental consent). However, most blood banks have no upper age 
limit. Donor weight should be at least 110 pounds (50 kg), and the donor must be 
in good health. The haemoglobin level should be at least 110 g/1. All donors 
must pass the physical and health history examinations given prior to donation. 
Volunteers with significant cardiovascular disease, uncontrolled hypertension, 
epilepsy, pregnancy, diabetes, active infection, and patients who are positive for 
anti HIV 1 and 2; anti-HCV; Hepatitis B surface antigen (HBs-Ag) or syphilis must 
not donate blood. Volunteers can donate platelets up to a maximum of four 
times per year, while whole blood can be donated once every eight weeks. The 
donor's body replenishes the fluid lost from donation within 24 hours. It may take 
up to two months to replace the lost red blood cells. The routine tests performed 
on drawn blood, are for ABO group (blood type), and Rh type (positive or 
negative), as well as for any unexpected red blood cell antibodies that may cause 
problems in the recipient. Some screening tests are also performed for evidence 
of donor infection with hepatitis viruses Band C, HIV 1 and 2 and syphilis. 
However, in some countries drawn blood is tested for human T-Iymphotropic 
viruses (HTLV) I and II (Greenwalt, 1997; Fiebig, 1998; Prati et aI., 1998). 
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1.5. Immunomodulation 
Allogeneic blood transfusions, surgery and haemorrhage lead to 
suppression of the body's immune defences against pathogenic micro-
organisms. These conditions invoke different biological mechanisms such that 
the impact on the immune system may be additive when two or more of these 
events occur together. 
1.5.1. Surgery-induced immunomodulation 
It is generally accepted that surgery-induced immunomodulation is 
manifest as increased post-operative infections such as pneumonia, peritonitis, 
urinary tract infections, septicaemia and wound infection (Baker et aI., 1987; 
Cheadle et aI., 1996). 
Multiple trauma and surgically induced trauma are associated with 
depression of cell-mediated immunity associated with lymphocytopenia and 
impairment of T-cell proliferative response to mitogens. The decrease in 
proportion of CD4+ T-cells is greater than CD8+ T-cells (O_Mahony et aI., 1984; 
Delogu et aI., 2000) 
In human and animal models, it was shown that during the early post-
operative period the effects of surgical trauma on the immune system were 
decreased production of pro-inflammatory cytokines, and depressed in-vitro 
lymphocyte blastogenesis and proliferation (Kojima et aI., 1983; Mack et aI., 
1996; Berguer et aI., 1999). 
Convincing evidence for the systemic effects of surgery-induced 
immunomodulation comes from controlled experiments using animal models. In a 
graft versus host disease (GVHD) model, skin incision to the F1 murine host 
inflicted one day prior to injection of parental spleen cells produced impairment of 
popliteal lymph node enlargement. The spleen cells of F 1 mice displayed 
suppressor activity on local graft versus host (GVH) reactions when injected 
together with paternal cells into naive syngenic F1 mice. This suppressor activity 
43 
was most marked 3 to 24 hours after the skin incision. Suppression was 
attributed to suppressor T lymphocytes in the host spleen and it showed that the 
local GVH reactions were suppressed by surgical trauma (Kojima et aI., 1983). 
In another animal model invasive surgery performed by laparotomy was 
associated with lower T-cell activation and more impairment in cell-mediated 
immunity than laparoscopic surgery with less tissue trauma (Berguer et aI., 1998). 
Ben-Eliyahu et al investigated the effects of two stress paradigms, forced swim 
and abdominal surgery, on NK cell regulated tumour development in rat. They 
observed that in both stress paradigms, NK cell function was suppressed, and 
tumour development and metastasis were enhanced (Ben_Eliyahu et aI., 1999a). 
Marshal et al observed a decrease in delayed hypersensitivity (OTH) response to 
a subcutaneous accumulation of Staphylococcus aureus and decrease in 
phagocytic clearance of Escherichia coli by hepatic macrophages following 
surgical trauma (Marshall et aI., 1987). 
Surgery-induced immunomodulation varies according to the severity of the 
surgery and patient characteristics. For example cholesystectomy and 
rectosigmoid carcinoma resection performed by laparoscopic surgery results in 
less immunomodulation than the same operation performed by conventional 
open surgery involving laparotomy (Berguer et aI., 1999). 
The general impression is that major surgery suppresses the ability of T-
cells to produce pro-inflammatory cytokines without initially enhancing producing 
of anti-inflammatory cytokines (Berguer et aI., 1999). Indeed levels of IL-4, one 
of the index anti-inflammatory cytokines, was depressed in some studies (Baker 
et aI., 1987; Berguer et aI., 1999). Later, as the immune system recovers an anti-
inflammatory profile emerges with sustained increases in IL-10 production. In 
patients with colonic cancer undergoing recto-sigmoidal surgery by laparotomy 
levels of IL-1 p and IL-6 were elevated compared to control patients operated by 
laparoscopy (Berguer et aI., 1999; Berguer et aI., 2000). In a similar study of 
cholesystectomy IL-2, IFNy and TNFa were all lower after open surgery than after 
laparoscopic surgery. IL-2 levels only rose transiently or not at all. IL-10 levels 
were initially unaffected, but rose later, supporting the view that an anti-
inflammatory profile emerged later after surgery, but monocyte antigen 
presenting function appeared to be unaffected (Hensler et aI., 1997). 
It was suggested that PGE2 released by macrophages may have been 
both the source of suppression of the inflammatory response leading to 
decreased IL-2 and IFNy activity and the cause of the deviation to an anti-
inflammatory profile (Droller et aI., 1979; Duffie et aI., 1988; Eisengart et aI., 
2000). 
Interestingly the anti-inflammatory pathway of T-cell differentiation (Th2) 
was associated with increased B-cell help (Di_Padova et aI., 1988). This may 
explain the odd observation that polyclonal B-Iymphoblastoid activation occurred 
between five and 14 days after cholecystectomy (DLPadova and Durig, 1988). 
The local sites of trauma appear to be rich in IL-10 despite normal IL-10 
blood levels. The immunosuppressive role of IL-10 is well known; it inhibits the 
synthesis of anti-inflammatory cytokines and antigen-presenting function of 
monocyteimacrophages by down-regulating expression of MHC Class II, CD54, 
CD80 and CD86, preventing the release of oxygen free radicals and nitrogen 
intermediates. Increased systemic IL-10 levels were related to the severity of 
injury and to post-traumatic complications (Klava et aI., 1997; Koller et aI., 1998). 
By contrast, after cardiac and aorta-femoral by-pass vascular surgery the 
picture was different with elevated TNFu, IL-6 and C-reactive protein (CRP) level, 
but this was related to volume of blood lost and may be more a manifestation of 
haemorrhage-induced immunomodulation (see section 1.5.2), than surgery-
induced immunomodulation (Gadaleta et aI., 1994; Hattler et aI., 1995; Diegeler 
et aI., 2000). 
Immunomodulation-induced by major surgery and allogeneic blood 
transfusion appear to be additive on the immune system (see section 1.5.3). In 
a cohort study, NK cell function, IL-2 and IFNy production were investigated in 
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136 patients who underwent surgery for gastrointestinal malignancy. The results 
showed a significant decrease in NK cell function, IL-2 and IFNy production after 
operation in both the transfused and non-transfused groups. However, the 
proportion of post-operative infections in transfused patients was 28% compared 
with 5% in the non-transfused patients. Thus, extra deleterious effects on cellular 
immunity resulted from transfusion (Quintiliani et aI., 1997). 
1.5.1.1. Effect of anaesthesia and morphine on surgery-induce 
immunomodulation 
General anaesthesia per-se is associated with transient in-vitro changes, 
but there is little if any evidence to support the view that it causes overt or lasting 
symptoms of immunosuppression. For example, in one study basal NK cell 
cytotoxic function against K562 was significantly depressed after general 
anaesthesia alone compared to surgery plus anaesthesia. This depressed NK 
cell cytotoxicity was restored to pre-operative levels by treating NK cells with 
IFNa (Kutza et aI., 1997). 
However, hypothermia, a common surgical complication under thiopental 
general anaesthesia, was shown in an animal experiments that it was associated 
with decreased NK cell function and compromised host resistance to metastatic 
tumour spread. This was attributed to adrenergic mechanisms (8en_Eliyahu et 
aI., 1999a; 8en_Eliyahu et aI., 1999b). 
In Kutza study has been proposed that a decrease in NK cell activity after 
surgery and anaesthesia may lead to enhanced susceptibility to infection and 
tumour dissemination (Kutza et aI., 1997; 8en_Eliyahu et aI., 1999a). 
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In breast cancer patients who underwent surgery, NK cell function and 
Iymphoproliferative response to phytohaemagglutinin (PHA) were reduced. No 
evidence was found to suggest this effect be related to a particular anaesthetic 
regime (Stanojevi+_Baki+ et aI., 1999). 
The opioid antagonist naltrexone appears to reverse the deleterious 
effects of surgery in the rat. The effect on surgically induced immunomodulation 
was evidenced by reversal of the decreased NK cell cytotoxic function, reduced 
B-cell and T-cell proliferation, and decreased IFNy production. Naltrexone 
administered at the time of surgery and every 4 hours thereafter reversed these 
effect (Nelson et aI., 2000) 
Exogenous morphine may induce down-regulation of lymphocyte, 
granulocyte and macrophage activity. In patients who underwent abdominal 
surgery for uterine carcinoma a decrease in NK cell function and 
Iymphoproliferative response to PHA, was observed. Patients treated with 10 mg 
of intra-muscular of morphine immediately before and after operation had a lower 
response to PHA two hours after the operation than those treated with 100 mg of 
another opioid derivative, tramadol (Sacerdote et aI., 2000) 
The effect of exogenous morphine on NK cell activity was studied in 
patients who underwent hysterectomy. These patients were treated with 0.5mg 
morphine administrated intrathecally. NK function was decreased after surgery 
(Yokota et aI., 2000). In a study on sixteen patients underwent coronary artery 
by-pass grafting an increase in endogenous morphine was observed that it may 
induce immunomodulation after surgery (Brix_ Christensen et aI., 1997). 
1.5.2. Haemorrhage-induced immunomodulation 
Clinical manifestations of haemorrhage-induced immunomodulation are 
rarely described except in its most extreme form of multi-organ failure because 
blood loss is seldom sustained for long periods without correction. Furthermore, 
haemorrhage-induced immunomodulation may often be masked by the 
immunomodulatory effects of surgery. In experimental rodent models substantial 
evidence has been obtained for systemic immunomodulation following severe 
uncorrected blood loss. In one of these experiments a significant increase in 
circulating transforming growth factor-beta (TGF-P) up to 24h following 
haemorrhage, was observed. The elevated TGF-p plasma level was associated 
with a decrease in concanavalin A-induced splenocyte proliferation and antigen 
presentation by splenic macrophages (Ertel et aI., 1992b; Ayala et aI., 1993; 
Ayala et aI., 1997). 
I n another animal experiment a decrease in splenocyte T-cell proliferation 
was associated with an increased in IL-4 and IL-10 synthesis. This IL-4 and IL-
10 increase was preventable by addition of ibuprofen as COX-2 inhibitor or 
monoclonal antibody against TGF-p. The TGF-p is a growth factor involved in 
tissue repair and T-cell impairment (Ayala et aI., 1994). 
In experimental models, mitogen induced proliferative responses by 
splenic lymphocytes were decreased, as was antigen presenting function by 
peritoneal macrophages and hepatic Kupffer cells. Expression of MHC Class II 
antigens by Kupffer cells and macrophages was suppressed. At the macrophage 
cell surface there was less expression of MHC Class II and IL-2R following 
haemorrhage (Abraham and Freitas, 1989; Abraham and Chang, 1992; Chaudry 
et aI., 1995). Zhu et al observed an increase in TNFa, IL-6 and TGF-p levels in 
the plasma and an increase in TNFa, IL-1 P and TGF-p mRNA message in 
Kuppfer cells, but not splenic macrophages (Zhu et aI., 1995). In a murine 
model Ertel et al demonstrated an increased release of PGE2 by macrophages , 
and Kupffer cells. Chloroquine treatment inhibited the secretion of PGE2 by 
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macrophages leading to decreased mortality from sepsis mice after haemorrhage 
compared to controls (Ertel et aI., 1991; Ertel et aI., 1992a). 
In a rabbit model of haemorrhage-induced immunomodulation were 
prevented by prior treatment with polyunsaturated fatty acids that suppressed 
PGE2 . In this study, the potential role of PGE2 in the development of multiple 
organ failure and the effects of antiserum directed against lipopolysaccharide 
(LPS) as the inducer of arachidonic acid metabolite, were investigated. 
Antiserum to LPS given intravenously at the onset of haemorrhage and four 
hours after resuscitation lead to no increase in the circulating PGE2 level after 
haemorrhage up to 24 hour after resuscitation. Lower LPS concentrations and 
significantly higher survival rates were observed after administration of LPS 
antiserum (Yao et aI., 1996). 
COX-2 converts arachidonic acid to PGE2 that is further metabolised to 
various prostaglandins, prostacyclin and thromboxane A2 . COX-2 inhibitors, such 
as ibuprofen suppress nuclear factor kappa B (NF-kB) dependent synthesis of 
PGE2 in macrophages. In turn PGE2 abrogates synthesis of TNFa and IL-6. In 
mouse macrophages were exposed to Escherichia coli LPS in the presence of 
ibuprofen. COX-2 mRNA expression and PGE2 was inhibited by ibuprofen. 
These agents attenuated LPS-induced NF-kB activity. (Gadd and Hansbrough, 
1990; Mansilla_Roselio et aI., 1996; Lo et aI., 1998; Wissink et aI., 1998). 
In a more extreme model of haemorrhage-induced immunomodulation 
leading to immunosuppression and multi-organ failure following haemorrhagic 
shock, serum PGE2 levels were reduced by antiserum directed against LPS 
(Manning et aI., 1989; Ayala et aI., 1997; Asanuma et aI., 1999). 
In a mouse model of haemorrhage-induced immunomodulation anti-IL-10, 
anti-IL-4 and ibuprofen inhibited PGE2 augmented IL-10 production by T-cells 
and reversed the in-vitro suppression of T-cell proliferation (Napolitano et aI., 
1996; Ayala et aI., 1997). It has also been reported that a significant decrease in 
IL-3, IL-5 and IL-6 synthesis occurred after haemorrhage that may lead to 
49 
impaired recruitment and maturation of monocyte/macrophage and antibody 
producing B-cells (Abraham and Freitas, 1989; Meldrum et aI., 1991). 
The effects of experimental haemorrhage-induced immunomodulation 
were also reversed by treatment with IFNy, or antibody to TGF-p or platelet 
agglutinating factor (PAF) antagonists (Stewart et aI., 1995; Zellweger et aI., 
1995). 
Clinical changes suggestive of haemorrhage-induced immunomodulation 
have been observed in colorectal cancer patients after being bled for 'pre-deposit' 
blood transfusions, especially after the donation of two blood units, a sustained 
decrease in NK cell function was observed in-vitro (Marquet et aI., 1993b). 
Lasek et al demonstrated for the first time a decrease in NK cell function, 
associated with blood donation by healthy donors (Lasek et aI., 1987). Then 
Ford et al confirmed this observation (Ford et aI., 1987). 
Marquet et al described a decrease in NK cell function at least five days 
after blood donation by healthy donors. However, this alteration was not 
associated with adverse clinical manifestations (Marquet et aI., 1993a; Mathiesen 
et aI., 1994; Quintiliani et aI., 1997). 
It is assumed that haemorrhage is a potent stimulator of corticosteroid and 
prostaglandin secretion, both of which inhibit NK cell function. Another 
possibility, which has been observed consequence of blood donation is that 
haemorrhage may lead to a shift of immature NK cells from the bone marrow into 
the blood leading to the recruitment of immature NK cells with lower activity in 
blood circulation (Marquet et aI., 1993a; Marquet et aI., 1993b; Rhind et aI., 
1999). 
In a clinical study following burning, decreases in the absolute number of 
circulating lymphocytes, CD4+ cells and the ratio of CD4+ to CD8+ were 
observed. There was decreased expression of monocyte HLA-DR, lymphocyte 
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proliferation after mitogen stimulation, CD4+, CD8+, IL-2R and transferrin 
receptor after mitogen stimulation (Hansbrough et aL, 1984; Zapata_Sirvent and 
Hansbrough, 1993). 
1.5.3. Allogeneic blood transfusion-induced immunomodulation 
The term blood transfusion-induced immunomodulation is generally used 
to refer to down regulation of the human immune system in response to 
allogeneic blood transfusions. Clinical evidence for allogeneic blood transfusion-
induced immunomodulation is well documented (Blumberg and Heal, 1996b). 
In 1945, Medawar noticed that some transfused animals rejected skin 
grafts from the blood donor in as short a time as animals immunised by prior skin 
grafts. This 'second-set' phenomenon occurred only if donor antigens shared by 
donor blood and skin were capable of inducing cell-mediated immunity. He 
concluded that tissues expressed the same antigens as blood and this 
information strongly influenced the early years of human organ transplantation 
(Brent and Medawar, 1967; Lance and Medawar, 1969). Medawar and others 
demonstrated that the administration of intravenous alloantigen could be 
tolerogenic and modulate the immune system against an allograft, although this 
phenomenon was not seriously addressed in a clinical trail until the end of 1960s 
(Billingham et aL, 1969; Brunson and Alexander, 1990; Perkins et aL, 1996). 
1.5.3.1. The beneficial effects of allogeneic blood transfusion 
I n the early 1970s, Opelz reported that allogeneic blood transfusion 
improved the outcome of renal allografts. He observed that when allogeneic 
blood transfusion was regularly administered during dialysis, the probability of 
graft survival was increased in kidney transplant recipients. It was shown that 
allogeneic blood transfusion was associated with immunomodulation in 
recipients, thus pre-transplant allogeneic transfusion became routine policy in 
kidney transplantation centres during the 1970s and the early 1980s (Opelz et aL, 
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1973; Rashid et aI., 1975; Rashid and Sengar, 1978; Sengar and Rashid, 1978; 
Opelz et aI., 1997). 
Opelz and Terasaki further demonstrated that the patients who received 
whole blood had the best allograft outcome compared to those who received 
other blood components. The best blood component after whole blood was 
packed cells. Those who received leukodepleted blood including frozen/thawed 
or washed red blood cells (RBC) had outcomes no better than non-transfused 
patients (Opelz and Terasaki, 1976; Opelz and Terasaki, 1978). 
Until this time allogeneic transfusions were only thought to induce RBC 
allo-antibody leading to haemolytic and non-haemolytic transfusion reactions. 
Billingham and Chaplain, in the early 60s, were among the first to recognise a 
role for leukocytes and platelets in precipitating febrile reactions after blood 
transfusion, and Perkins demonstrated a semi-quantitative relationship between 
non-haemolytic febrile reactions and contaminating leukocytes, particularly 
granulocytes (Perkins et aI., 1996). Thus transfusions appeared to have two 
contrasting effects on allo-immunity; they stimulated as humoral immunity 
inflammatory reactions, but suppressed cellular immunity to HLA antigens. 
Auto-immune processes also appear to benefit from allogeneic 
transfusion-induced immunomodulation since transfusions given to patients with 
Crohn's disease modified the course of disease and those who received 
transfusions during bowel resection operations had less post-transplant 
recurrence of their disease than non transfused patients (Peters et aI., 1989; 
Williams and Hughes, 1989; Tartter, 1995). Allogeneic leukocyte transfusions 
may be beneficial in women suffering primary recurrent miscarriage. Higher 
successful pregnancies have been claimed in the women who received paternal 
cells compared to those who received their own cells (Mowbray et aI., 1987; 
Mowbray, 1988). This however, remains controversial. 
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1.5.3.2. The detrimental effects of allogeneic blood transfusion 
During the last three decades, awareness of the potential risks associated 
with blood components due to impairment of immunologic function in recipients, 
particularly those associated with cell mediated immunity, has increased 
(Blumberg and Heal, 1996b; Dzik et a!., 1996; Blajchman, 1998). 
The functional, cellular and molecular changes that accompany allogeneic 
blood transfusion-induced immunomodulation have been studied extensively in 
rodent models and in man. Experiments in animal models supported the idea 
that allogeneic transfusion alters the immune system by enhancing production of 
anti-inflammatory cytokines, decreasing NK cell number and NK cell cytotoxicity 
and decreasing macrophage migration in response to inflammatory stimuli. In 
man, the effects of allogeneic transfusion include: decreased CD4:CD8 
lymphocyte ratios; decreased NK cell function; decreased antigen presentation; 
suppression of lymphocyte blastogenesis; and reduced delayed hypersensitivity 
(Bordin et a!., 1994; Vamvakas et a!., 1995; Blumberg and Heal, 1998). 
These alterations are linked to enhanced metastatic spread and growth of 
tumour cells (Francis and Shenton, 1981; Horimi et a!., 1983; Tartter and Francis, 
1988; Busch et a!., 1993a; Hoynck_van_Papendrecht et a!., 1993). Animal 
models have shown that allogeneic transfusion the possibility after allogeneic 
blood transfusion is an independent risk factor of enhanced tumour recurrence 
(Gantt, 1981). 
Retrospective and prospective clinical studies supported the idea that 
allogeneic transfusion had detrimental effects on host immune defences. 
Burrows and Tarter were the first to show a deleterious effect of allogeneic 
transfusion in patients with colorectal cancer (Burrows and Tartter, 1982). They 
and others reported that administration of allogeneic blood was an important 
factor in recurrence of colorectal malignancy and decreased survival. 
Allogeneically transfused patients also displayed higher rates of post-operative 
infection than non-transfused patients did (Blumberg and Heal, 1987; Burrows et 
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aI., 1987; Tartter, 1988c; Tartter, 1988a; Jensen et aI., 1992; Busch et aI., 1993b; 
Houbiers, 1994). Similar results were observed in patients undergoing radical 
resection for oesophageal carcinoma and gastric adenocarcinoma. In both 
studies allogeneic transfusion was associated with poor outcome and decreased 
survival (Fong et aI., 1994; Dresner et aI., 2000). 
Furthermore, in another study on patients who underwent elective 
colorectal surgery a correlation between the development of post-operative 
infection and allogeneic transfusion was observed despite antibiotic prophylaxis 
(Jensen et aI., 1990). 
Leukocyte-depleted allogeneic RBC or buffy coat depleted packed RBC 
are also associated with higher infection rates and lower survival rates compared 
with non-transfused patients (Houbiers et aI., 1994a; Mathiesen et aI., 1998; 
Innerhofer et aI., 1999a; Innerhofer et aI., 1999b). 
In patients with non-malignant diseases who received spinal fusion surgery 
the number of units transfused was the major predictor of increased in-hospital 
infection, as well as days on antibiotics and length of stay (Triulzi et aI., 1992). 
Studies on orthopaedic patients including joint replacement have 
demonstrated that the incidence of post-operative infections and delayed wound 
healing after surgery in patients receiving allogeneic transfusions was higher 
compared to those receiving autologous or no transfusions (Murphy et aI., 1991; 
Fernandez et aI., 1992; Triulzi et aI., 1992; Howard et aI., 1993; Carson et aI., 
1999; Innerhofer et aI., 1999b). 
Moreover, cytokine studies in patients undergoing hip replacement surgery 
who received allogeneic transfusions showed no change in IL-2 but IL-10 and IL-
4 production were enhanced (Kirkley et aI., 1998). Cytokine studies in patients 
undergoing recto-sigmoidectomy who received allogeneic transfusions showed 
an increment in blood levels of IL-6 (Ishijima and Suzuki, 1998). 
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Evidence from animal models further supports the idea that allogeneic 
transfusion is associated with more bacterial infections. The percentage of viable 
bacteria in some organs including liver, lung, spleen, lymph nodes, peritoneal 
cavity and blood was significantly higher in allogeneic transfused compared to 
non-transfused groups. (Tartter, 1989; Scorza et aI., 1990; Gianotti et aI., 1992; 
Eaves_Pyles and Alexander, 1997). Also, transfused mice showed higher 
mortality rates compared to non-transfused mice (Tartter, 1995; Blajchman, 
1998). 
In addition, experiments in animal models showed an increase IL-4 levels 
and a decrease in I FNy levels after allogeneic blood transfusion (Babcock and 
Alexander, 1996; Frede et aI., 1997; Levy et aI., 1997). 
It was shown that a significant increase in PGE2 synthesis after allogeneic 
blood transfusion in an animal model may lead to impair of cell-mediated 
immunity. This deleterious effect was abrogated by indomethacin (Shelby, 1987; 
Shelby et a\., 1987; Perez et a\., 1997). 
At the pragmatic level the detrimental effects of allogeneic transfusions 
can be avoided by reinfusion of autologous blood drained from the operation site 
(Schaff et a\., 1978a; Schaff et a\., 1979). Results from patients who received 
salvaged autologous blood showed that this approach prevented detrimental 
effects on cell mediated immunity in recipients compared with allogeneic 
transfusions (Murphy et a\., 1991; Heddle et a\., 1992; Mezrow et a\., 1992; Heiss 
et a\., 1993; Houbiers et a\., 1994a; Heiss et a\., 1997a). 
In two studies of patients who received autologous post-operative 
unwashed salvaged blood, the concentration of released cytokine, including IL-6 
and IL-8 in transfusate, was not reduced by filtration. This lead to an increase IL-
6 and IL-8 in concentration of these products in the recipients' plasma, whereas 
in those patients who received washed and centrifuged shed blood, no elevation 
in released cytokines was observed in the recipients' plasma. Similar, increases 
in plasma concentrations of IL-6 were shown in patients who received post-
operatively salvaged blood (Arnestad et aI., 1994; Arnestad et aI., 1995). 
Autologous blood salvage reduces the need for allogeneic blood whereas 
some results demonstrated that the number of patients who needed allogeneic 
blood transfusion was reduced up to 50% in Schaff's study and 45% in Dalen's 
study (Schaff et aI., 1978a; Dalen et aI., 1996). Furthermore, it is cost effective 
and the alkaline pH of salvaged blood reduces acidosis associated with massive 
transfusion (Ritter et aI., 1994; Spence et aI., 1995; Dalen et aI., 1996; Blumberg, 
1997; Duffy and Tolley, 1997). 
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1.6. Mechanisms of immunomodulation-induced by surgical trauma 
1. IL-10. IL-10 may cause immunomodulation. Monocyte HLA-DR, 
mRNA expression and serum IL-10 levels were studied in 48 patients who 
underwent major elective resectional surgery. There was a significant decrease 
in monocyte HLA-DR expression 24 hours after surgery that remained low during 
the first postoperative week. An increase in IL-10 mRNA expression and serum 
IL-10 were also observed on the first postoperative day. Furthermore, there was 
a significant correlation between HLA-DR antigen expression and the presence of 
IL-10 mRNA transcript on the first post-operative day (Klava et aI., 1997). 
The contribution of polymorphonuclear neutrophil fractions to the 
development of surgery induced immunomodulation was evaluated. The 
concentration of IL-10 in culture supernatants of 30 individual PMN fractions was 
higher in traumatised patients compared with healthy donors (Koller et aI., 1998). 
In one clinical study it has been proposed that the dominance of anti-
inflammatory reaction may cause surgery-induced immunomodulation (Decker et 
aI., 1996). 
In an animal model it was shown that severe injury leads to a shift in 
production of anti-inflammatory cytokines including IL-4, IL-5, IL-6 and IL-10, 
which may contribute to immunomodulation (Mack et aI., 1996). 
In another animal experiments was shown that bilateral femur fractures 
and mechanical tissue injury, lead to decreased splenic T-cell proliferation in 
response to concanavalin-A (con-A). Furthermore, there is a decrease in IL-2 
and IFNy synthesis in cultures of con-A stimulated splenic T-cell. Interestingly, 
IL-10 synthesis was decreased in these traumatised rats (Meert et aI., 1998). 
2. PGE2. A role for PGE2-mediated suppression and high production of 
the arachidonic acid metabolite PGE has also been proposed. One group 
showed that the PGE derivative impaired neutrophil migration into burn wounds. 
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It also decreased macrophage migration in response to inflammatory stimuli, 
decreased NK cytotoxic function and down-regulated expression of cell-surface 
molecules involved in antigen presentation. This increased the risk of 
development of MOF(Waymack et aI., 1987; Winslow et aI., 1996; Koga et aI., 
2000; Liu et aI., 2000b). 
3. Reactive oxygen species (ROS). In a clinical study a significant 
decrease in the in-vitro NK cytotoxic function following trauma was unaffected by 
the addition of anti-IL-4, anti-TGF-p1 and anti-IL-10 antibodies. But, removal of 
monocytes from buffy coat mononuclear cells reversed this NK cell suppression 
suggesting that immunomodulation may have been attributed to production of 
reactive oxygen species (ROS) by monocytes (Joshi et aI., 1998). 
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1.7. Mechanism of immunomodulation induced by allogeneic blood 
transfusion 
Transfused allogeneic blood, and its various components, may interact 
with the immune system in a variety of ways. Several hypotheses have been 
suggested and each of them has been experimentally investigated. They are 
briefly explained below. However, the precise mechanism of immunomodulation 
induced by allogeneic blood transfusion has not yet been elucidated. 
1. Role of leukocytes (WBC). Some publications investigated the role of 
allogeneic WBC. They proposed that donor allogeneic leukocytes express 
mismatched HLA Class II antigens that react with recipient T-cells by increasing 
reactivity of the recipient's cytotoxic T -cells. The subsequent interaction between 
activated recipient cytotoxic T -cells and the blood donors' mismatched HLA Class 
II antigens leads to proliferation and differentiation of T-cells that down-regulate 
cell-mediated immunity in the recipient (Dzik, 1994b; Blumberg and Heal, 1996a; 
Blajchman, 1998; Vamvakas and Carven, 1998b; Vamvakas and Blajchman, 
2000). 
However, the results obtained with buffy coat-depleted blood components 
do not support the view that donor WBCs are the only cause of 
immunomodulation, since this appears to result at least in part from the 
allogeneic erythrocyte transfusion (Houbiers et aI., 1994a; Andersen et aI., 1998; 
Kirkley et aI., 1998; Mathiesen et aI., 1998; Innerhofer et aI., 1999a; Innerhofer et 
aI., 1999b). 
In recent rat study transfusion of leukocyte-depleted blood impaired 
intestinal anastomotic healing. Both allogeneic leukocyte-depleted blood and 
non-leukocyte-depleted blood were associated with an increase in anastomotic 
abscesses compared with the "no transfusion" group (Apostolidis et aI., 2000). 
2. Role of red blood cells (RBCs). Tarnvik and others showed that the 
response of human peripheral blood lymphocytes to mitogen was equally 
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enhanced by autologous and allogeneic erythrocytes (Tarnvik, 1970; Shau and 
Golub, 1988). In-vitro studies following a single blood transfusion demonstrated 
how RBCs increases T-cells suppressor numbers and function in response to 
Con-A and PHA and how monocytes increased the production of PGE2 (Gafter et 
al.,1992). 
Kalechman et al hypothesised that peripheral blood lymphocytes have 
receptors for autologous RBC that are barely expressed in the resting cells but 
become evident after mitogenic stimulation. They showed that T-cell proliferation 
in response to mitogens, production of TNFa, IFNy, IL-2, IL-6, and IL-2R 
expression on MNC were increased in the presence of autologous RBC 
(Kalechman et aI., 1993) 
3. Effects of storage. A series of investigations by Mincheff et al showed 
that blood storage contributes to the alteration of the recipients' immune system. 
In these studies, the role of leukocyte necrosis during refrigerated blood stored 
up to 2 weeks was studied. Production of IgM and IgG1 anti-donor antibody was 
increased as a consequence of transfusion of lysed donor leukocytes. In 
addition, transfusion of lysed donor leukocytes led to suppression of subsequent 
delayed hypersensitivity (OTH) to donor antigens, possibly through induction of 
anergy or apoptosis in allo-reactive recipient cells (Mincheff et aI., 1993; Mincheff 
et aI., 1995; Mincheff and Meryman, 1995). 
In a study by Mynster and et ai, the leukocytes of heparinised blood were 
collected from whole blood and SAGM (saline, adenine, glucose and mannitol) 
blood after 1, 21 and 35 days. These were stimulated and cultured by LPS and 
PHA to measure TNFa and IL-2 synthesis after PHA stimulation. IL-2 and TNFa 
synthesis decreased in both stored whole blood and SAGM blood compared to 
controls. After PHA stimulation TNFa synthesis was decreased and IL-2 was 
undetectable in LPS-stimulated cultures but the synthesiS of both cytokines was 
dependent on storage time. Thus, transfusion-induced immunomodulation blood 
storage may change with in storage time (Mynster et aI., 1998). 
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Zallen et al described how stored packed red cells can provoke neutrophils to 
release inflammatory cytokines including IL-8, IL-1, TNFa and secretory 
phospholipase A2 possibly leading to multiple organ failure after transfusion 
(Zallen et aI., 2000). 
In another study, increased levels of anaphylatoxins in whole blood and 
plasma were observed in refrigerated blood. Concentrations of the 
anaphylatoxins C3a and C5a increased during storage. The transfusion of large 
amounts of these activated complement components may increase the risk of 
developing organ dysfunction (Hyllner et aI., 1997). 
4. Other factors. In patients haemodialysed with cuprophane 
membranes, the number of NK cells and their cytotoxic activity against K562 
targets was significantly decreased, compared to patients haemodialysed with 
polyacrylonitrile membranes. This reduced NK function could be reversed by 
changing membranes from cuprophane to more biocompatible membranes (Cala 
et aI., 1990; Gascon et aI., 1996). 
In 1992, Riches et al showed that the anticoagulant lithium heparin 
induced IL-6 and IL-1 production in stored whole blood, whereas EOTA was 
ineffective (Riches et aI., 1992). 
In a randomised clinical trial comprising 697 transfused patients who 
underwent colorectal cancer surgery, plasma micro aggregates and citrate were 
insignificant as risk factors in post-operative infection (Houbiers et aI., 1997). 
In a review of patients who underwent elective surgery for gastric cancer a 
large quantity transfused blood (>1500 ml), that took longer to administer was 
associated with a worse clinical outcome (Bellantone et aI., 1998). 
Some publications suggested that soluble HLA Class I, C095 (Fas) and 
Fas ligand (FasL) molecules are present in blood components were biologically 
active in-vitro and may produce immunomodulation. These molecules, if present 
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In sufficient concentration, could inhibit mixed lymphocyte responses and 
cytotoxic T-cell activity in allogeneic and autologous combinations and induce 
apoptosis in CD95+ cells. Also, these molecules were able to down-regulate NK 
cell function via a receptor for Class I molecules (Ghio et aL, 2000; Puppo et aL, 
2001 ). 
Kirkley demonstrated an increase in anti-inflammatory cytokine synthesis 
In patients receiving allogeneic blood transfusion compared to those who 
received autologous blood. He proposed that shifting toward anti-inflammatory 
reaction may be attributed to allogeneic blood transfusion-induced 
immunomodulation (Kirkley et aL, 1998). 
In animal and human models, it was also shown an increased PGE2 
production in allogeneic transfused patients or animals (Ross et aL, 1990; Gaffer 
et aL, 1992; Perez et aL, 1998; Koga et aL, 2000). 
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1.8. Goals of this study 
1- Develop an in-vitro method for quantitating the absolute number of 
natural killer precursor (NKp) cells in the peripheral blood mononuclear cells. 
2- Measure the frequency of NKp cells before and after surgery and 
transfusions with: 
a) allogeneic or autologous blood 
b) allogeneic leukodepleted or allogeneic non-Ieukodepleted 
blood 
c) non-transfused patients 
3- Measure in-vitro synthesis of IFNy, IL-10 and IL-4 before and after 
surgery and transfusions. 
4- Investigate the correlation between immune system changes after 
major surgery and blood transfusions. 
5- Investigate whether CD56 is an adequate marker for measuring 
functionally active NK cells that lyse the K562 target cell line. 
6- Investigate the correlation between post-operative infections and 
the type of blood transfusion. 




Materials and methods 
2.1. Study patients 
2.1.1. Ethical approval 
The experiments described in this study were fully approved by the local 
hospital research ethics committee and informed consent was obtained from all 
volunteers. Patients were interviewed and informed about this study. If they 
agreed to take part, the voluntary consent was signed. 
2.1.2. Patient criteria 
All patients studied underwent elective total knee replacement (TKR) or 
total hip replacement (THR) surgery at the Avon Orthopaedic Centre, Southmead 
hospital, Bristol. Patients were excluded from the study if they had pre-existing 
infection, previous blood transfusion, malignancy, autoimmune disorders and 
diabetes. 
2.1.3. Sample collection 
Heparinised blood was collected from 125 patients who voluntarily took 
part in this study. The PBMC and plasma were separated later. The pre-
operative samples were collected at the orthopaedic assessment clinic, Avon 
Orthopaedic Centre, South mead Hospital. The post-operative samples were 
taken five days after operation on the wards. The blood samples of 29 patients 
who had signed the voluntary consent were not collected for the following 
reasons; seventeen cases for poor veins; five cases for diabetes; four cases for 
recent blood transfusion history. Samples from two patients were taken in the 
wrong anti-coagulant and one had cardiac problems that prevented the operation 
going ahead. 
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Seventeen post-operative samples were not collected, for different reasons: nine 
patients were discharged earlier than expected (before five days); two samples 
were not taken; four patients refused to be bled; one sample was lost and one 
patient was transferred to LT.U following cardiac arrest during his operation. 
Twelve patients were treated at a hospital other than the Avon Orthopaedic 
Centre where the pre-operative samples had been collected. There were five 
paired collected samples that were excluded from the study due to diabetes (2), 
recent blood transfusions (2) and pre-existing infection (1). 
2.1.4. Clinical Data 
Data collected from patients' medical records included: age; gender; 
admission haematocrit (Hct); white blood cell count; total absolute lymphocyte 
count before and after operation; surgical procedure; type of operation; diabetes 
history; length of hospital stay; days with fever more than 38°C; number and type 
of blood transfusions including post operative autologous blood collection; and 
postoperative infection including culture result and site of infection. 
2.1.5. Patient groups and numbers 
120 Patients were divided into five groups (Gp) according to the type of 
blood transfusion: 
• Gp-1: Allogeneic non-Ieukodepleted blood, 8 patients 
• 
Gp-2: AllogeneiC leukodepleted blood, 30 patients 
• 
Gp-3: Autologous post-operatively salvaged blood, 40 patients 
• 
Gp-4: Autologous pre-donated blood, 10 patients 
• 






The Neubauer counting chamber 
I I 'I I 
, i l 1 
'-T T 







Figure-6.2: Schematic diagram of the squares of the Neubauer counting chamber. The centre 
was used for counting PBMC. The four corner squares of chamber were used for counting when 
the number of PBMC in the centre square was below 100. 
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2.4. Cell freezing in Dimethysulphoxide (DMSO) 
2.4.1. Material 
20% Dimethyl sulfoxide (DMSO) medium 
200/0 DMSO medium consisting of RPMI 1640 (Sigma) supplemented with 
20% DMSO (Sigma) was stored at 4°C until required. Antibiotics containing 
penicillin and streptomycin (Sigma) were added prevent bacterial contamination. 
2.4.2. Method 
For preserving the viability of PBMC for future assays, cells were stored in 
liquid nitrogen. To prevent ice crystal damage to cells and maintain a viable 
state, cells were frozen in a mixture of fetal calf serum and DMSO. 
The cell suspension was diluted in CCM-1 containing 50%) FCS to 
concentration of 5 x 106 cells per ml and placed on crushed ice to cool. The 
20% DMSO medium was added drop-wise to an equal volume of the cell 
suspension giving a final concentration of 200/0 FCS and 10% DMSO medium. 
The cell suspension was dispensed into pre-cooled cryovials by putting them in 
crushed ice with between 5-15 x 106 PBMC per vial. All the procedures were 
carried out in a laminar flow hood. The cryovials were immediately placed in a 
freezing tray of a small liquid nitrogen container because DMSO is too toxic for 
cells using a 'plug' inserted into the neck of the Dewer flask. The cells were 
gradually frozen in the nitrogen vapour at a rate of approximately 1°C per minute. 
Cryovials were left in the small liquid nitrogen container for a minimum of 
two hours before being transferred to racks and stored in the liquid phase of a 
large liquid nitrogen tank at -190°C. 
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2.5. Thawing of cryopresevered cells 
2.5.1. Material 
Thawing medium 
Thawing medium consisting of RPMI 1640 (Sigma) supplemented with 20/0 
fetal calf serum (Sigma) and 3mM L-glutamine (Sigma) was stored at 4°C until 
required. 
2.5.2. Method 
Frozen cells were thawed carefully to prevent cell loss and preserve 
viability for functional assays. The comparison between frozen/thawed PBMC 
and fresh PBMC for NK cell functional assay in a healthy adult sample (AG) were 
shown to be comparable (see section 4.2.5). 
Cryovials were removed from the liquid nitrogen tank and immediately 
thawed in a pre-warmed water bath at 37°C, while being constantly swirled and 
mixed. When the mixture was almost thawed, small lumps of ice being still 
visible, the vial was wiped, dried with tissue and transferred to the laminar flow 
hood. Thawing medium was gradually added to the cryovials whilst mixing 
gently. Thereafter, the cell suspension was transferred to a 15 ml Falcon tube 
containing thawing medium and the remaining medium added over the next five 
minutes while being mixed gently, allowing the OM SO to diffuse out of the cells. 
All the procedures were carried out under laminar flow hood. 
The tube was centrifuged at 400 g for 10 minute, resuspended in washing 
medium, and centrifuged another 10 minutes at 1500 rpm. The supernatant was 
removed and the cell pellet resuspended in 1 ml of CCM-1 then counted. 
72 
2.6. NK precursor frequency (NKpf) cytotoxicity assay 
2.6.1. Principle 
The cytotoxic function of NK cells is usually determined by methods based 
on the release of different markers from the lysed target cells. In general, these 
markers are compounds containing radioactive isotopes such as 51 chromium, 
75 selenium, or titanium. I n the 1960s, Goodman introduced an in-vitro method 
to determine cytotoxic function of cells based on released radioactive 51 
chromium C1Cr) from lysed target cells. The 51Cr release assay is one of the 
most commonly used methods that is easy to perform, highly sensitive, non-toxic 
to the cells and gives low spontaneous release (Holm, 1967; Brunner et aI., 
1968). The method does not change the morphology or the characteristics of the 
target cells and detection is easy and sensitive and was extended to cover other 
cytolytic reactions (Berke and Amos, 1973; Kemp and Berke, 1973; Stulting and 
Berke, 1973). 
However, the use of 51Cr has some well-known drawbacks, such as: short 
life of labelling reagent; a radioactive waste problem; slow release making 
incubation time long (usually 4 hours) because 51Cr binds to cellular proteins in 
target cells in its ionic form, CrO/- and 51 Cr is only released when target cells are 
sufficiently damaged; health hazards that increase risk to working personnel; 
cumbersome equipment; and emission of gamma rays. 
This situation led to the development of a non-radioactive cytotoxicity 
assay using "Europium (Eu3+)" that was described for the first time by Blomberg 
and his co-workers in 1986. The detection of the released marker is based on 
time-resolved fluorometry, where the fluorescence from long-lived fluorescent 
probes is measured after short-lived background fluorescence has decayed. 
After release of the complex from lysed target cells, Eu3+ is chelated with a p-
diketon known as enhancement solution. This chelate is highly fluorescent and 
can be quantified by time-resolved fluorometry. The chelate reduces the 
background fluorescence and enhances the sensitivity of the assay. Also, the 
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fluorescent decay time of Eu chelates is in the range of 100-1 OOOns compared to 
10-20ns decay times for fluorescent biological samples (Blomberg et aI., 1986b; 
Blomberg et aI., 1986a; von_Zons et aI., 1997). 
The method is simple, sensitive, specific and rapid (2-3 hours incubation 
time) because Eu-OTPA is an inert chemical complex that does not bind to 
cellular proteins in target cells, and there are no health hazards. Finally, for the 
measurement of NK cell activity in many samples such as a population study, a 
cytotoxicity assay using non-radioactive reagents is desirable. This method has 
been used to measure human NK cell activity, cytotoxic T lymphocyte (CTLs) 
activity, Iymphokine-activated killer (LAK) cell activity and complement-mediated 
cytolysis (Hem mila et aI., 1984; Blomberg et aI., 1996; Nagao et aI., 1996; Haque 
et aI., 2001). 
2.6.2. Limiting dilution analysis (LOA) 
The limiting dilution analysis (LOA) allows the frequency of a particular 
cell in a population of cells to be estimated per unit volume of solution. LOA is 
used in many areas of bio-research including immunology, bacteriology and cell-
biology. LOA differentiates between a positive or negative response in each well 
of an experiment. The proportion of negative wells is used to estimate the cell 
frequency. A negative well assumes that there is no cell of the type being 
measured. By contrast, a positive well demonstrates that there is one or more 
such cells. The positive wells cannot be used to estimate the cell frequency 
because it is unclear how many cells give the response in each individual well 
(Strijbosch et aI., 1987; Strijbosch et aI., 1988). 
The percent of the replicated wells at each responder cell dilution that 
were negative was recorded and plotted against the responder cell concentration. 
The point on the plot where 37% of the wells were negative corresponded to an 
average of one NK cell per well. On the basis of this assumption, the NKpf was 
calculated, using a computer program. This gave the mean NKpf plus 95% 
confidence intervals. It also calculated the goodness of fit (g.oJ). If g.oJ was> 
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15, results could not be attributed to single hit kinetics, i.e., probably more than 
one cell type was responsible for cytolysis (Strijbosch et aI., 1987; Strijbosch et 
aI., 1988). 
2.6.3. Materials 
a) Human AB serum (Sigma) 
AB serum from healthy male individuals was heated at 56°C for 30 
minutes. This was aliquotted and stored at -20°C. 
b) Human AB serum (Quest) 
AB serum pooled from non-transfused healthy male individuals had been 
heated and sterile filtered by Quest-Bio medical. This was aliquotted and stored 
at -20°C. 
c) Complete culture media (CCM-2) 
Complete culture medium (CCM-2) consisted of RPMI 1640 (Sigma) 
supplemented with 10% heat inactivated human AB serum from normal healthy 
male donors (Sigma) and 3mM L-glutamine (Sigma). Antibiotics were not added 
to CCM-2 as this reduced assay sensitivity. 
d) Recombinant Interleukin-2 (rIL-2) 
Each vial of r1L-2 (Eurocetus, Amsterdam) contained 18 x 106 IU = 3x 
106Cetus unit. 3 ml of PBS were added to the vial and mixed well until dissolved. 
This gave a concentration of 1 x1 06 Cetus Units per ml, that was diluted further to 
1: 10 with PBS (1 x1 05 Cetus unit per ml). This stock solution was stored at -20°C. 
Prior to use in the culture a vial of stock solution was thawed and diluted further 
1:10 by adding 1 ml of stock to 9 ml of filtered RPMI and then storing at -20°C. At 
this concentration (1 x1 04 Cetus Units per ml) 11J1 contained 10 Cetus Units. 
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e) Recombinant Interleukin-15 (rIL-15) 
Each vial of r1L-15 (R&D, UK) contained 5~g of the Iyophilised rIL-15. 1.0 
ml of sterile phosphate-buffered saline containing 1 % human serum albumin was 
added to the vial and mixed well until dissolved. The concentration of this stock 
was 10ng/ml. This stock solution was aliquotted and stored at -20°C. For use, in 
the culture, the contents of each stored vial (20 ~I) were added to 50ml RPMI to 
give a concentration of 10ng/ml. 
f) Preparation of irradiated allogeneic stimulator cell pool 
PBMC were prepared by Ficoll-Isopaque gradient from four healthy 
randomly selected apheresis donors. PBMC were pooled and then irradiated (30 
Gy) using a Cobalt source. 
g) Phosphate buffer saline (PBS) 
Stock solution of 0.05 molar (M) concentration of each buffer was made up 
with 3.45g sodium di-hydrogen phosphate (NaH2P04 H 20), and 3.55-g di-sodium 
hydrogen phosphate (Na2HP04) dissolved in 500 ml H20. Thereafter, 95 ml of 
NaH2P04 plus 405 ml Na2HP04 were mixed and 4.5g sodium chloride added. 
The pH was checked and adjusted to 7.4 and stored at 4°C until use. 
h) HEPES Buffer 
50 mM HEPES (5.958 g), 93 mM sodium chloride (2.178 g), 5 mM 
potassium chloride (0.187 g) and 2 mM magnesium chloride 6H20 (0.204 g) were 
weighed out and dissolved in 500 ml of distilled water. The pH was adjusted to 
7.4 and stored at 4°C. 
i) Calcium chloride 
I) 100 mM solution: 0.147 mg was dissolved in 10 ml of sterile distilled 
water. 
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II) 1 M solution: 1.47 g was dissolved in 10 ml of sterile distilled water and 
stored at -20°C until required. 
j) Diethylene triamino pentacetate (DTPA) 
98.33 mg of 25 mM OTPA was dissolved In 10 ml of 0.01 M sodium 
hydroxide by heating in a water bath at 60-650C for 1 hour and storing at -20°C 
until required. 
k) Europium chloride (EuCI3) 
36.9 mg EuCI3 was dissolved in 0.01 M HCL and stored at -20°C. 
I) Dextran sulphate 
100 mg of dextran sulphate was dissolved in 10 ml of sterile distilled water 
at 37°C. This was divided into aliquots of 0.5 ml and stored at -20°C until 
required (not filtered). 
m) Triton 
Triton x -100 was made up to 2% triton by dissolving in PBS solution and 
storing at 4° C until required. 
2.6.4. Method 
2.6.4.1. Setting up the NKpf assay 
The principles of LOA are illustrated as follows. PBMC was titrated in 
seven two-fold dilutions in CCM-2. The two-fold cell dilutions ranged from a 
concentration of 4X104 and to 0.0625X104 PBMC per 1 OO~I/well in a 96-well, 
round-bottomed Falcon, culture plate (i.e. 4X104 , 2X104 , 1 X1 04, 0.5X104 , 
0.25X104 , 0.125X1 04 , 0.0625X104 ) using 24 replicates per dilution. The baseline 
control consisted of 1 OO~I of CCM-2 medium alone without PBMC. The assay 
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plates were incubated for 1 to 10 days at 37°C in 5% C02 in a humidified 
atmosphere. All the procedures were carried out under laminar flow hood. 
2.6.4.2. Addition of r1L-2 and r1L-15 
After adding the dilution of PBMC to the wells, the r1L-2 (Eurocetus, 
Amsterdam) in CCM-2 was added to cultures to give a final concentration of 25 to 
50 Cetus units/ml. This implies 2.5-5.0 Cetus units/well. The r1L-15 (R&D, UK) 
was similarly diluted to a final concentration of 10 or 20 ng/ml, depending on the 
experimental conditions. Both r1L-2 and r1L-15 were added on day 0 when setting 
up the assay and during feeding on day 5. All the procedures were carried out 
under laminar flow hood. 
2.6.4.3. Adding the irradiated allogeneic stimulator cell pool 
The pooled irradiated PBMC were added in a single concentration of 
50,000 cells per 100 J.l1/well to responders on day zero and incubated at 37°C in 
5% CO2 in a humidified atmosphere for 1,5 and 7 days. 
2.6.4.4. Incubation time and feeding cultures 
The duration of incubation varied through1B hrs, 5, 7 or 10 days. The 7 
and 10 days assays were refreshed with CCM-2 on day 5. 
2.6.4.5. Culture and maintenance of K562 cell lines 
The HLA negative NK sensitive human erythro-Ieukaemic cell line, K562 
(ECACC, UK) was used as a target for quantitating NKpf. The cell line was 
grown in stationary suspension cultures consisting of RPMI 1640 supplemented 
with 2% AB serum (Sigma) and 3mM L-glutamine (Sigma) in vented tissue 
culture flasks (25 cm2, Falcon). To ensure optimal growth, culture media were 
replaced on the second day and harvested on days 4 to 5. The cell line was 
regularly screened for mycoplasma (Mycloplasma Test Medium Kit, Sigma). All 
the procedures were carried out under laminar flow hood. 
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2.6.4.6. Eu-Iabelling of K562 target cells 
The K562 cell line was transferred from culture flasks into a 50 ml 
polypropylene tube (Falcon) and centrifuged at 400g for 10 minutes in the cold 
temperature (4°C). Cells were washed twice with PBS. The approximate cell 
counts were performed after the first wash to calculate the amount of europium to 
be added. Labelling buffer consisted of 1 mL HEPES buffer (Sigma), plus 40/-l1 of 
a solution of 100/-lM Diethylene triamino pentacetate (DTPA, Sigma), plus 20/-l1 of 
a 20/-lM solution of europium chloride (EuCb, Fluka). Then one ml of labelling 
buffer and 50/-l1 of a solution of 500mM dextran sulphate (Fluka) were added to 
each 5x106 K562 cells to increase cell permeability and allow the Eu-DTPA 
complex to enter the cell. The cell suspension was incubated for 15 minutes at 
4°C and gently, but thoroughly mixed between incubations. After 15 minutes, 
30/-l1 of a 100mM solution of CaCI2 was added to stop the labelling reaction and 
then incubated for a further 10 minutes at 4°C. After a total of 25 minutes 
incubation, the K562 cells were washed four times with a washing buffer 
containing, RPMI 1640, 3mM L-glutamine and 79/-l1150ml of 1 M CaCb and 
centrifuged at 300g for 6 minutes at 4°C. Thereafter, they were washed twice with 
CCM-2 and centrifuged at 400g for 6 minutes at 4°C. Finally, the Eu-DTPA 
labelled cells (Eu-K562) were re-suspended in CCM-2 and adjusted to the 
desired count for cytotoxicity assays. All the procedures were carried out at 4°C. 
2.6.4.7. Quantitation of cytotoxicity 
The last stage of the NKpf assay was performed by adding 5,000 to 
10,000 Eu-K562 in 100/-l1 to each well in a 96-well culture plate. At the same time 
as each cytotoxicity assay, a control plate was set up to control the reagents used 
and to determine spontaneous release. The control plate was set up with16 
replicates for each reagent used in the assay including, CCM-2 only, triton only, 
enhancement solution only, CCM-2 plus triton, Eu-K562 plus CCM-2 and Eu-
K562 plus triton. 
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All plates were briefly centrifuged at 200g at room temperature for one minute to 
accelerate the reaction, and then incubated for 3 hours at 37°C in 5% CO2 in 
humidified atmosphere. After incubation, plates were again centrifuged for 5 
minutes at 600g at room temperature (RT). 
Thereafter, 20J.l1 aliquots of supernatant from each well of the assay plate 
were transferred to a new reader plate (Nunc) pre-filled with 200J.l1 of 
enhancement solution. Finally, Eu-OTPA release was read in counts per second 
(c.p.s.) in a time resolved fluorometer (Oelfia, Finland). The spontaneous release 
was determined by incubating target cells with CCM only, and maximum release 
was obtained by lysing the target cells with 2% Triton X-100. The percent 
spontaneous release was calculated by dividing spontaneous release by 
maximum release and multiplying by 100. If spontaneous release was > 15% 
assays where discarded. 
The fluorometer reading was in c.p.s.. The mean and standard deviation 
(SO) between replicate wells of the baseline culture was calculated. Any test-well 
that exceeded the baseline plus three times the SO was scored "positive" and 
any test-well value below baseline plus three times the SO was scored "negative". 
In summery, using the principle of LOA, an NKpf assay was performed by 
the Eu release method. This fluorescence assay is used for quantitation of 
natural killer cell precursor. The K562 target cells were labelled with Eu-OTPA 
chelates, a complex that is chemically inert. The Eu-OTPA has the advantage of 
being relatively small and therefore able to leave the target cells just after they 
are rendered permeable by exposure to Perforin/Granzymes produced by 
responder cells. 
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2.7. Cytokine analysis by ELISA 
2.7.1. Principle 
A solid phase sandwich ELISA (Enzyme-Linked Immunosorbent Assay) 
was used to measure the cytokine levels. The method was designed in the early 
1970s and has been shown to be a sensitive technique for the rapid detection of 
serum proteins, circulating antibodies, and cell-surface antigens and cell 
products. The specific monoclonal antibody for each cytokine, called a capture 
antibody (Ab), is coated to a 96-well immunosorbent plate. The samples and 
standard dilutions were added to appropriate wells along the plates and any 
specific cytokine (Ag) present in the samples bound to the coated specific 
antibody. The second antibody acting against the one measuring specific 
cytokine was added to each well. If the first Ag-Ab complex developed, the 
second complex Ab-Ag-Ab (sandwich) was produced (Beech et aI., 1997; Ishijima 
and Suzuki, 199B). 
The supernatants of parallel cultures for pre and post-operative samples 
were collected after 5 days culture containing CCM-2, 25 Cetus unitlml r1L-2 and 
10 ng/ml rIL-15, and kept at -BOoC until required. The ELISA assay was used to 
measure IL-10, IL-4 and IFNy. 
2.7.2. Materials 
a) Bicarbonate Buffer 
0.636 g Na2C03 (Sigma) and 1.172 g NaHC03 (Sigma) were dissolved in 
400 ml distilled water, adjusted to pH 9.6 and stored at 4°C until required. 
b) Coat plate for IFNy ELISA assay 
15~g of IFNy capture antibody solution (Pharmingen, CA) was added to 
5ml bicarbonate buffer then 50 ~g of this solution multi-pipetted across the Nunc 
immunobsorbent plates (Nalge Nunc, Denmark). The plates were gently tapped 
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to ensure antibody solution completely covered the base of the well. The plate 
was covered with a lid or sealing strip and stored at 4° C until required. 
c) Coat plate for IL-10 ELISA assay 
35J-lg of IL-10 capture antibody solution (Pharmingen, CA) was added to 
5ml bicarbonate buffer then 50 J-lg of this solution multi-pipetted across the Nunc 
immunobsorbent plates. The plates were gently tapped to ensure the antibody 
solution completely covered the base of the well. The plate was covered with a 
lid or sealing strip and stored at 4° C until required. 
d) PBS/~. 1 % tween solution 
10 g PBS (Sigma) was weighed out and dissolved in 1000 ml of distilled 
water then 3ml tween (Sigma) added and mixed and stored at RT until required. 
e) PBS/1 % Bovine serum albumin (BSA) solution 
1 g PBS (Sigma) and 1 g BSA (Sigma) were dissolved in 100 ml of distilled 
water and stored at RT until required. 
f) Preparation of reference solutions for in IFNyassay 
15 minutes before use, cryopreserved stock tubes of IFNy (Pharmingen, 
CA) were removed from _BOo C thawed and diluted as described below: 
For the top reference standard, 75J-l1 of IFNy stock was added to 175 /-11 
RPMI (Sigma) at a final concentration of 30ng/ml. For the high quality control, 
10J-l1 of IFNy stock was added to 490 J-li RPMI to give a concentration of 2ng/ml. 
For the low quality control, 2.5 J-li of IFNy stock was added to 497.5 /-11 RPMI to 
give a concentration of 0.5ng/ml. All solutions were mixed gently before adding 
to the assay. 
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g) Preparation of reference solutions for IL-10 assay 
15 minutes before use, the stock tubes of IL-10 (Pharmingen, CA) were 
removed from -80° C and thawed and diluted as described below: 
For the top reference standard, 25!J.1 of IL-10 stock was added to 225 !J.I 
RPMI (Sigma) to give a final concentration of 10ng/ml. For the high quality 
control, 5!J.1 of IL-10 stock was added to 495 !J.I RPMI to give a concentration of 
1 ng/ml. For the low quality control, 1 !J.I of IL-1 0 stock was added to 499 !J.I RPMI 
to give a concentration of 0.2ng/ml. All solutions were mixed gently before 
adding to the assay. 
h) Preparation of detection antibody solution for IFNyassay (per plate) 
15 minutes before use, 17.5 !J.I of the biotinylated anti-I FNy antibody 
(Pharmingen, CA) was removed from 4° C, then added to 5 ml PBS/ 1 % BSA 
solution and mixed well. 
i) Preparation of detection antibody solution for IL-10 assay (per plate) 
15 minutes before use, 15 !J.I of the biotinylated anti-IL-10 antibody 
(Pharmingen, CA) was removed from 4° C, then added to 5 ml PBS/ 1 % BSA 
solution and mixed well. 
j) Streptavidin peroxidase (per plate) 
15 minutes before use, 5 !J.I of the Streptavidin peroxidase (Sigma) was 
removed from 4° C, then added to 5 ml PBS/ 1 % BSA solution and mixed well. 
k) TMB (3,3,5,5 tetramethyl benzidine) /OMSO 
100 mg TMB (Sigma) was weighed out and dissolved in 10 ml of DMSO 
(Sigma) then aliquotted at 0.5 ml per bottle and stored at _20° C until required. 
The final concentration of this stock was 10mg/ml TMB in DMSO. 
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I) Phosphate Citrate Buffer 
3.6459 g Na2HP04 (Sigma) and 2.553 g Citric acid.H20 (Sigma) were 
weighed out and dissolved in 500 ml distilled water and stored at 4°C until 
required. 
m) TMBIOMSOIH20 21phosphate citrate solution (per plate) 
3 ~I H20 2 (Sigma) and 1 00 ~I of thawed TMB/DMSO were added to 10ml 
phosphate citrate (Sigma) mixed well and kept at RT until required. 
2.7.3. Method (measurement of IFNy and IL-10) 
Nunc immunosorbent plates (Nunc, Denmark) coated with captured 
antibodies specific for either IFNy or IL-10 (Pharmingne, CA) was stored at 4°C 
overnight. Plates were then blocked with 200~1 PBS 1010 bovine serum albumin 
(Sigma) and kept at 37°C for one hour. After the desired incubation time, plates 
were washed twice with PBS/O.1 0/0 tween, and twice with PBS. The left-over PBS 
in the plates prevented them from drying out before samples, standards and 
blanks were added. Standard dilution curves, and high and low quality controls, 
were prepared. PBS was emptied from the plates by decanting and tapping them 
on soft tissue. 50~1 of diluent (RPMI) was applied to the standard wells in 
duplicate across the plates except for the top standard wells to make up the 
volume to 1 00~1. 1 OO~I of top standards for either IFNy or IL-10 were transferred 
into the top standard wells. Rinsing the pipette tip allowed mixing of the well 
contents. 50~1 of the top standard were aspirated, and added to the next wells. 
This serial dilution continued to the lowest concentration of the standard wells 
across the plates. Then, 50~1 aliquots of cultured supernatant for test samples, 
blanks (RPM I), and high and low controls were transferred into appropriate wells 
along the plates and incubated for 2 hours at room temperature (RT). After 
incubation, the plates were rinsed four times by PBS/O.1°/0 tween, and after the 
last time, they were decanted by tapping on soft tissue to remove any residual 
PBS/O.10/0 tween. They were then reacted with 50~1 aliquots of detection 
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antibodies (Pharmingne, CA). Plates were left for one hour at RT then rinsed six 
times with PBS/O.1 % tween, and after the last time decanted by tapping on soft 
tissue to remove any residual PBS/O.1 % tween. 50/-11 streptavidin peroxidase 
(Sigma) was added to each well and left for a further 30 minutes at RT. Plates 
were rinsed six times and 100/-11 TMB/H202/phosphate citrate (Sigma) added. 
When the blue colour started to show in the penulimate standard, 50/-11 of 2M 
H2S04 was added to stop the reaction. Finally, absorbance at 450nm within 30 
minutes of stopping the reaction was read on the scanner (Dynatech, UK). 
2.8. Measurement of IL-4 
100/-11 of standard diluent was pipetted into each standard well across the 
coated plates in duplicate, except for the highest standard wells (30pg/ml), for 
which 100/-11 of the highest standard was added into the second top standard 
wells. Rinsing the pipette tip allowed mixing of the well contents. 100/-11 of 
standard was aspirated and serially diluted and continued to the lowest 
concentration of the standard wells to give a range between 30-0.47 pg/ml. 
Then, 100/-11 aliquots of culture supernatants, blanks and positive controls were 
transferred into appropriate wells along the plates in duplicate. Plates were 
covered with plate sealer and incubated for two hours at RT. The contents of the 
wells were decanted and the plates rinsed four times with PBS/O.1 % tween, and 
after the last time, decanted by tapping on soft tissue to remove any residual 
PBS/O.1 % tween. 100/-11 of prepared working detector (Pharmingne, CA) was 
added to each well and plates were covered and left for another hour at RT. 
After incubation well contents were decanted and plates rinsed seven times with 
PBS/O.1 % tween, and after the last time, they were decanted by tapping on soft 
tissue to remove any residual PBS/O.1 % tween. 100/-11 of prepared substrate 
solution was pipetted into each well and the plates incubated at RT for 30 
minutes. After incubation 50/-11 of stop solution was added to each well. Finally, 
the absorbance at 450nm was read on the scanner (Dynatech, UK) within 30 
minutes of stopping the reaction. 
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2.9. Immunophenotyping studies 
The PBMC were set up in parallel cultures under various conditions 
mentioned above. At 5 days, cells were collected from culture plates and 
adjusted to 1 x1 06 cells per ml in RPMI 1640. 5/-l1 (1/-lg) of each antibody was 
added to 100 /-ll of cell suspension at 1 x1 05 / ml, and mixed. The cell/antibody 
mixture was incubated at 4°C for 30 minutes, washed once at 700g for 10 
minutes and re-suspended in 300/-l1 of RPMI 1640. Finally, the flow cytometric 
analysis was performed on a Coulter Epics®XL (Luton, UK). 
Monoclonal antibodies specific for the human cell differentiation (CD) 
marker were used for two-colour flow cytometric analysis of CD3-CD56+, and 
CD3-CD16+ cells. Monoclonal antibodies directly conjugated to fluorochromes 
and controls were CD56 fluorescein isothiocyanate (FITC) (Becton Dickinson, 
UK), CD16 FITC (DAKO), CD3- phycoerythrin (PE) (DAKO) and FITC neg. 
(DAKO). The CD16+ and CD56+ population was calculated as a percentage of 
the total CD3- cell population by flow cytometric analysis. Figure-7.2 
demonstrates the gates that were used for enumeration of CD3-CD56+ cells by 
flow cytometry. Cells of interest were defined as those expressing CD56 or CD16 
in the CD3 negative population. These were selected using electronic gating with 
double staining by combined antibodies against the CD3 and CD56 or CD3 and 
CD16. The CD3- cells were selected by drawing the region (B) horizontally 
against the region (A) in gate-2 and only the cells in region (B) were analysed for 
the next step. After identification of CD56+ or CD16+ cells in the CD3-
population, identified cells were selected in gates-3 by drawing region (C) 
vertically against the gate-3 in CD3- population. A histogram of CD56 or CD16 
expression was shown in region (D) in gate-4. Cells in region (C) or (D) were 
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Figure 7-2: Schematic diagram of different gates using for enumeration of C03-C056+ cells . Flow cytometry dot plots gated on C03-
cells (B) show populations defined by reactivity with C056 MAb (C). Upper left quadrant forward versus side scatter; upper right, C03-
cells (inside gate B), lower plots show expression of C056 positive cells in C03- population gated vertically by B. Lower left shows a 








3.1. Student t-test 
Student t-test compares the means of two samples between two 
underlying groups whether there is a significant or not significant of the difference 
between the means of two samples. The p-value (the probability value or 
significance level) is used to determine significant or non-significant of results. If 
the p-value equals or less than 0.05 (p<0.05), there is a significance difference 
between the means of two samples group. By contrast, if the p-value is more 
than 0.05 (p>0.05), there is no significant difference between the means of two 
samples (Bradford Hill, 1988; Campbell and Machin, 2001). 
3.2. Confidence intervals 
Confidence intervals (CI) indicates the precision of study estimates as 
population values and the width of confidence intervals is associated with the 
standard deviation (SD) and the sample size of a normally distributed set of 
values. 95% confidence intervals (95% CI) is the most common choice that 
determines that, if the experiment is repeated one hundred times 95 of the values 
would be included in the upper and lower parameters (Bradford Hill, 1988; 
Campbell and Machin, 2001). 
3.3. Standard deviation 
The standard deviation (SD) is a measure of the variability or scatter of the 
observations between individuals, around the average value (the mean) of the 
sample being investigated. The standard deviation is usually signed as '~SD' in 
publications (Bradford Hill, 1988; Campbell and Machin, 2001). 
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3.4. The correlation coefficient 
The correlation coefficient (r-squared value) measures the relation 
between two or more variables in a group of subjects. The correlation coefficient 
is a number between -1 and +1. The correlation coefficient is signed as "r" in 
publications. The value between zero and one (0<r<+1) indicates there is a 
positive linear relationship between two characteristics of a population (r is 
positive). Thus two characteristics are positively correlated implying that low or 
high value of one characteristic of a population correlate with low or high level of 
another characteristic in same population respectively. By contrast, a value 
between zero and minus one (-1zr<0) indicates there is a negative correlation (r 
is negative) between two characteristics of a population. Thus negative 'r' implies 
that low value of one characteristic of a population correlates with high level of 
another characteristic in the same population and vice-versa. Finally, a value 
equal to zero (r=O) indicates there in no correlation between two values implying 
that low or high value of one characteristic of a population do not correlate with 
low or high level of another characteristic in same population being investigated 
within a population (Bradford Hill, 1988; Campbell and Machin, 2001). 
3.5. Analysis of limiting dilution data 
The mean and standard deviation Eu-release of the control containing only 
CCM-2 medium and Eu-K562 without PBMC are calculated. If the value of each 
Eu-release assay wells is less than the mean plus three standard deviation 
(mean+3S0) of Eu-release of the control wells, these assay wells are scored as 
negative. Then the numbers of negative wells within each replicate and the total 
number of replicates are used to determine the frequency of a particular cell 
(NKp) in a population of cells (PBMC). The numbers of negative assay wells are 
recorded and plotted against the responder cell concentration and the numbers 
of replicates. The point on the plot where 37% of the wells are negative 
corresponds to an average of one particular cell (e.g. NKp) per well. Using this 
assumption, the NKpf was calculated in this study with a computer program 
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based on the generalised linear interactive modelling (GUM) software package 
(Taswell, 1981; Strijbosch et aI., 1987). 
3.6. Median 
The median is a particular value that equally divides the distribution of a 
variable. Thus median determines that the half of the values of a variable are 
greater than the median, and half of the values are less (Bradford Hill, 1988; 




4.1. Development a method for quantifying natural killer precursors (NKp) 
The frequency of natural killer cell precursors (NKpf) was measured in 
human peripheral blood mononuclear cell (PSMC) samples, where functional 
maturity was reflected in lysis of K562 target cells. Initial experiments defined the 
factors influencing the NKpf. A method for quantitating the absolute number of 
natural killer precursor (NKp) cells was then developed. The technique was 
based on the principle of limiting dilution analysis (LDA). The NKpf assay was 
set up with a range of cell dilutions from 40,000 to 625 per 1 OO~I/well in 96-well 
culture plates in different culture conditions. At the end of the culture period, the 
K562 cell line labelled with Europium (Eu-K562) was added and Eu release was 
measured in culture supernatants using time-resolved fluorometry. To avoid 
individual variation during the development of the technique, venous blood was 
taken from one healthy adult (AG) at different times. The NKpf estimates were 
expressed as a mean of 24 replicates with 95% confidence intervals (95%CI). 
The significance of the difference between NKpf results for each group was 
analysed with the two-tailed student It' test. Results were expressed as a mean 
NKpf with 95% CI estimate plotted on a Log1o scale with 95% confidence 
intervals. 
4.1.1. Effect of culture duration and timing of r1L-2 addition 
These experiments were performed to define the influence of added r1L-2 
and culture duration on NKpf. Figure-8.4 shows the results obtained from 3 to 7 
different experiments. PSMC were cultured in CCM-2 containing heat inactivated 
Sigma-AS for 1, 5, 7 and 10 days incubation in the absence and presence of rlL-
2 at 25 Cetus units/ml. The r1L-2 was added on the day of set-up (day 0) of the 
assay and during feeding on day five. 
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Culture in the absence of IL-2, resulted in the rapid decrease of the NKpf (per 106 
PBMC) from 63+ 6 on day one, 10±4 on day five, 3±1 on day seven and 4±2 on 
day ten. NKpf was almost immeasurable after seven days (fig-B.4a). By 
contrast, when r1L-2 was added, NKpf increased rapidly from 105±4 on day one, 
BOO±145 on day five, 1026±206 on day seven and 1255±123 on day ten. The 
increment between days one and five implied rapid maturation of non-functional 
precursor (NKp). The small but significant increment in NKp numbers between 
days five and ten after adding extra r1L-2 on day five implied that even at this time 
cultures contained NKp at different stages of maturation (p<0.004 between days 
5&10) (fig-B.4b). 
The lower limit of detection was one NKp per 106 PBMC (fig-B.4a). The 
maximum NKpf detected after seven days of culture was 2,450 NKp per 106 
PBMC (0.25%), obtained from experiments with r1L-15 (see fig-12.4 below). 
4.1.2. Effect of extra r1L-2 on day 5 
These experiments were designed to observe the effect of extra r1L-2 
added during feeding on day five. Figure-B.4c shows the results obtained from 4 
different experiments, when PBMCs were cultured for 5, 7 and 10 days after 
adding 25 Cetus units/ml rIL-2, only on day o. There was no significant 
difference between NKpf estimates between days five and ten (776±151 on the 
five, B16±174 on day seven and B21±19B on day ten). By contrast, when extra 
r1L-2 (25 Cetus unitlml) was added, on day five, the NKpf rose from 761±160 at 
five days to 1 043±137 at seven and 1134+131 at 10 days (fig-B.4d). There was 
no significant difference between days 7 and 10 but both differed from the day 5 
result (p<0.005) (fig-B.4d). 
However, the absence of a significant difference between days five and 
ten, without additional r1L-2 on day 5 suggested that a fraction of late maturing 
NKp became IL-2 sensitive during the latter period of culture (fig-B.4c). This was 
confirmed when additional r1L-2 was added on day five in a second experiment in 
which NKpf was significantly augmented between five and seven days (p<0.004) 
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(fig-B.4d). In most cases, NKpf reached a plateau between seven and ten days 
(p>O.4), suggesting that all available r1L-2 sensitive precursors had been 
activated (fig-B.4c-d). 
These results confirmed that the differentiation of NKp and maintenance in 
culture was dependent on the continued presence of rIL-2, and that the full 
potential NK function was reflected only in NKpf assays cultured to maturity over 
seven days. 
Notwithstanding this observation, all ensuing assays were terminated at 
day five; the rationale being that of technical simplicity and greater sensitivity 
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Figure-8.4: Mean NKpf (95% CI) plotted at different times of culture on a log10 scale ranging from 1-104 in a and b 
and 10-104 in c and d. a) no added cytokines, p<0.05 between day 1&5; b) r1L-2 added on days one and five 
together with fresh CCM-2, p<0.05 between days 1&5, 5&7, 5&10 and p>0.05 between day 7&10; c) r1L-2 added 
on day zero but only fresh CCM-2 on day five, p<0.05 between days 1&5, p>0.05 between days 5&7, 5&10 and 
7&10, d) r1L-2 added on day zero and day 5 in fresh CCM-2, p<0.05 between days 1&5,5&7 and 5&10, p>0.05 
between day 7&10. Results are from three to seven experiments with cells from AG. 
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4.1.3. Effect of allo-activation 
The effect of activating NKp with a pool of irradiated allogeneic cells on 
day 0 was investigated. Figure-9.4 shows the results obtained from five different 
experiments in which PBMCs were co-cultured for 5 days with an irradiated pool 
of allogeneic cells with or without r1L-2 added on day zero. 
Allogeneic cells without added r1L-2 gave an NKpf estimate of 190±82. 
When r1L-2 was added, this rose to 1919±307 compared with r1L-2 alone, which 
gave 1044+169 suggesting two hypothesis: firstly, r1L-2 may have rescued NK 
progeny destined for apoptotic cell death; secondly, allo-activation may stimulate 
a separate subset of NKp, termed NKT-cell precursors (NKTp) that have the 
hallmarks of both thymus processed T and non-thymically processed NK cells. 
Alloactivation plus r1L-2 gave significantly greater NKpf estimates than r1L-2 
alone, (p<0.05) suggesting that additional differentiation signals may have been 
generated in the culture. 
This concept was tested in a single experiment where the increment 
between r1L-2 and r1L-2 plus allo-activation was estimated on days one, five and 
seven and found to be significantly different. After one day of culture in the 
presence of an irradiated pool of allogeneic cells added on day zero only, the 
NKpf (95% CI) rose rapidly from 26 (18-34) to 83 (58-108) and 152 (113-192) 
respectively. In the presence of r1L-2 at 25 Cetus unitlml alone NKpf (95% el) 
rose rapidly from 55 (41-69) to 517(471-864) to 762 (629-899) respectively. 
Finally, when an irradiated pool of allogeneic cells and r1L-2 were added on day 
zero and five, NKpf (95% CI) rose rapidly from 86 (71-99) to 683 (593-775) to 877 
(710-1025) respectively (fig-1 0.4). This increment persisted until day seven 
(p<0.001) supporting the view that an allogeneiC stimulus was associated with 
activation of an additional cell subset. 
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Figure-9.4: Mean NKpf (95% CI) after five days of culture plotted on a log10 scale ranging from 102-104 
after co-culturing with an irradiated pool of allogeneic cells with or without added r1L-2 (25 Cetus units/ml) 
alone on day zero p<0 .05 between alloactivation alone and only rIL-2. between only r1L-2 and 
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Figure-10.4: Mean NKpf (95% CI) after one, five and seven days of culture plotted on a log10 scale ranging 
from 1-104 after co-culturing with an irradiated pool of allogeneic with or without added r1L-2 (25 Cetus 
unitlml) on day zero and day 5. p<0.05 between days 1&5, 1&7 and 5&7 in all above conditions. Results 








4.1.4. Effect of r1L-15 on NKpf estimates 
r1L-15 was a candidate cytokine that may have accounted for some of the 
allo-activation effect. Therefore, adding r1L-15 to the culture was investigated in 
the knowledge that it played a pivotal role in differentiation of NK cells from their 
progenitors and shared many functions ascribed to IL-2. Figure-11.4 shows the 
NKpf estimates with different concentrations and combinations of r1L-2 and rlL-
15. 
Thus NKpf estimates were highest, when PBMC were cultured with r1L-15 
at 10-20 ng/ml. Indeed, these levels were significantly higher than with r1L-2 at 
50 Cetus unit/ml alone (p<0.05). Furthermore, no incremental effect on NKpf 
resulted from the addition of r1L-2 to rIL-15. 
Figure-12.4 shows the results obtained from 4 different experiments, for 
which r1L-15 alone, or r1L-15 plus r1L-2 gave significantly greater NKpf estimates 
than r1L-2 alone (p<0.05). Additionally, in presence of r1L-2 at 25 Cetus unitlml 
NKpf (±SO) was 622+79, in presence r1L-15 at 10ng/ml 1924±180 and finally, in 
presence of r1L-2 at 25 Cetus unitlml plus r1L-15 at 10ng/mI2014±229. This 
confirmed that r1L-15 alone is significantly (p<0.05) more effective in driving 
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Figure-11.4: Mean NKpf (95% CI) after 7 days of culture plotted on a log10 scale ranging from 1 02 _1 04 after 
adding different concentrations and combinations of r1L-2 and rlL 15 on both day zero and 5. p<0.05 
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Figure-12.4: Mean NKpf (95% CI) after 5 day of culture plotted on a IOg10 scale ranging from 10L_104 
after adding different concentrations and combinations of r1L-2 and rlL 15 on day zero as indicated. 
p<O.05 between only r1L-2 & only rIL-15, only r1L-2 & rIL-2+rIL-15 , and p>O.05 between only r1L-15 & 
rIL-2+rIL-15. Results are from four experiments with cells from AG. 
4.2.1. Effect of different source of human AB serum (Quest) 
Figure-13.4a shows the results obtained from three different experiments 
where PSMC were cultured in CCM-2 containing heat inactivated human AS 
serum where the heat inactivation had been done by the company (Quest) for 5, 
7 and 10 days in the presence of 25 Cetus units/ml rIL-2. The r1L-2 was added 
on day 0 and during feeding on day 5. The estimated mean for all experiments 
NKpf (+SD) was 132±15 after five, 138±13 after and 146±7 after ten days. 
Compared to the results obtained with Sigma heat inactivated human AS serum 
there was no increment with culture duration and NKpf estimates with Quest 
serum were significantly less than with Sigma serum. 
In the next attempt, the effects of additional heat inactivation of Quest-AB 
serum on NKpf estimates and Sigma-AS serum were investigated. Figure-13.4b 
shows the results obtained from three different experiments. The NKpf (±SO) 
was only 11 ±6 after five days incubation with 100/0 heat inactivated Quest AB 
serum, compared to heat inactivated Sigma-AB serum, which was 781±160. This 
NKpf estimate was significantly less than NKpf that obtained after one-day 
incubation without r1L-2 (p<0.05). 
Further results showed that after adding different concentrations of Quest-
AS serum in CCM-2, there was a significant decrease in NKpf with increasing 
serum concentration confirming the deleterious effect of Quest AS serum, used 
as the only nutriment on the culture media. This effect was prevented by adding 
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Figure-13.4: a) NKp (95% CI) plotted at 
different times of culture on a log 10 scale 
ranging from 1-103 . PSMC were culture with 
10% Quest-AS serum and 25 Cetus unitlml 
rIL-2. b) NKp (95% CI) after 5 days of 
culture plotted on a log 10 scale ranging 
from 1-103 . PSMC were cultured with 10% 
heat inactivated Quest-AS serum, 10% 
Quest-AS serum and 10% heat inactivated 
Sigma-AS serum in the presence 25 Cetus 
unitlml rIL-2. c) NKp (95% CI) after 5 days 
of culture plotted on a log scale ranging 
from 101-103 after adding different 
concentrations and combinations of Quest-
AS serum and heat inactivated Sigma-AS 
serum in the presence 25 Cetus unitlml rlL-
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4.2.2. Effect of the human bladder carcinoma cell line 5637 derived 
cytokines 
The human bladder carcinoma cell line 5637 is a well-known source of 
haematopoietic cytokines and has been used to accelerate the growth of normal 
cells such as granulocyte and monocyte progenitors and malignant haemopoietic 
cells and cell lines. 5637 is an inexpensive source of cytokines used to maintain 
leukaemia cell lines in long-term culture. 5637 secretes granulocyte-stimulating 
colony factor (G-SCF), GM-CSF, macrophage-colony stimulating factor (M-CSF), 
SCF, I L-1 ~ and I L-3 (Quentmeier et aI., 1997; Ferrero et aI., 1999). 
To observe the effects of 5637 on NKpf estimates, PBMC were cultured 
with 5637 supernatant at 10 and 20% for five days without adding r1L-2 or rIL-15. 
The NKpf (+SO) estimates were 14±2 with 10% and 6±2 with 20% 5637 
supernatant confirming that it is unable to act on NKp cells. 
4.2.3. Effect of incubation time with Eu-K562 
Adding Eu-K562 to each culture plate constitutes the final stage of the 
NKpf assay. The plate is centrifuged to accelerate the reaction and incubated at 
37°C in 5% CO2 in a humidified atmosphere. In these experiments, plates were 
incubated for two or three hours at 37°C in 5% CO2 in a humidified atmosphere. 
Table-2.4 shows the results obtained from three different experiments, when 
plates were incubated for two and three hours. 
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Table-2.4: NKpf obtained from three experiments 
Experiments 2h incubation 3h incubation 
1 1117 950 
2 1056 1242 
3 800 781 
p>0.05 
Spontaneous release is the normal release of europium during the assay 
without added responder cells and the maximum release is that obtained by 
lysing the target cells with 2% Triton X-100. In the next experiment, the effect of 
incubation time on spontaneous release was measured (table-3.4). The 
percentage of spontaneous release was calculated by dividing spontaneous 
release by maximum release and multiplying by 100. 
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Table 3.4: The percent spontaneous release from eight experiments after 
2 and 3 hours incubation of control plates 
Percent spontaneous release 
Experiments 2 hours 3 hours 
1 9 14 
2 10 16 
3 11 12.5 
4 13 16 
5 13.5 11 
6 15 12 
7 15 13 
8 15 14 
p>0.05 
The results obtained from both tables' shows that the plates in the final 
stage of the NKpf cytotoxicity assay could be incubated for two hours confirming 
that the Eu-Iabel is released after shorter incubation time than radioactive 51Cr 
assay (usually 4 hours). 
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4.2.4. Effect of number of Eu-K562 added 
In the next experiments sensitivity of the assay to target cell number was 
investigated. 5,000 and 10,000 Eu-K562 were added in 100/-11 to each individual 
well of a 96-well culture plate. Table-4.4 shows the NKpf estimates obtained 
from four different experiments. 
Table-4.4: NKpf obtained after adding 5000 and 10000 of Eu-K562. 
Experiments 5,000 target cells/well 10,000 target cells /well 
(E:T ratio 8: 1) (E:T ratio 4: 1 ) 
1 650 608 
2 816 776 
3 664 745 
4 757 795 
p>0.05 
4.2.5. Effect of freezing on NKpf 
To observe the effect of freezing/thawing process on NKpf estimates, 
fresh PBMC and frozen/thawed PBMC were cultured from one healthy adult (AG) 
for five days. The NKpf (+SO) estimates were 668±134 with fresh PBMC and 
630±130 with frozen/thawed PBMC. These were not significantly different 
(p>0.05) confirming that the freezing/thawing process does not significantly affect 
on NKpf estimate. Meanwhile, all samples including patient samples were 
treated by the same process during this study and frozen/thawed samples were 
assayed throughout. 
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4.3. Immunophenotyping studies in normal sample 
The next step was to determine whether unique subsets of PBMC could 
be identified by flow cytometry that correlated with functionally mature progeny of 
NKp after five days of culture, and how and whether percent CD56+ cells in the 
CD3- population correlated with NKpf estimates. 
Monoclonal antibodies specific for the human cell differentiation (CD) 
markers CD16, CD3 and CD56 were used for a two-colour flow cytometric 
analysis. Thus, the CD3- CD56+ and CD3- CD16+ populations were measured 
after five days of culture with r1L-2 and rIL-15. Figure-14.4 shows the mean 
percentage of the total CD3- population expressing CD56 and CD16 after five 
days of culture with different concentrations and combinations of r1L-2 and r1L-15 
added on day zero and with a control containing no cytokines adding on day zero 
or on day five. The significance of the difference in percentage of CD3- CD16+ 
and CD3- CD56+ in relation to NKpf was analysed by the two-tailed student "t' 
test. 
The obtained results with no cytokines showed that there was no change 
in the percentage of CD3- CD16+ and CD3- CD56+ on day zero and day five, 
while after adding r1L-2 or rIL-15, a significant boost in the percentage of CD3-
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Figure-14.4: Mean percentage (95% CI) of total C03- population expressing the C03-C056+ and 
C03-C016+ phenotypes after five days culture with no cytokine or with different combinations of r1L-2 
and r1L-5 added on day zero . p<O .05 between C03-C016+ cells with r1L-2 alone and other cytokine 
legends. Results are the mean of five experiments with cell from AG . 
In the next experiments the CD3- CD56+ populations was investigated on day 
Zero, two and day five after exposure to different combinations of r1L-2 and rlL-
15. The obtained results from five experiments showed a significant increase in 
the percent of CD3- CD56+ cells between days two and five suggesting that NK 
cell differentiation was cytokine sensitive and time dependent consistent with the 
observed increase in functional NK cells (fig-15.4). 
The CD3-CD16+ population was higher in assays cultured with r1L-2 
compared with assays cultured with rIL-15. Monocytes are also CD3-CD16+, and 
it is possible that the large increase seen in CD3-CD16+ population in culture 
containing r1L-2 compared to r1L-15 was due to r1L-2 driven proliferation of 
monocytes as well as NK cells. The CD3- CD56+ population increased both in 
the presence of r1L-2 and rIL-15, but the latter appeared to be associated with a 
higher increase than the former (fig-15.4). 
The effects of r1L-2 and r1L-15 were tested separately and together. The 
CD3-CD16+ population was higher with r1L-2 compared with r1L-15 alone, or r1L-2 
plus r1L-15 together (fig-16.4). This confirmed that the r1L-2 activated subsets of 
PBMC other than NK cells (e.g. monocytes). In all immuno phenotyping studies 
the percent CD3- CD56+ cells were the same with different combinations and 
concentrations of r1L-2 and rIL-15, whereas the NKpf obtained with IL-15 was 
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Figure-15.4: Mean percentage of total C03- population at days 0, 2 and 5 expressing C03-C056+ (95% 
CI) plotted on a log10 scale ranging from 1-102 with different combinations of r1L-2 and r1L-5 added on day 
zero p<0 .05 between days 0&2, 0&5 , and 2&5 in all above conditions. p>0.05 between r1L-2 alone & rlL-
15 alone, r1L-2 alone & rIL-2+rIL-15, r1L-15 only & rIL-2+rIL-15. Results are from three experiments with 
cells from AG. 
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25 cetus unitlml r1L-2 10 ng/ml r1L-15 
Figure-16.4: Mean percentage of total C03- population at day five expressing C03-C056+ and C03-
C016+ (95% CI) with different combinations of r1L-2 and r1L-5 added on day zero. p<O.05 in C03-
C016+ celis between r1L-2 alone & r1L-15 alone, r1L-2 alone & rIL-2+rIL-15. p>O.05 in C03-C056+ 
cells between r1L-2 alone & r1L-15 alone, r1L-2 alone & rIL-2+rIL-15 and r1L-15 alone & rIL-2+rIL-15. 
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4.4.1. Patient characteristics 
Table-5.4 shows patient characteristics of 120 patients including age, sex, 
type of surgery, admission and post operative haematocrit (Hct), admission and 
post operative white blood cell count (WBC), admission and post operative total 
lymphocyte count, length of stay in hospital, blood transfusion regimen, number 
of post-operative infections, post-operative infection site and cause. 
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Table 5.4: Characteristics of patients 
Allogeneic non- Allogeneic Autologous Autologous No-transfused 
Type of transfusion: leukodepleted leukodepleted salvage pre-deposit 
Number of patients 8 30 40 10 32 
Female: Male 6:2 19: 11 20: 20 3:5 1 7 : 15 
TKR:THR 5:3 13: 17 40: 0 0:8 22: 10 
Age (years) 72± 8 70 ± 13 72 ± 9 57± 8 68 ± 10 
Admission Hct (%) 0.37±0.05 0.38±0.05 OAO± 0.04 OAO±0.05 OAO± 0.04 
Post-operative Hct (%) 0.33±O.O5 0.31±O.05 0.31± 0.04 0.30±0.05 0.30± 0.04 
Change - 0.03 - 0.07 - 0.09 - 0.10 - 0.10 
-' Admission WBC (X109/L) 7.9± 2 7.9±2 7.0±1.6 7.0±1.5 6.9± 1.6 -' 
w 
Post-operative WBC (X109/L) 7.9± 2 9.6±2.7 8.7±1.5 8.0±1.0 8.9±2.5 
Change 0 +2.0±0.7 +1.7±0.1 +1.0±0.5 +2.0±0.9 
Admission lymphocyte count (X1 09/L) 1.90±0.5 1.50±OA 1.83±0.6 1.63±0.5 1.70±0.5 
Post-operative lymphocyte count(X1 09/L) 1.60±0.5 1.20±0.2 1.56±0.5 1.36±OA 1.40±0.4 
Change -O.30±O.2 -O.30±O.1 -O.27±O.1 -O.27±O.2 -0.3±O.1 
Length of stay (day) 10±3.0 12± 6 11± 6 7± 1 9± 3 
Number of transfused blood (unites) 2-4 1-7 0* 2 No 
Number of post-op infections 1 5 4 0 4 
Values are expressed as mean.± SO. 
The age of patients ranged between 40 and 87 years, the mean being 70±10 
years. The age range of 65 female patients was between 42 and 87 years with a 
mean of 72+9 years. The age of 55 male patients ranged between 40 and 84 
years, with a mean of 67±11 years. There were significantly more males below 
55 years and more females over 75 years (fig-17.4). 
The mean age of patients who received autologous pre-deposit blood 
(57±8 years) was lower compared to other patient groups. There being greater 
motivation to travel to the transfusion centre for blood depositing in the younger 
fitter group. 
Local policy determined that only the patients who underwent THR were 
eligible for pre-deposit blood transfusion programme, while only patients who 
underwent TKR surgery were eligible for post-operatively salvaged autologous 
blood programme. 
Twice as many of patients underwent TKR (80) compared with THR (40). 
The total number of female and male patients who underwent TKR was 42 and 
38 respectively. The total number of female and male patients who underwent 
THR was 23 and 17 respectively. 
The post-operative haemotcrit declined significantly in all patient groups 
compared to the admission Hct level (p<0.05). The post-operative total WBC 
count rose significantly in all patient groups (p<0.05), except those who received 
allogeneic non-Ieukodepleted transfusion, which showed no change. By contrast, 
this post-operative lymphocyte count was observed to decline in all patient 
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Figure-18.4: The haematology 
results of 120 individuals plotted 
before and after operation. a) Mean 
percentage haematocrit (Hct) level 
with 95% CI (p<0 .05), b) mean total 
white blood cell count (WBC) with 
95% CI (p<0 .05, except in allogeneic 
non-Ieukodepleted group), c) Mean 
absolute number of lymphocyte with 
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Those patients receiving autologous pre-deposit blood discharged earlier than 
the others. In contrast, the length of stay in hospital in patents that received 
allogeneic leukodepleted blood was higher than other patients group. 
The number of post-operative infections in those who received allogeneic 
leukodepleted transfusion was more than the other groups. Post-operative 
infection was not observed in the autologous pre-deposit transfused patients. 
Finally, details of numbers of the number of units of blood given to each 
patient in the allogeneic non-Ieukodepleted group were two units to seven 
patients, and four units to one patient. In the allogeneic leukodepleted group one 
patient received one unit, thirteen patients received two units, ten patients 
received three units, three patients received four units and three patients 
received five, six and seven units, respectively. 
The numbers of units of autologous pre-deposit blood given to each 
patient were two units to all ten patients in this group. All autologous pre-deposit 
patients were transfused with whole blood. Finally, the volume of autologous 
salvage blood reinfused averaged 650±246 mls. 
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4.4.2. Quantitation of NKpf before and after surgery 
Figures-19.4-23.4 show the NKpf before and five days after operation in 
the five patient groups. In non-transfused patients and those who received 
allogeneic leukodepleted, allogeneic non-Ieukodepleted or autologous pre-
deposit, the post-operative NKpf was significantly reduced (p<0.05). By contrast, 
in patients given unwashed autologous post-operatively salvaged blood, the post-
operative NKpf increased significantly (p<0.05). 
4.4.2.1. NKpf before surgery 
Individual pre-operative NKpf estimates ranged from below 500 to above 
3,000 NKpf/106 PBMC. The mean pre-operative NKpf±SD for each study group 
was: 1512±382 for the non-transfused group; 1397±604 for the allogeneic 
leukodepleted group; 1013±487 for the allogeneic non-Ieukodepleted group; 
1447±539 for the autologous pre-deposit group and 1163±473 for the autologous 
salvage group. These estimates did not differ significantly between the five 
groups nor between gender, disease or operation types (fig-24.4). A combined 
mean for these groups gave a value of 1411 ±513. 
4.4.2.2. NKpf after surgery 
In contrast to the pre-operative values the mean post-operative NKpf±SD 
varied significantly between groups. It was 1095+415 for non-transfused group; 
697±397for the allogeneic leukodepleted group; 567±187 for the allogeneic non-
leukodepleted group; 757±377 for autologous pre-deposit group and 1757±477 
for autologous salvage. Individual post-operative NKpf estimates varied between 
individuals, but in the majority of cases they retained the same rank order within 
their group as their corresponding pre-operative values. In four of the five groups 
the mean post-operative NKpf estimates were significantly lower than their pre-
operative values (p<0.05) (figs-19.4-22.4). However, in those receiving 
autologous unwashed salvaged blood NKpf estimates were significantly higher 
than their pre-operative values (p<O.05) (fig-23.4). 
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By comparing results obtained with the different transfusion groups the question 
of whether or not this decrement in NKpf in those who received allogeneic blood, 
autologous pre-deposit blood was attributable to surgical trauma or blood 
transfusion or both. Thus the NKpf decrement observed in the allogeneic 
leukodepleted group (fig-20.4), was also observed in the allogeneic non-
leukodepleted group (fig-21.4) excluding the possibility that it was wholly 
attributable to transfused allogeneic leukocytes. The autologous pre-deposit 
group further excluded allogenicity of the transfusate (fig-22.4) and the non-
transfused group exonerated transfusions all together (fig-19.4). Therefore, the 





















Figure-19.4: Mean NKpf (95% CI) at 5 days of culture plotted on a linear scale ranging from 0-
3000/106 PBMC before and five days after surgery in patients (32) who did not receive blood transfusion ( 




















Figure-20.4: Mean NKpf (95% CI) at 5 days of culture plotted on a linear scale ranging from 0-3000 
1106PBMC before and five days after surgery in patients (30) who were transfused with allogeneic 























Figure-21.4: Mean NKpf (95% CI) at 5 days of culture plotted on a linear scale ranging from 0-3000 
/106PBMC before and five days after surgery in patients (8) who were transfused with allogeneic non-




















Figure-22.4: Mean NKpf (95% CI) at 5 days of culture plotted on a linear scale ranging from 0-
3000/106 PBMC before and five days after surgery in patients (10) who were transfused with autologous pre-
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Figure-23.4: Mean NKpf (95% CI) at 5 days of culture plotted on a linear scale ranging from 0-
3000/106PBMC before and five days after surgery in patients (40) who were transfused with autologous 





o Female o Male 
1000 T 














40-45 46-50 5 .... -55 56-60 6 .... -65 66-70 7 .... -75 
Patient age in year 
Figure-24.4: Mean NKpf (95% CI) at five days of culture plotted on a log10 scale rang ing 1-104 110tipBMC 
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A more marked decrease in NKpf was observed after allogeneic (Ieukodepleted 
and non-Ieukodepleted) and autologous pre-deposit transfusions compared to 
the non-transfused group. These estimates did not differ significantly between 
the two allogeneic transfused (Ieukodepleted and non-Ieukodepleted) groups 
(p>O.4). The combined groups who received allogeneic bloods gave a mean 
decrement of 647 compared to non-transfused group with a mean decrement of 
418 suggesting that allogeneic transfusions per-se contributed to the decrement 
(p<0.05). 
Figure-25.4 shows the comparison of the NKpf change in four patient 
groups who were, non- transfused group (fig-25.4a), transfused with allogeneic 
blood (Ieukodepleted and non-Ieukodepleted) (fig-25.4b), transfused with 
autologous pre-deposit blood (fig-25.4c). Figure-26.4 shows the NKpf change in 
those patients who transfused with autologous salvaged blood. The NKpf 
decrease in allogeneic transfused groups was more than non- transfused group. 
In contrast those who transfused with autologous post-operatively salvaged blood 
showed an increase in NKpf compared to individual pre-operative counterparts. 
This was observed in 37 of the 40 patients. The three who showed an NKpf 
decrement were indistinguishable from the remaining members of the group by 
all characteristics studied. 
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Figure-25.4: NKpf change plotted on a linear 
scale, ranging from -2000 to +2000 1106 
PBMC in different patients groups. a) non-
transfused group, b) the pooled of allogeneic 
leukodepleted and non-Ieukodepleted 









tj -1500 ~LIW 
-2000 
































































-1000~1 ------------------------____________ ~ 
Figure-26.4: NKpf change plotted on a linear scale, ranging from -1 000 to +2000 110° PBMC in those 
patients who transfused with autologous post-operatively salvaged blood group. 
4.4.3. Cytokine profiles 
The production of interferon gamma (IFNy) as an example of pro-
inflammatory cytokine and interleukin 10 (IL-10) as an example of anti-
inflammatory cytokine, were studied pre and post-operatively. Samples were 
obtained from culture supernatants at the fifth day of culture in the presence of 
the recombinant cytokines IL-2 and/or IL-15. 
4.4.3.1. Establishment of the specificity of the assay 
Initial experiments defined the maximum secretion of IFNy and IL-10 in 
culture supernatants. To avoid individual variation during the development of the 
technique, venous blood was taken from one healthy adult (AG) at different 
times. 
In the absence of added r1L-2 and r1L-15 the levels of IFNy ranged from 
0.016 to 0.96 and IL-10 from 0.001 to 0.003 nanograms per ml (ng/ml). In the 
presence of added r1L-2 and r1L-15 the levels of IFNy ranged from 0.41 to 9.15 
and IL-10 from to 0.003-0.312 ng/ml. 
Figure-27.4 shows the results obtained from eight different experiments 
with AG cells in which PBMC were cultured in absence and presence r1L-2 and 
r1L-15 for 1, 2, 3,4, 5 and 7days. The r1L-2 and r1L-15 were added on day 0, 
when setting up the assay. 
After one day culture in the absence of cytokines, the IFNy release in 
culture supernatant fell rapidly from 0.34±0.04 on day one to 0.057±0.02 ng/ml 
on day seven in culture (p<0.05). By contrast, when r1L-2 and r1L-15 were added, 
the IFNy level rose rapidly from 0.67±0.13 on day one to 7.36±2.2 ng/ml on day 
three (p<0.05). There was no significant increase after day three (p>0.05). The 
increase between days one and three implied rapid secretion of IFNy in culture 
(fig-27.4a ). 
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In the absence of added r1L-2 and r1L-15 the IL-10 release in culture supernatant 
was 3 picograms (pg/ml) on day one and it was almost unmeasurable by day two 
(fig-27.4b). When r1L-2 and r1L-15 were added, IL-10 levels increased rapidly 
from 5+0.6 on day one to 241±2 pg/ml on day five (p<0.05). There was no 
significant increase after day five (p>0.05). The increase between days 1-5 
implied r1L-2 and r1L-15 dependent cytokine synthesis. 
In summary, the results showed that cytokine driven IFNy levels increased 
significantly (p<0.05) with duration of culture and reached a maximum plateau at 
day three. In all experiments IFNy secretion levels maintained a plateau between 
days three and seven. Cytokine driven IL-10 levels also rose significantly 
(p<0.05) with duration of culture and reached a plateau between days five and 























Figure-27.4: Mean cytokine synthesis (95% CI) in culture 
supernatant after days 1-5 and 7 after adding (grey) or not 
adding (black) r1L-2 plus r1L-15 on day zero . a) The IFNy level 
Increased between days 1 &3 (p<0.05) in the presence of 
cytokines and a significant decrease was observed after day-1 
In the absence of cytokines (p<0.05). b) The IL-10 level 
increased between days 1 &5 in the presence of cytokines 
(p<O 05) and no Increase was observed in the absence of 
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4.4.3.2. IFNy synthesis pre and post-operatively 
Pre-operative values spanned a range from below 0.003 to above 50 
ng/ml. The post-operative values covered a similar range but the general trend 
was towards lower post-operative values. In four of the five experimental groups 
including non-transfused, allogeneic (Ieukodepleted and non-Ieukodepleted) 
blood transfused and autologous pre-deposit transfused groups IFNy synthesis 
showed a non significant decrease in post-operative samples (p>0.05). In 
contrast to the other four groups, those who received autologous post-operatively 
salvaged blood showed a non significant increase in IFNy synthesis after surgery 
(p>0.05) (fig-28.4a). Thus, surgical traumas as well as allogeneic and pre-
deposit blood transfusions suppress the ability of IFNy synthesis. IFNy plays a 
pivotal role in both innate and adaptive immunity against infection and 
malignancy. By contrast, autologous post-operatively salvaged blood reversed 
this phenomenon by increasing IFNy synthesis after surgery. 
Furthermore, the result obtained shows that decrement or increment in the 
mean value of IFNy levels corresponded with decrement or increment in the NKpf 
estimates in all patient groups. However, there was individual patient variation of 
IFNy value within all groups. The correlation coefficient value (r) between 
changes in NKpf and changes in IFNy changes was 0.21 in non-transfused 
group, 0.31 in allogeneic leukodepleted transfused group, 0.41 in allogeneic non-
leukodepleted transfused group, 0.49 in autologous pre-deposit transfused 
group, 0.17 in autologous post-operatively salvaged blood group. However, the 
correlation coefficient value (r) between NKpf and IFNy in all patient groups 
combined was 0.11 (fig-28.4b). As above result shows there was a variable 
correlation among patient groups suggesting that stimulated NK cells were not 
the only source of IFNy synthesis in culture supernatants. Although, the 
strongest correlation was in patients receiving allogeneic leukodepleted or 






Figure-28.4: a) Pre and post-operative 
mean (95% CI) IFNy synthesis at day five of 
culture in supernatant in patient groups. 
r1L-2 at 25 Cetus unitJml plus r1L-15 at 10 
ng/ml were added on day zero. b) The 
correlation between changes in NKpf and 
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4.4.3.3. IL-10 synthesis pre and post-operatively 
Pre-operative values spanned a range from below one to above 1500 
picograms per ml (pg/ml). The post-operative values covered a similar range but 
the general trend was towards lower values. In four of the five experimental 
groups including non-transfused, allogeneic transfused (Ieukodepleted and non-
leukodepleted) and autologous pre-deposit transfused groups a non significant 
decrease in IL-10 synthesis was shown in post-operative samples (p>0.05). In 
contrast, the unwashed post-operatively salvaged autologous group showed a 
non significant increase in IL-10 synthesis in post-operative samples (p>0.05) 
(fig-29.4a). Thus, major surgical trauma and allogeneic and pre-deposit 
transfusions suppress IL-10 synthesis. By contrast, autologous post-operatively 
salvaged blood reversed this phenomenon by increasing in IL-10 synthesis. 
Interestingly, decreases and increases in the mean IL-10 levels 
corresponded with decreases and increases in NKpf estimates in all groups. 
The correlation coefficient value (r) between changes in NKpf and changes in IL-
10 changes was 0.12 in non-transfused group, 0.1 in allogeneic leukodepleted 
transfused group, 0.5 in allogeneic non-Ieukodepleted transfused group, 0.4 in 
autologous pre-deposit transfused group, 0.2 in autologous post-operatively 
salvaged blood group. However, the correlation coefficient value (r) in all patient 
groups combined was 0.16 (fig-29.4b). The strongest correlation was in patients 
receiving allogeneic leukodepleted or autologous pre-deposit blood, this is more 
likely to have been affected by small sample size. 
Also, the IL-10 synthesis results showed that the mean value of IL-10 
levels decreased or increased with the mean value of I FNy levels in all patients 
groups, however, there was individual patient variation of IL-10 values within all 
patient groups. 
The correlation coefficient value (r) between changes in IFNy and changes 
in IL-10 changes was 0.23 in non-transfused group, 0.07 in allogeneic 
leukodepleted transfused group, 0.2 in allogeneic non-Ieukodepleted transfused 
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group, 0.15 in autologous pre-deposit transfused group, 0.34 in autologous post-
operatively salvaged blood group. 
Figure-30.4 shows the correlation between changes in IFNy and IL-10 in 





Figure-29.4: a) Pre and post-operative 
mean (95% CI) IL-10 synthesis at day five 
of culture in supernatant in patient groups. 
r1L-2 at 25 Cetus unitlml plus r1L-15 at 10 
ng/ml were added on day zero. b) The 
correlation between changes in N Kpf and 
changes In IL-10 In all patient groups 
combined (r=O.16). 
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Figure-30.4: IFNy change plotted on a linear scale, ranging from -30 to +30 ng/ml verse IL-10 changes 
ranging from -0.4 to +0 .6 in all patient groups combined (r=0 .13). r1L-2 at 25 Cetus uniUml plus r1L-5 at 10 
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4.4.3.4. IL-4 synthesis pre and post-operatively 
In the next experiment the correlation between IL-4 and IFNy synthesis 
was investigated. Figure-31.4 shows the results obtained from selected samples 
from three groups of patients where IFNy synthesis was detectable post-
operatively. The rationale was that in pilot studies in some culture supernatant 
samples IL-4 was not measurable. The values shown in figure-31.4 are for 
patients receiving no blood (12), allogeneic leukodepleted blood (10) and 
autologous post-operatively unwashed salvaged blood (19). 
Allogeneic leukodepleted transfusion showed a non significant increased 
IL-4 synthesis (p>O.05) and a significant decreased IFNy synthesis (p<0.05). By 
contrast, those who received autologous post-operatively salvaged blood showed 
a non significant decrease in IL-4 synthesis (p>O.05) and a significant increased 
IFNy synthesis (p<O.05). Although, the mean value of IL-4 levels inversely 





Figur~1.4: Pre and post-operative mean (95% CI) 
cytokine synthesis at day five of culture ~th r1L-2 at 
25 Cetus unitlml plus r1L-5 at 10 ng!rTi added on 
day zero. Results are from selected patients that 
they ~re 12,10 and 19 experirnmts in patients 
receiving no blood, allogeneic leukodepleted blood 
and autologous post -operatively unwashed 
salvaged blood, respectively. a) I FNy synthesis, 
p<O.05 in non-transfused, allogeneic leukodepleted 
and in autologous salvaged b) IL-4 synthesis, 
p>O.05 in non-transfused, allogeneic leukodepleted 
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4.4.4. Immunphenotyping studies pre and post-operatively 
The percent CD56+ in the CD3- population before and five days after 
operation in all patient groups are shown in figure-32.4. The question was 
whether enumeration of NK cells by flow cytometry could substitute for the 
assessment of NKpf. 
The figure-33.4 shows no correlation between changes in NKpf and 
changes in the percentage CD56+ cells in the CD3- population after five days of 
culture with r1L-2 and r1L-15 in all patient groups(r=O). 
The variation of percent CD3-CD56+ was between 10 and 74% in females 
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Figure-32.4: Mean percentage (95% CI) of total CD3 negative population expressing CD56 after five days 
culture plotted on a log10 scale ranging from 1-102 for patient groups. r1L-2 at 25 Cetus unitJml plus r1L-5 at 10 
ng/ml were added on day zero (p>0 .05 in all patient groups). 
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Figure-33.4: NKpf change plotted on a linear scale, ranging from -2000 to +2000 1106 PBMC verse CD3-
CD56+ cells changes ranging from -50 to +60 in all patient groups combined (r=O). r1L-2 at 25 Cetus unitlml 
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Figure-34.4: Mean percenta~e (95% CI) of total CD3 negative population that express CD56 plotted on a 
10glo scale ranging from 1-10 distributed by age and gender. 
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4.4.5. Post-operative infection 
A total of 14 post-operative infections were identified in 14 of 120 patients 
in where result were available, giving an overall infection rate of 120/0. Table-6.4 
demonstrated the numbers of post-operative infections in all patient groups. 
Figure-35.4a shows the proportion of post-operative infections in all patient 
groups. The proportion of post-operative infections were, 12% in allogeneic non-
leukodepleted transfused group, 16% in allogeneic leukodepleted transfused 
group, 10% in unwashed post-operatively salvaged autologous group, 0% in 
autologous pre-deposit group and 12% in non-transfused group. The proportion 
of infections in patients who received allogeneic blood (Ieukodepleted and non-
leukodepleted) was 15% compared to 8% for those that received autologous 
blood (pre-deposit and post-operative salvage), and 12% for control patients (fig-
35.4b). 
Due to the number of post-operative infections (table-7.4), testing for an 
association between NKpf changes and post-operative infections was no 
possible. Meanwhile, other parameters of innate immunity may also have been 
associated with incidence of post-operative infections mainly by extra-cellular 
bacteria. 
This limited data on post-operative infections indicated no correlation 
between the risk of post-operative infection and gender or type of surgery. 
Table-7.4 shows the site and the number of infections. The most common 
sites of infection were urinary tract and the site of wound. The most common 
infections in urinary tract and the wound sites were with gram-negative bacilli and 
Staphylococcus aureus respectively. 
Table-6.4: The number and the proportion of post-operative infections 
Type of transfusion: Allogeneic non- Allogeneic Autologous Autologous No-transfusion 
leukodepletion leukodepletion salvage pre-deposit 
Number of post-operative infections 1 5 4 0 4 
~ 
~ 




Figure-35.4: The percentage of post-
operative infection in a) five patient groups 
and b) these patient groups including pooled 
allogeneic (Ieukodepleted and non-
leukodepleted) group, non-transfused group 
and pooled autologous (pre-deposit and 
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Table-7.4: The cause and the site of post-operative infections 
Allogeneic non- Allogeneic Autologous Autologous No transfused 
Tvpe of transfsion: Infection Site leukodepletion leukodepletion salvaqe__ore-d_eposit 
Coliforms UTI 1 1 1 1 
Staphylococcus Aureus wound 1 1 1 
Pseudomonas UTI 2 
Coagulase negative Staphylococcus* wound 1 
Escherichia coli UTI 1 
Candida UTI & intestine 1 
Entercoccus+ Escherichia coli UTI 1 
Clostridium 
*Coagulase negative Staphylococcus was the cause of post-operative infection in one case. The patient was treated with 
antibiotics. 
4.4.6. Length of hospital stay 
Figure-36.4 shows that autologous pre-deposit transfused patients 
appeared to be discharged earlier from hospital than the other groups. By 
contrast, the patients who received allogeneic leukodepleted blood stayed in 














allogeneic non- non transfused autologous pre-
leukodepleted deposit 
Rgure-36.4: fv1ean length of hospital stay (95% CI) in all patient groups. Patients receiving autologous pre-
deposit blood significantly (p<O.05) discharged earlier than the other groups. 
Section 5. 
Discussion 
5.1. Development of an assay to measure natural killer precursor frequency 
(NKpf) 
A novel method for quantifying the number of precursors of functionally 
active NK cells within a PBMC sample was described. It was shown that 
proliferation and maturation of functionally viable NK cells was absolutely 
dependent on the continued presence of r1L-2 and r1L-15 in the culture and that 
functional viability dwindled beyond 24 hours in their absence. Following allo-
activation with an irradiated pool of PBMC, NKpf was lower than when cytokines 
were added. Individual variation in NKpf estimates ranged from 300 (0.03%) to 
2,500 (0.15%) per 106 PBMC. The observation that r1L-2 and r1L-15 were 
effective is consistent with the view that they both share the same signalling 
pathways. The reason for using at r1L-2 the concentration of 25 Cetus unitlml 
was due to previous experiments in our laboratory that showed that this was the 
optimal. This concentration also prevented non-specific reactions in cellular 
functional assay by LOA based on Eu-release assay (Bouma et aI., 1992; Bouma 
et aI., 1995; Haque, 1997). The justification for using r1L-15 is already outlined in 
section-2 and is based on the several observations (Carson et aI., 1994; Allavena 
et aI., 1997; Carson et aI., 1997; Nguyen et aI., 1998; Perera et aI., 1999). 
Unlike short-term, quantitative assays used extensively elsewhere the 
novelty of this assay is that it permits accurate estimation of the full potential NK 
function within a blood sample (Gharehbaghian et aI., 2002). For example, in 
Ottenhof's method fresh PBMC in whole blood were assayed directly after 
retrieval leading to an underestimation of the full potential for NK cytotoxic 
function (Ottenhof et aI., 1981). 
In Blomberg's experiments fresh PBMC were assayed for NK cytotoxic 
function without pre-incubation with cytokines(Blomberg et aI., 1986b; Blomberg 
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et aI., 1986a; Blomberg et aI., 1996). In Nagao's study on NK cytotoxic function 
fresh PBMC were also assayed directly without an activating period of culture 
with cytokines (Nagao et aI., 1996). von-Zons cultured the PBMC samples 
overnight (18 hours) without cytokines for both NK cytotoxic function and 
Iymphokine-activated killer (LAK) activity with 6000 IU of r1L-2 (von_Zons et aI., 
1997). Whereas, in Volgmann's study on LAK activity PBMC were cultured for 3-
4 days with 1000 U/ml r1L-2 (Volgmann et aI., 1989). In Bromelow's method 
PBMC were assayed without pre-incubation but the whole blood co-incubated 
with K-562 target cells for 18 hours to increase the sensitivity of the assay 
(Bromelow et aI., 1998). However, this would still fail to account for NK cell that 
mature over five days in culture with rIL-2. 
In this method, NKpf rose to a plateau after culturing PBMC for seven days 
and the increment in NKpf between days seven and ten was insignificant, 
suggesting all-available precursors had matured into functionally viable NK cells. 
In-vivo the story may vary with location and cytokine-producing micro-
environment. The observed variation in NKpf between healthy individuals (pre-
operatively values) reflects variables that have yet to be fully explored, such as 
clone size, specificity and number. 
The present assay was based on a modification of the well-established 
non-radioactive Eu-release technique developed by Blomberg (Blomberg et aI., 
1986b; Blomberg et aI., 1986a; Haque et aI., 2001). It is relatively simple, 
sensitive and non-hazardous and performs well with non-adherent tumour cell 
targets. Released Eu is measured rapidly as a highly fluorescent chelate using a 
time-resolved fluorometer. In addition, Eu-EDTA is an inert chemical complex 
and does not bind to cellular proteins in target cells. It is also a small molecule 
and therefore more able to leave target cells after they are rendered permeable 
by exposure to perforin/granzymes produced by responder cells (Blomberg et aI., 
1996). 
The Eu release method has also been shown to be as sensitive as the 
51 Cr release method for measuring functional NK cells (Blomberg et aI., 1986b; 
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Blomberg et aI., 1986a; Nagao et aI., 1996). In clinical studies, the Eu3+ release 
assay has been applied to measure NK activity in 68 healthy donors, 36 auto-
immune patients and 21 cancer patients. The results obtained were almost 
identical with the 51 Cr release method and Eu release assay and it was 
concluded that the latter could be used as a method for measurement of human 
NK cytotoxic function of in large populations (Nagao et aI., 1996). In von-Zons et 
al study, the comparison between Eu3+ release and 51Cr release assays for NK 
and LAK function in 15 apparently healthy volunteers and 31 patients were 
shown to be comparable (von_Zons et aI., 1997). 
An advantage of this NKpf assay is that LDA are relatively insensitive to 
target cell concentration since the presence or absence of a culture well that is 
positive for Eu-release is the only criterion used to detect the presence of one or 
more functional NK precursor. This assumption was confirmed by showing that 
NKpf estimates obtained with 5,000 or 10,000 target cells per well were not 
significantly different. Another advantage of this method compared to 51Cr 
release is the shortening of incubation times from 3 to 2 hours. 
Both r1L-2 and r1L-15 in culture medium drove proliferation and maturation 
as evidenced by the plateau at day seven of culture. Although, there was a rapid 
and significant increase in NKp in the presence of cytokines on day 5, there was 
also a small increment beyond day 5 and 7 in the presence of extra cytokines 
added on day 5. This implied that NKp sensitisation to cytokines varied at 
different stages of maturation, but the majority of NKp required five days to reach 
maturity. When both cytokines were given together there was no increment in 
NKpf suggesting that the same signalling pathways were used to equal effect by 
both cytokines. However, in the absence of experiments with purified cell 
subsets, it is impossible to know whether these cytokines were operating directly 
through receptors on NK precursors and/or indirectly via helper T -cells in the 
culture. Since receptors for both cytokines shared the same P and common y-
chain they were likely to have used the same signalling pathway (Carson et aI., 
1997; Waldmann et aI., 1998). 
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Human IL-15 and IL-2 ligated the p and y sub-units of their receptors and 
transduce signals that cause the CD56+ subset to activate, proliferate and 
differentiate into functionally mature active NK cells. Gaddy and Broxmeyer 
showed that IL-2 and IL-15 induced functional and phenotypic maturation of cord 
blood NK cell subsets leading to acquisition of the CD16+56+ phenotype (Gaddy 
and Broxmeyer, 1997; Carayol et aL, 1998). Incubation of PBMC with 10 ng/ml 
IL-15 for 18 h increased the antibody-dependent cellular cytotoxicity (ADCC) by 
three fold (Nguyen et aL, 1998; Seidel et aI., 1998). 
Children and adults who carried the human immunodeficiency virus (HIV) 
were shown to have an increase in NK cytotoxic function, ADCC and the 
percentage of CD56+CD16+ cells when their PBMC were treated with r1L-15 for 
one week. This showed that IL-15 restored impairment of NK function in HIV 
positive patients, suggesting that autologous NK cells activated with IL-15 can be 
used to maximise the immuno therapeutic protocols for AIDS (Loubeau et aI., 
1997; Lin et aL, 1998). 
In-vivo, NK clonal expansion would be subject to regulatory mechanisms 
leading to clonal contraction by activation induced cell death or apoptosis. In-
vitro, similar processes might operate explaining why the NKpf estimates 
following allo-activation alone were less than when cytokine was added. If, in a 
proportion of culture wells, apoptosis occurred this would result in lower NKpf 
estimates. In this allo-activation study NK cells destined for apoptosis would 
have been 'rescued' by r1L-2 thereby explaining the synergistic effect of the two 
stimuli. However, the additive effect of r1L-2 added to the allogeneic stimulus was 
observed as early as day one supporting an alternative view that two or more 
populations of cells were activated. Cells with capacity to kill K562 target cells 
are known to be of diverse origins. Whereas most have no T-cell characteristics 
others have characteristics of T-cells and are termed NKT-cells 
(Leite_de_Moraes and Dy, 1997; Godfrey et aI., 2000). 
In assays of T -cells, peptide-specific T-cell precursor frequencies 
measured by LOA give lower frequency estimates than when measured by 
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tetramer analysis (without LOA). This may be a consequence of the need for 
interactions between several different cell populations during T-cell maturation 
(e.g. T-cells and dendritic cells). Maturation and proliferation of NKp requires 
only the presence of soluble growth factors and may be less susceptible to this 
artefact. Tetramer analysis using a range of HLA Class I peptides might 
complement this NK functional assay by offering an insight into the distribution of 
inhibitory receptors, but it would be wrong to assume that all cells carrying 
inhibitory receptors have the potential to lyse K562 targets and vice-versa. 
Hence the shortcomings observed with estimates of T-cell precursors are unlikely 
to be applicable to the current NKpf assay. 
It is suggested that the method described here gives more accurate 
estimates of the potential number of NKp than previous short term, single dilution 
assays. 
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5.2. Changes in NKpf after surgery and blood transfusions 
In the present study NK cytotoxic function was measured in the knowledge 
that NK cells playa pivotal role in the first line of defence against intra-cellular 
micro-organisms. As such, NK cells perform a vital role in suppressing, 
controlling or slowing infection and neoplasia. Patients with reduced, non-
functional or absent NK cells have a high frequency of infections and malignancy 
(Pross and Lotzova, 1993; Biron et aI., 1999). Activated NK cells are able to 
move in solid tissues, localise to the site of metastases and kill tumour cells 
(Pross and Lotzova, 1993; Rabinowich et aI., 1995; Okada et aI., 1996). A 
significant correlation was shown between NK cell cytotoxic function and fewer 
metastases (Son et aI., 1982; Schantz et aI., 1987). Bruunsgaard showed a 
significant positive correlation between low number of NK cells and rapid 
progression to AIDS (Bruunsgaard et aI., 1997). Thus a decrease in NK cell 
function could be reflected in increased post-operative infection leading to 
prolonged stay in hospital and poor prognosis after surgery. 
The main findings of the current study were that joint replacement surgery 
was followed by a reduction in NKpf and allogeneic (Ieukodepleted and non-
leukodepleted) blood transfusions added to this decrement. By contrast, 
transfusion with unwashed salvaged blood drained from the wound site post-
operatively was not only associated with a restoration of NKpf to pre-operative 
levels, but in many cases to levels over and above their pre-operative values. 
Since these assays may reflect the integrity of innate immunity against 
pathological micro-organisms, they may have clinical and economic significance. 
Some studies in orthopaedic surgery suggested that patients receiving 
allogeneic blood transfusions showed lower NK cytotoxic function associated with 
higher post-operative infection, longer hospital stay and higher hospital charges 
(Murphy et aI., 1991; Triulzi et aI., 1992; Heiss et aI., 1997a; Blumberg and Heal, 
1998; Bordin et aI., 1999). Furthermore, in patients with malignancy suppression 
of NK cytotoxic function after allogeneic blood transfusions was associated with 
increased risk of tumour recurrence and decreased survival (Tartter and 
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Martinelli, 1987; Tartter et aI., 1987; Tartter, 1988d; Tartter et aI., 1989; Jensen et 
aI., 1990; Jensen et aI., 1992; Mathiesen et aI., 1994; Mathiesen et aI., 1998). 
Studies comparing immune function after laparotomy as opposed to laparoscopic 
surgery confirmed the association between surgical trauma and lower NK 
cytotoxic function (Pollock et aI., 1992; Griffith et aI., 1995; Bruns et aI., 1996; 
Kutza et aI., 1997; Andersen et aI., 1998; Stanojevi+_Baki+ et aI., 1999). Thus 
allogeneic blood transfusions given at the time of malignant and non-malignant 
surgeries induces immunomodulation morbidity and mortality. 
By contrast, several retrospective and prospective clinical studies 
supported the idea that autologous blood does not induce immunomodulation. 
Patients transfused with autologous blood showed a better prognosis and less 
post-operative complications including lower post-operative infection, shorter 
hospital stay and lower tumour recurrence compared to those who received 
allogeneic transfusions (Murphy et aI., 1991; Fernandez et aI., 1992; Heddle et 
aI., 1992; Mezrowetal., 1992; Howard etal., 1993; Busch etal., 1994a; Houbiers 
et aI., 1994b; Blumberg et aI., 1996; Blumberg and Heal, 1998). Autologous 
transfusion was also associated with reduce the demand for allogeneic blood and 
reduced hospital charges (Schaff et aI., 1979; Blumberg et aI., 1996; Duffy and 
Tolley, 1997; Schmidt et aI., 1998). 
In the majority of the above studies there was no attempt to address the 
mechanisms underlying immunomodulation. The results obtained in the current 
study suggest that surgical trauma was a greater cause of immunomodulation 
than allogeneic blood and that leukodepletion was unable to prevent impairment 
of NK cytotoxic function. 
The change in NK cytotoxic function in the group receiving autologous pre-
deposit blood could have been due to haemorrhage-induced immunomodulation 
leading to a shift of mature NK cells from the blood to the bone marrow and 
recruitment into the blood circulation of immature NK cells with weaker function 
(Ford et aI., 1987; Lasek et aI., 1987; Marquet et aI., 1993a; Marquet et aI., 
1993b). However, this was an unlikely explanation in this study in view of the 
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lack of difference between the pre-operative NKpf values of the non-transfused 
(no significant haemorrhage) and the pre-deposit autologous group's (significant 
haemorrhage ). 
The NKpf decrement following surgery and allogeneic transfusions may 
have been accounted for either by a decreased inflow of NK precursor cells from 
the bone marrow into the blood or an increased outflow of NK precursor cells 
from the circulation into inflammatory sites. Alternatively NK precursors may 
have been inhibited or destroyed within the blood. 
The reversal of this effect by unwashed post-operatively salvaged blood 
drained from the wound site may have been caused by soluble substances 
acquired from the damaged tissue. The mechanisms of action are not 
understood, but some possibilities are described below: 
1) Cytokines. There are increased concentrations of IL-1a, IL-1~, IL-6 
and I L-8 in the collected blood (Arnestad et aI., 1994). Transfusion of unwashed 
salvaged blood increased IL-6 and IL-8 levels in the recipients' plasma. Whereas 
transfusion of washed salvaged blood, resulted in no elevation in these cytokines 
(Arnestad et aI., 1995). 
IL-6 is produced by Th2 cells, leukocytes, fibroblasts, hepatocytes and 
gastric epithelial cells and acts as a proliferation and differentiation factor for B-
cells, mast cells and eosinophils (Romagnani et aI., 1998; Ding et aI., 2000a). 
IL-1a and IL-1 ~ are produced by keratinocytes, monocytes/macrophages 
and 8-cells. IL-1 a and IL-1 ~ play an important role in inflammatory and innate 
immune responses. They cause differentiation of T- and B-cells and induce IFNy 
production by NK cells (Biron et aI., 1999; Pan et aI., 2001). They also stimulate 
fibroblast proliferation and chemotaxis, leukocyte chemotaxis and keratinocyte 
migration. They can act synergistically with TNFa. Moreover, IL-1 production by 
fibroblasts is induced by TGF-~ (Schaffer and 8arbul, 1998; Gharaee_Kermani 
and Phan, 2001). 
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TNFa is produced by monocytes/macrophages, activated NK and T -cells. It 
stimulates macrophage function, fibroblast proliferation, IL-1 production and 
degradation of extra-cellular matrix components by fibroblasts (Schaffer and 
Barbul, 1998; Gharaee_Kermani and Phan, 2001). 
IL-8 is a pro-inflammatory cytokine produced by monocytes/macrophages 
and NK cells and acts as chemokine (Lanier, 2000a; Maghazachi, 2000). IL-8 is 
a member of the CXC chemokine subfamily and is chemotactic for neutrophils, 
monocytes, lymphocytes and NK cells (Maghazachi, 2000). Other cytokines that 
can recruit NK cells from bone marrow to blood circulation are IL-2, TNFa, GM-
CSF, I FNy, L T a/TNF~ (Ito et aI., 1999; Glas et aI., 2000). 
2) Chemokines. Chemokines (chemotactic cytokines) are low molecule-
weight signalling proteins that recruit various types of cells into inflammatory 
sites. They are divided into four subfamilies including CXC (a), CC (~), C (y) and 
CX3C (8) (Maghazachi, 2000; Inngjerdingen et aI., 2001). The CC family is 
chemotactic for monocytes, neutrophils and lymphocytes. Lymphotactin (Ltn) 
and fractakline (neurotactin) are members of C and CX3C subfamily, respectively 
that induce the migration of NK cells (Maghazachi, 2000). It was shown that 
macrophage inflammatory protein-1a (MIP-1a), the factor termed, "regulated 
upon activation normal T-cell expressed and secreted" (RANTES), macrophage 
chemotactic protein- 1,2,3 (MCP-1,2,3), interferon-induced protein-10 (IP-10) and 
MIP-1 ~ are chemotactic for NK cells (Biron et aI., 1999; Glas et aI., 2000). 
Inngjerdingen showed that NK cells express the receptors for monokine 
induced by interferon (MIG), MIP-3~ and IL-8. NK cells also express CCR4-the 
receptor for stromal-derived factor-1 (SDF-1), CCR8-the receptor for 1-309, and 
the receptor for growth related oncogene-a (GRO-a) (Inngjerdingen et aI., 2001). 
Campbell showed that CD56+CD16+ NK cells migrate in response to IL-8 
(Campbell et aI., 2001). Otto showed an increase in expression of MIP-1a and its 
receptor CCR5 on NK cells after closed head injury in mice (Otto et aI., 2001). 
Production of MCP-1 by epithelial cells is stimulated by IL-1~, TNFa and IL-6 
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(Biswas et aI., 1998). DiPietro showed that MIP-1 a produced at the site of injury 
strongly recruits macrophages to the injury site (DiPietro et aI., 1998). 
Cosman reported that NK cells produced 1-309, a ligand for CCR8 that 
recruited and activated NK cells and macrophages (Cosman et aI., 2001). 
In Perera's study it was shown that IL-15 was a potent inducer of CC, 
CXC, and C chemokines subfamilies in lymphocytes. It also enhanced the 
secretion of MIP-1 a and RANTES, and induced the expression of CC chemokine 
receptors (Perera et aI., 1999). 
Dinarello showed that IL-18 stimulated both CXC and CC subfamilies of 
chemokine. IL-18 IS a pro-inflammatory cytokine producing by 
monocytes/macrophages and keratinocytes and its production is stimulated by IL-
1, TNFa, LPS, and exotoxins from gram-positive bacteria (Dinarello, 1999). 
Interestingly, Moore reported that Iodine released from the lodosorb 
wound dressing recruited macrophages to the wound site resulting in increased 
TNFa synthesis, decrease in IL-6 synthesis and an influx of monocytes and T-
cells into the site of wound (Moore et aI., 1997). 
Table-8.5 shows those chemokine that can stimulate NK cell proliferation, 
recruitment and activation. 
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Table-8.5: Chemokines acting on NK cells 
chemokine subfamily receptor source Target 
GRO-o. CXC (a) CXCR2 MQ/MO, leukocyte, MQ/MO, 
endothelial cells NK cell, lymphocyte 
IP-10 CXC (a) CXCR3 MQ/MO, neutrophil, 
leukocyte, MQ/MO, 
epithelial & endothelial 
NK cell, lymphocyte cells 
IL-8 CXC (a) CXCR1,2 leukocyte, MQ/MO, 
MQ/MO, NK cell 
NK cell, lymphocyte 
MIG CXC (a) CXCR3 MQ/MO, neutrophil, leukocyte, MQ/MO, 
epithelial & endothelial NK cell, lymphocyte cells 
SDF-1o. CXC (a) CXCR4 BM stromal cells, CD34+haematopoietic progenitor cell, leukocyte, 
endothelial cells MQ/MO, NK cell, iYmphocyte 
6Ckine CC (~) CCR7 MQ/MO, keratinocytes dendritic cell, 
epithelial & endothelial NK cell, lymphocyte 
cells 
1-309 CCW) CCR8 MQ/MO, lymphocytes, leukocyte, MQ/MO, 
NKcell NK cell, lymphocyte 
MCP-1,2,3 CCW) CCR2 MQ/MO, keratinocytes leukocyte, MQ/MO,NK cell, 
epithelial & endothelial lymphocyte, platelet, mast 
cells cell, fibroblast 
MIP-1o. CCW) CCR1,5 MQ/MO, keratinocytes, leukocyte, MQ/MO, NK cell, 
NK cell, endothelial lymphocyte, fibroblast 
cell, platelet 
MIP-1 ~ CC (~) CCR1,5 MQ/MO, keratinocytes, leukocyte, MQ/MO, NK cell, 
NK cell, endothelial cell lymphocyte, fibroblast 
MIP-3~ CCW) CCR7 MQ/MO, keratinocytes, NK cell, lymphocyte 
endothelial cells 
RANTES CC W) CCR1,5 T-,NK,NKT-cell, leukocyte, MQ/MO, 
MQ/MO, endothelial NK cell, lymphocyte 
cell, chondrocyte 
Lymphotactin C (y) XCR1 NK cell, T-cell, mast leukocyte 
(Un) cell NK cell, lymphocyte 
Fractakline CX3C (8) CX3CR1 endothelial and T -cell and NK cell epithelial cells, dendritic 
(neurotactin) cell 
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3) Complement production. C5b is a component of the complement 
system produced during the formation of the C5b-9 membrane attack complex 
that causes destruction of target cells or micro-organisms. C5b is a chemotaxin 
and activator of neutrophils. It also mediates an inflammatory reaction at the site 
of injury by stimulating endothelial cells (Rawal and Pangburn, 2001). 
Figure-37.5 summarises the possible effect of some cytokines on inflow of 
NKp into blood from bone marrow or the effect of some monokines in blood on 
NKp proliferation and activation following unwashed autologous post-operative 
salvaged blood. 
Individual variation in NKpf was apparent both before and after operation 
presumably reflecting different clone sizes. 
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Figure-37.5: Schematic diagram of inflow and 
maturation of NKp in peripheral blood following 
autologous post-operative unwashed salvaged 
transfusion. The release of some cytokines and 
monokines at the site of surgery may have a positive 
effect on NKp migration, proliferation and/or activation. 
The diagram illustrates those cytokines that can 
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5.3. Changes in cytokine synthesis after surgery and blood transfusions 
The level of IFNy and IL-10 were examined pre and post-operatively as 
examples of pro-inflammatory and anti-inflammatory cytokines. I FNy is secreted 
mainly by activated NK cells, NKT-cells and Th1cells and is involved in both 
innate and adaptive immunity. It is a pro-inflammatory cytokine that plays an 
important role in early defence against a number of different infectious agents 
and neoplasia. IFNy produced by NK cells is part of innate immunity that 
provides a rapid response to viral infections before the involution of adaptive 
immunity. Virus-infected cells induce I FNy and I FNa/p synthesis by activated NK 
cell within hours of primary infections. Thus, NK cell-mediated cytotoxicity and 
IFNy production act against virally infected cells before adaptive immunity 
develops (Biron and Brossay, 2001; Guidotti and Chisari, 2001). Moreover, IFNy 
activates phagocytic cells and induces oxygen free radical and nitric oxide-
dependent microbicidal effects in macrophages against intracellular infections 
before clonal expansion of T- and B-cells (Trinchieri, 1997). 
In the current study, there was a decrease in mean IFNy synthesis in 
non-transfused, allogeneic (Ieukodepleted and non-Ieukodepleted) transfused 
and autologous pre-deposit groups but, an increase in those who received 
unwashed post-operatively salvaged blood. This suggests that surgical trauma 
and allogeneic transfusions were associated with decreased IFNy synthesis as a 
reflection of reduced NK function. Several clinical studies have shown that the 
IFNy response decreases after major surgery (Redmond et aI., 1992; Berguer et 
aI., 1999; Brune et aI., 1999; Berguer et aI., 2000). This is specially so in those 
patients who were also transfused with allogeneic blood (Tietze et aI., 1995; 
Blumberg and Heal, 1996b; Quintiliani et aI., 1997; Baudouin et aI., 1998). 
IL-10 IS an anti-inflammatory cytokine, secreted by Th2 cells, 
monocytes/macrophages, B-cells, eosinophils, mast cells, keratinocytes, 
intestinal epithelial cells and bronchial epithelial cells (Autschbach et aI., 1998; 
Romagnani, 1999; Okada et aI., 2000). Human IL-10 inhibits the production of 
pro-inflammatory cytokines by T -cells and NK cells and the release of oxygen 
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free radicals and nitric oxide-dependent microbicidal activity by macrophages and 
neutrophils. It also inhibits antigen-specific activation, proliferation and the 
expression of CD54, CD80, and CD86 by T-cells (de_WaaLMalefyt et aI., 1991b; 
Groux et aI., 1998). However, other studies show that IL-10 increases NK cell 
cytotoxic function and cytokine release. These studies also show that NK cells 
express IL-10R and can produce IL-10 thereby inhibiting pro-inflammatory 
cytokines production within the vicinity of NK cells (Liu et aI., 1994; Carson et aI., 
1995a; Mehrotra et aI., 1998; Peritt et aI., 1998). 
In this study an attempt was made to correlate IL-10 synthesis with 
surgical trauma and different kinds of transfusion. The result obtained was that 
patients receiving unwashed post-operatively salvaged blood drained from the 
wound showed an increase in the IL-10 synthesis compared to the other groups. 
This was of interest firstly because, increased IL-IO was assumed to decrease 
IFNy synthesis. Secondly, because it begged the question of the source of IL-10 
synthesis and whether this it was produced from NK cells or other cells in the 
culture. 
There was a positive correlation between changes in NKpf and changes in 
IFNy (r=0.28) and between NKpf changes and IL-10 changes (r=0.16) in all 
patient groups combined. Furthermore, there was a positive correlation between 
changes in IFNy and changes in IL-10 (r=0.13) in all patient groups combined. 
Other studies support a correlation between the NK cell cytotoxic function and 
IFNy synthesis in various patient groups (Quintiliani et aI., 1997; Andersen et aI., 
1998; Bordin et aI., 1999). In contrast, the IL-10 result was not supported by 
previous studies that mainly demonstrated a decrease in post-operative IL-10 
production (Heiss et aI., 1997b; Klava et aI., 1997; Kirkley et aI., 1998; Koller et 
aI., 1998; Berguer et aI., 1999; Berguer et aI., 2000). 
The present studies involved IL-2 and IL-15 activated PBMC cultures. 
Thus IL-10 could have been produced by Th2 or NK cells. Liu and Carsons' 
studies showed that activated NK cells were able of producing IL-10 (Liu et aI., 
1994; Carson et aI., 1995a). Joshi showed a significant decrease in NK cell 
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cytotoxic function when PBMC were cultured for 40 hours with plasma samples 
derived from trauma patients and this phenomenon was not reversed by adding 
neutralising anti-IL-10 antibody. However, removal of monocytes from the 
cultured cells significantly reversed the NK cell cytotoxic function (Joshi et aI., 
1998). This does not exclude the possibility that IL-2 activated Th2 cells 
produced IL-10 in our studies. But it begs the question as to why more IL-10 
was not produced in groups that showed post-operative suppression of NKp. 
IL-10 acts by inhibiting prostaglandin E2 (PGE2) production and is one of 
the main regulators of the immune response. PGE2 production increases after 
surgery and has a deleterious effect on NK cell function (Rees and Platts, 1983; 
Ertel et aI., 1993; Wang et aI., 1997; Kim et aI., 1999; Rhind et aI., 1999; Liu et 
aI., 2000b; Deichman et aI., 2001; Moore et aI., 2001). Thus reduced IL-10 
synthesis observed post-operatively in our studies may have contributed to 
increased PGE2 production and decreased NK function. It also holds that the 
reverse is true following transfusion of autologous salvaged blood. 
The IL-4 results are less reliable due to sample selection. Several 
previous studies reported similar results, whereby IL-4 synthesis increased after 
surgical trauma and allogeneic transfusions (Ayala et aI., 1994; Coimbra et aI., 
1996; Mack et aI., 1996; Levy et aI., 1997; Baudouin et aI., 1998; Zedler et aI., 
1999; Koga et aI., 2000; Ochoa et aI., 2001). IL-4 is produced mainly by Th2 cells 
and is regulated by IFNy produced by Th1 cells (Romagnani et aI., 1998). 
However observation in the current study showed a negative correlation between 
IL-4 and IFNy synthesis. 
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5.4. Is CD56 adequate as a unique marker for functional NK cells? 
NK cell cytotoxicity is an important indicator for evaluating baseline 
immune defence, monitoring progress during cancer immuno-therapy and 
treatment of AIDS. 
Different methods are being used to assess NK cytotoxic function such as 
51Cr release assay, lactate dehydrogenase (LDH) release assay, Eu-release 
assay, Calcein cytotoxicity assay, flow cytometric assay of intracellular cytokine in 
NK cells, MTT assay (measuring the cell viability via mitochondrial activity in 
target cells) and 125lUdR-release assay (measuring DNA fragmentation in target 
cell) (Morales and Ottenhof, 1983; Blomberg et aI., 1986b; Blomberg et aI., 
1986a; Chang et aI., 1993; Umemoto et aI., 1997; Roden et aI., 1999; Mendes et 
aI., 2000). 
In the flow cytometry assay the number of NK cells in the circulating blood 
is determined by double or triple staining with monoclonal antibody against CD3, 
CD16 and CD56. For precise enumeration of NK cells among PBMC cells the 
sample should be stained by a combination of anti-CD3 and anti-CD56 (double 
staining) or anti-CD16 (triple staining) (Mendes et aI., 2000). Furthermore, it is 
possible to quantitate activated NK cells by flow cytometry by determining HLA-
DR, CD25 (IL-2Ra), CD69 and CD71 (transferrin receptor) expression in the 
CD3-CD56+ cell population. However, it is not clear that the expression of these 
activation markers correlates with NK cell cytotoxic function (Whiteside and 
Herberman, 1994; Whiteside and Herberman, 1995b). 
Attempts to relate immuno phenotype to NK cytotoxic function have been 
made by others (Roder et aI., 1980; Whiteside and Herberman, 1989; Whiteside 
and Herberman, 1994). In humans CD16 exists in two isoforms: a 56-60 KDa 
trans-membrane isoform (FcyRIIIA) mainly expressed on NK cells, mast cells and 
monocytes/macrophages and a GPI-linked 48 KDa isoform (FcyRIIIB) expressed 
exclusively on neutrophils. CD16 may also be expressed on CD3+ T-cells in 
certain individuals. CD56 is expressed on some human haemopoietic cells 
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including NK cells and a sub-population of T lymphocytes termed NKT-cells. It is 
also expressed in adult neural tissues, muscle and embryonic tissues. A number 
of tumour cell types are positive for CD56 including some myeloid leukaemias, 
myelomas, neuroblastomas, Wilmls tumour and small cell carcinomas (Barclay et 
aL, 1997; Carayol et aL, 1998; Godfrey et aL, 2000). 
Observations in the present study suggested that rlL-2 alone 
preferentially activated CD3-CD16+ compared to CD3- CD56+ cells whereas rlL-
15 activated a higher percentage of CD3-CD56+ population. This result suggests 
that although IL-2R and IL-15R can both be ligated by IL-2 and IL-15 by virtue of 
the shared p and yc chain, they reserve their highest specificity for their specific 
cytokines. Furthermore the result suggests these proliferation that are IL-2R+, IL-
15R-; IL-2R+, IL-15R+ and IL-2R-, IL-15R+. 
Lack of correlation between percent CD3-CD56+ cells and NKpf (r=O) was 
consistent with the notion that although most NK cells may express C056+, not 
all cells expressing CD56+ exhibit NK function, and circulating C056+ cells may 
vary in their state of cytotoxic activation (Whiteside and Herberman, 1995a). Also 
LOA assay measures the number of precursors of functionally active NK cells 
within a PBMC sample with very high sensitivity compared to flow cytometry 
assay, which enumerates the proportion of C03-C056+ cells within a PBMC 
sample with lower sensitivity. 
These results support the previous observations that enumeration of NK 
cells by flow cytometry is unable to measure reliably NK cytotoxic function and 
that the CD3-CD56+ cell is an inadequate marker (Roder et aL, 1980; Whiteside 
and Herberman, 1989; Whiteside and Herberman, 1994). Figure-38.5 is 
schematic summery of measuring NKpf by LOA and enumeration of percent 











o ~ ~ 
o ~ ~ .. Quantitated by CD3-CD56+(flow cytometry) 
Figure-38.5: Schematic diagram of measurement of 
the frequency of NK cell precursors (NKpf) by LOA 
and enumeration of percent C03-C056+ cells by 
__ --', flow cytometry. 
5.5. The correlation between post-operative infections and type of 
transfusion 
There was a trend towards a higher incidence of post-operative infections 
were shown after allogeneic (Ieukodepleted and non-Ieukodepleted) transfusions 
(16.5%) than after autologous (pre-deposit and unwashed autologous post-
operative salvaged blood) transfusion (8%) and the proportion of infection was 
greater after autologous transfusion than after no transfusion (12.5%). 
Many previous clinical studies have reported that allogeneic transfusion is 
associated with a higher incidence of post-operative infections compared to non-
transfused and even autologous transfused patients. I n a well-conducted meta-
analysis by Houbiers involving eleven studies the post-operative infection rate in 
allogeneic transfused patients was more than two times that in non-transfused 
patients (Houbiers, 1994). In another study, Houbiers observed a higher 
incidence of post-operative infection in patients receiving allogeneic buffy coat-
depleted packed red cells or white cell-reduced packed red cells compared to 
non-transfused patients (Houbiers et aI., 1997). Patients undergoing surgery for 
malignant disease have a similar increase in post-operative infections associated 
with allogeneic transfusions compared to non-transfused patients (Tartter, 1988a; 
Tartter, 1989; Braga et aI., 1992; Jensen et aI., 1992; Tartter, 1993; Vignali et aI., 
1996; Jensen et aI., 1997; Edna and 8jerkeset, 1998a; Vamvakas and Carven, 
1998a; Chang et aI., 2000). 
In patients undergoing orthopaedic surgery, an association was shown 
between allogeneic transfusions and higher post-operative infections compared 
to non transfused patients and those who received autologous blood (Murphy et 
aI., 1991; Fernandez et aI., 1992; Triulzi et aI., 1992; Vamvakas et aI., 1995; 
Carson et aI., 1999; Innerhofer et aI., 1999b). 
The question generated with all clinical investigations is whether allogeneic 
blood transfusions are a major cause of post-operative infections or an effect 
superimposed on surgical trauma and anesthesia. Many studies have clearly 
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shown that major surgery is strongly associated with deleterious effects on the 
immune system leading to increased risk of post-operative infections (Rodrick et 
aI., 1986a; Pollock et aI., 1992; Griffith et aI., 1995; Bruns et aI., 1996; Hoffman et 
aI., 1996; Kutza et aI., 1997; Andersen et aI., 1998; Berguer et aI., 1999; 
Stanojevi+_Baki+ et aI., 1999; Berguer et aI., 2000). But, it is difficult to 
quantitative this result because of surgical and anaesthetic techniques, and even 
drugs are strikingly different from centre to centre. 
Since there is strong evidence that NK cells playa key role in defence 
against intra-cellular micro-organisms, NKpf assays may reflect susceptibility to 
infection. However, clearly these assays take too long to be of routine prognostic 
value. Notwithstanding this NKpf changes may reflect major immunomodulatory 
effects of surgical trauma and/or blood transfusions.:. NKpf assays could also be 
used to explore the efficacy of a factor that clearly exists in wound drainage fluids 
that, if isolated, may reverse the immunosuppression induced by surgical trauma. 
Other parameters of innate immunity including cellular components and/or 
soluble mediators such as PMN cells, monocytes/macrophages, complement and 
antibody may also have been affected by surgical trauma and/or allogeneic blood 
transfusions resulting in an increase in the risk of post-operative infections mainly 
by extra-cellular bacteria. 
The results at the present study suggest that surgical trauma and 
allogeneic blood transfusions induce immunomodulation by impairment in NK 
cytotoxic function, decreased IFNy synthesis and IL-10 synthesis and that these 
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Appendix 
Literature review of some studies 
1. A retrospective study in colorectal malignancy patients showed that 
the proportion of tumour recurrence in those who received allogeneic blood was 
significantly more than patients non-transfused. In this study, the records of 177 
transfused and 118 not transfused patients who underwent surgery for colorectal 
malignancy were examined. They observed that ninety-five percent (95%) of not 
transfused patients were recurrence free at the end of 1 year compared to eighty-
six percent (86%) of those patients, who transfused before operation. This 
difference persisted for the 5 years of the study. In addition, transfused patients 
in any of the pathological stages had lower recurrence-free rates in every 
postoperative year compared to allogeneic transfused patients (Burrows et aI., 
1987). 
2. Tartter is one of the most important pioneers to have increased 
awareness of the phenomena that allogeneic transfusion is associated with 
immunomodulation in the host immune system. He found significant depression 
of NK cell activity, higher risk for tumour recurrence, longer hospital stays, higher 
incidence of post-operative infection and higher hospital charges after allogeneic 
transfusion in colorectal cancer patients. In addition, he noticed that the mean 
number of units of allogeneic blood received by colorectal malignancy patients 
who developed infectious complications significantly exceeded the number for 
patients without infectious complications. Of the 343 patients who underwent 
surgery 134 patients received allogeneic transfusions. A total of 33 post-
operative infections were identified in 33 of the 134 patients, giving an infection 
rate of 25 percent. By contrast, of the 209 patients who did not receive 
allogeneic transfusion 9 patients developed post-operative infection given 
infection rate of 4.30/0 (Tartter, 1988b; Tartter, 1988c; Tartter, 1988a; Tartter, 
1992). 
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3. Blumberg in a series of papers has shown that allogeneic blood 
transfusion was not only associated with deleterious effects on host immune 
defences, but also with additional costs of up to $1500 per unit. Hospital charges 
were estimated in patients undergoing hip-replacement surgery. The main 
outcome was increased hospital costs per unit transfused. The mean of total 
hospital charges among donors of autologous blood was $4,800. Whereas, the 
mean of total hospital charges was $7,200 for recipients of allogeneic 
transfusions. Thus, each allogeneic transfusion was associated with additional 
cost of $1,480. Blumberg is one the pioneers who believe that allogeneic 
leukocytes in cellular blood products are the main reason why allogeneic 
transfusion induces immunomodulation. He has also suggested that 
leukodepletion of allogeneic blood reduced or prevented these deleterious 
effects. In addition, he speculated that the mechanism may involve altered 
cytokine regulation with a shift toward an anti-inflammatory response (Blumberg 
and Heal, 1987; Blumberg et aI., 1996; Blumberg, 1997) 
4. In two interesting studies on NK cells, in 1987, it was shown that 
blood donation was associated with a decrease circulating NK cell levels and 
function in the healthy volunteer. However, these effects was not associated 
with adverse clinical manifestations in the healthy blood donor (Ford et aI., 1987; 
Lasek et aI., 1987). 
5. In 1990, was suggested that allogeneic blood was associated with 
later hospital discharge, a higher rate of post-operative infection and more 
antibiotic therapy compared to autologous blood transfusion. In this retrospective 
study, 190 patients who underwent hip replacement surgery were analysed. 34 
patients were transfused with 2 or 3 units of autologous blood and 50 patients 
were transfused with 2 or 3 units of allogeneic blood. Other patients were 
excluded from the study for a number of different reasons. A total of 16 post-
operative infections were identified in 16 of the 50 patients, giving an overall 
infection rate of 32 percent. By contrast, only one of the autologous transfused 
patients, (30/0), developed post-operative infection. Thus, the proportion of post-
operative infections in allogeneic transfused patients was 10 times more than the 
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autologous transfused groups. In addition, patients identified as being infected 
required significantly more antibiotic therapy (mean, 7.6 days) and lengthier 
hospital stays (mean, 15.5 days) than patients who remained free of infection 
(Murphy et aI., 1991). 
6. In a study that compared the effects of allogeneic and autologous 
blood transfusions on post-operative infection rates, allogeneic blood transfusion 
was associated with higher post-operative infection compared to autologous 
transfusion. Fifty patients received autologous blood and 50 allogeneic blood but 
underwent the same procedure. The proportion of post-operative infection, 
confirmed with positive cultures, was sixteen percent of the allogeneic transfused 
patients and 4 percent in the autologous patients (Mezrow et aI., 1992). 
7. In 500 patients who underwent surgery for pancreatic and 
gastrointestinal cancer the amount of blood transfused and the volume of per-
operative blood lost were independent risk factors in the development of post-
operatively infection (Braga et aI., 1992). 
8. In patients who underwent spinal fusion operations an increase in 
post-operative infection and longer hospital stay were found in patients receiving 
allogeneic transfusion compared to those who received autologous or no 
transfusion. They also noticed that surgical trauma, allogeneic blood transfusion 
and anaesthesia decreased the number of NK cells. Of 109 patients, 60 received 
autologous blood; 24 received at least one unit of allogeneic blood, and in 25 had 
no transfusions. A total of 22 post-operative infections were identified in 22 of 
109 patients. These occurred while in hospital (8) and in after discharge (14) and 
gave an overall infection rate of 22.2 percent. Twenty-two patients developed 
bacterial infections. The post-operative infection rates were, 3.3 percent in 
autologous transfused patients, 20.8% in allogeneic transfused patients and 4 % 
in no transfused. In addition, multivariate logistic and linear regression analysis 
revealed that the number of allogeneic units transfused was the only significant 
predictor of in-hospital infection or days on antibiotics and length of stay (Triulzi et 
aI., 1992). 
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9. In 1992, it was shown that allogeneic blood transfusion impaired NK 
cell function for up to 30 days after operation in patients who underwent 
colorectal surgery. Also, in this study the effect of leukodepletion and platelet 
depletion on post-operative infection rate was researched. Of 197 patients 
undergoing elective colorectal surgery, 48 received blood free from leukocytes 
and platelets and 56 received whole blood transfusion. The number of post-
operative infections were, 13 in transfused patients with whole blood (23 0/0), one 
in patients transfused with filtered blood (2%») and two in the non transfused 
patients (20/0) (Jensen et aL, 1992). They also showed a decrease in lymphocyte 
proliferation and CD4+CD8+ ratios, and a higher proportion of post-operative 
infection in allogeneic blood transfused patients (Jensen et aI., 1997). 
10. In three different studies in patients who underwent colorectal 
surgery, Busch et al observed that allogeneic blood transfusion was associated 
with poor prognosis and a significantly higher risk of tumour recurrence compared 
to those who did not receive blood transfusion, either allogeneic or pre-deposit 
autologous. In a randomised study on 475 patients who underwent colorectal 
cancer the risk of recurrence was investigated. 236 patients out of a total of 475 
patients received allogeneic transfusions and 239 patients received autologous 
pre-deposit transfusion. Patients in the autologous-transfusion group were 
required to donate two units of blood before their surgery. The cancer-specific 
survival rates at four years were 67 percent in the allogeneic transfused patients 
and 62 percent the autologous pre-deposit transfused group. Thus, no significant 
difference in prognosis was observed. By contrast, the risk of recurrence was 
significantly increased in the allogeneic or autologous pre-deposit groups, as 
compared with non-transfused patients (Busch et aI., 1993b; Busch et aL, 1994b; 
Busch et aL, 1994a). In the same study, the effects of allogeneic and autologous 
pre-deposit blood transfusions on patients who underwent colorectal cancer were 
investigated. The post-operative infection rate with autologous was significantly 
less than allogeneic blood transfused patients. In this study of 120 patients, 58 
patients donated their blood before operation. The number of post-operative 
infections was 7 (120/0) in transfused autologous pre-deposit patients and 
17(270/0) in the allogeneic transfused patients. Thus, the proportion of post-
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operative infection in allogeneic transfused group was 2.25 times more than 
autologous pre-deposit transfused group, despite the similarity between the 
groups in risk factors known to affect post-operative infections (Heiss et aI., 
1993). 
11. A meta-analysis confirmed these observations and provided the 
foundation for a prospective randomised control trial. This showed that 
allogeneic transfusion was associated with increased mortality due to post-
operative infection but the increase was not due to recurrence of the colorectal 
cancer. In this study, the data from 871 patients with colorectal cancer was 
collected from 16 hospitals. Patients, who received allogeneic transfusions of 
any, sort (leukocyte-depleted red cells or packed cells without buffy coat) had a 
lower three-year survival and a higher infection rate than non-transfused patients. 
This confirmed that allogeneic transfusion, leukocyte-depleted red cells or packed 
cells without buffy coat, were associated with poor patient survival. By contrast, 
colorectal cancer recurrence rates, were not influenced by blood transfusion 
(Houbiers et aI., 1994a). 
12. In 27 patients who underwent hip replacement surgery the effects of 
allogeneic and autologous buffy coat-depleted red cells on cytokine levels in 
serum were investigated. The result showed a decrease in IL-2 and IFNy serum 
levels, and an increase in IL-6 levels post-operatively in both groups (Tietze et aI., 
1995). 
13. In a big review study by Landers, he found strong evidence that 
allogeneic transfusion was associated with an increase in cancer recurrence, 
post-operative infections and longer hospital stays (Landers et aI., 1996). 
14. In a prospective study on 267 patients who underwent colorectal 
cancer 47 of 142 patients receiving allogeneic transfusion developed post-
operative infection. Multivariate analysis identified allogeneic transfusion as the 
only variable related to the occurrence of postoperative infections (Vignali et aI., 
1996). 
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15. In a study, of NK and LAK cell (Iymphokine-activated killer) activity, 
allogeneic transfusion was associated with post-operative decrease in NK cells 
and LAK activity. By contrast, autologous transfusion was associated with 
increased NK cell activity (Heiss et aI., 1997a). 
16. A significant reduction of NK cell cytotoxic function against K562 
target was observed in allogeneic transfused patients was observed compared to 
patients who did not receive transfusions (Mathiesen et aI., 1994) 
17. Both leukodepleted and non-Ieukodepleted blood transfusions 
impaired NK cell function post-operatively. Of 129 patients who underwent 
surgery for colorectal malignancy, 42 received transfusions. Of these 42, 21 
received leukocyte-depleted products and 21 non-leukocyte-depleted products. 
A significant reduction in 0/oCD4+ lymphocytes at 6 months post-operatively was 
observed in the latter group. In contrast, no significant changes in %CD4+ 
lymphocytes were observed in leukocyte-depleted transfused patients. There 
was a marginal decrease in HLA-DR+ lymphocytes in the non-leukocyte-depleted 
transfused patients without a history of previous transfusion (Mathiesen et aI., 
1998). 
18. In a literature review, it was speculated that allogeneic red cell 
transfusion was a risk factor for impairment of phagocyte cells in bacteria 
clearance. Post-operative infection in 697 patients with colorectal cancer who 
received buffy coat-depleted packed red cells and white cell-reduced (filtered) 
packed red cells, were compared with non transfused patients. The proportion of 
post-operative infections with both types of red cells was greater than the non-
transfused group (39 vs. 24%, p < 0.01). In addition, multivariate analyses 
identified that red cell transfusion and tumour location were the only significant 
independent risk factors for postoperative bacterial infection (Houbiers et aI., 
1997). 
19. In studies of 446 patients who underwent resection of colorectal 
adenocarcinoma, allogeneic blood transfusion was an independent risk factor for 
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the development of post-operative hospital infections (Edna and BJ'erk t ese, 
1998a). They also studied 336 patients who underwent colorectal surgery for 
adenocarcinoma and showed that there was a significant correlation between 
per-operative transfusion and death (Edna and Bjerkeset, 1998b). 
20. A study of 487 patients who underwent colorectal cancer surgery 
speculated that later discharge from hospital and higher hospital charges were 
associated with a higher post-operative infection rate due to allogeneic 
transfusion. The mean length of stay in hospital was, 16.7 days in transfused 
patients and 10.3 days in the non- transfused patients. The mean hospital 
charge was a $28101 in transfused patient and $15978 in non-transfused 
patients. The length of stay in hospital was increased by a average of 1.3% per 
unit of blood transfused (p<0.05) and hospital charges increased by 2.0% per unit 
of blood transfused (p<0.05) (Vamvakas and Carven, 1998a). 
21. Innerhofer et al indicated that transfusion of buffy-coat depleted 
blood was associated with increased post-operative infections in orthopaedic 
patients. 385 patients undergoing elective surgery were transfused with either 
allogeneic buffy coat-depleted or autologous transfusions. The proportion of 
post-operative infections was, 4.6 % in the non-transfused or autologous groups 
and 11.9 % in the allogeneic transfused group (Innerhofer et aI., 1999b). They 
also showed impairment of cell mediated immunity after allogeneic transfusion in 
recipients with changing T-cell proliferation and T-cell balance (helper-suppressor 
ratio ). T-cell proliferation, PHA stimulation and mixed lymphocyte culture, were 
all significantly decreased in transfused allogeneic leukocyte-reduced compared 
to the autologous transfused group. This reduction persisted up to 10 days after 
transfusion. A trend toward decreased T-cell proliferation was observed in 
allogeneic buffy coat-depleted transfused patients. The number of CD4+ T -cells 
was also significantly lower in both kinds of allogeneic transfusions compared to 
autologous transfusion. In addition, a decrease in the numbers of CD3+ T-cells 
and an increased CD4:CD8 ratio was observed in allogeneic transfused patients 
(Innerhofer et aI., 1999a). 
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22. Other studies supported the idea that allogeneic transfusion alters 
host cellular immunity by decreasing the number of lymphocytes and NK cells. 
In Bordin's study, the effect of leukodepletion and non-Ieukodepletion on 
allogeneic transfusions on host cell-mediated immunity, was evaluated. Using 
PHA stimulation of 47 patients undergoing hip replacement surgery, 17 received 
allogeneic transfusion and 16 were non-transfused. The post-operative 
lymphocyte and NK cell numbers were significantly decreased in those 
transfused with 3 or more units of blood, compared with non transfused patients. 
Post-operatively, IL-2 and IFNy synthesis following PHA stimulation was 
decreased in transfused patients. In another study, 51 women with stage II 
breast cancer who underwent surgery were studied. The CD3+, CD4+, CD8+, 
and CD20+ cells were analysed by flow cytometry before surgery and three 
weeks after operation. No significant differences between pre- and post-
operative lymphocyte subset levels were seen in non-transfused patients but 
there was a significant increment in the CD8+ cell count, a decreasing CD4+ cell 
count and decreased CD3+ cell count levels in the transfused group (p< 0.05) 
compared with the non-transfused patients (Bordin et aI., 1999; EroYlu et aI., 
1999). 
23. A retrospective cohort study in patients who underwent hip 
replacement showed a correlation between allogeneiC transfusion and a higher 
incidence of post-operative bacterial infection. The records of 9598 patients 
undergoing surgical repair for hip fracture were evaluated. 58% of patients 
received at least one allogeneic blood transfusion. There was a serious post-
operative bacterial infection in 437 patients (4.60/0) of whom 28.8% died during 
their hospital stay. The most common site of infection was urinary tract, (12.1 %). 
Pneumonia occurred in 3.8% of patients. The hospital charges in those who 
developed post-operative infections was $14,000 more than those with no 
infection. In total, transfusion was associated with a 35% higher risk of post-
operative bacterial infection and a 52% greater risk of pneumonia (Carson et aI., 
1999). 
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24. In a prospective study, 1,349 patients undergoing colorectal surgery 
in 11 centres across Canada were analysed. Of these 282 were transfused with a 
total of 832 allogeneic blood units. The incidence of post-operative infection was 
significantly higher after allogeneic transfusion. The proportion of post-operative 
infections was, 25.9% after allogeneic transfusion and 14.2% after no 
transfusion. The most common sites of post-operative infections were the wound 
area and intra-abdominal sepsis. Multiple regression analysis identified 
allogeneic transfusion as a significant independent predictor for post-operative 
bacterial infection (Chang et aI., 2000). 
25. In a recent study of 442 patients who underwent colorectal surgery 
and received either allogeneic leukodepleted or non-Ieukodepleted transfusion. 
The proportion of post-operative infections were 45% in leukodepleted group, 




26. In clinical studies of 18 patients with severe traumatic injury a 
significant decrease in IL-2 production up to 50 days after injury was observed 
(Rodrick et aI., 1986b). 
27. In 85 patients who underwent surgical resection for solid tumours a 
significant decrease in NK cell cytotoxic function was observed (Pollock et aI., 
1992). 
28. In 34 patients who underwent laparoscopic cholecystectomy less 
depression of cell-mediated immunity was observed than those with open 
cholecystectomy (Griffith et aI., 1995). 
29. In clinical studies a significant decrease in NK cell cytotoxic function 
occurred in two groups of patients who underwent esophageal carcinoma and 
non-malignant thoracic and abdominal surgery (Bruns et aI., 1996). 
30. In a study of tumour recurrence and survival in patients undergoing 
laparoscopic and open colorectal cancer surgery for primary colorectal cancer, no 
adverse patterns of recurrence or survival was observed in the laparoscopic 
method compared to another one (Hoffman et aI., 1996). 
31 . I n rat and pig DTH response after laparoscopy and open colon 
resection was investigated. There was a higher and better preserved DTH 
response after laparoscopic resection than after open colon resection (Bessler et 
aI., 1994; Trokel et aI., 1994). 
32. In mice the effects of laparoscopic and open laparotomy bowel 
resection on tumour establishment and growth were investigated by Allendorf et 
al. Tumours were more easily established and grew more aggressively after 
open laparotomy than laparoscopy (Allendorf et aI., 1995a; Allendorf et aI., 
1995b; Allendorf et aI., 1996; Allendorf et aI., 1998). 
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33. A study on NK cell function and general anesthesia found that 
trauma, due to surgery and general anesthesia, has deleterious effects on NK 
cell activity. In this study, the peripheral blood mononuclear cells (PBMC), one 
hour pre-operatively and 20-24 hour post-operatively, were assayed for basal and 
IFN-alpha-stimulated NK cytotoxic function, in patients under isoflurane/N20 
anesthesia. The basal NK cytotoxic function against K562 declined significantly 
after general anesthesia and surgery. However, the post-operative decrease in 
NK function was reversed after IFNa treatment (Kutza et aI., 1997). 
34. Another study on NK cells in patients following diagnosis of breast 
cancer and surgery showed that trauma, due to operative stress was associated 
with decreasing NK and T-cell activity. NK cell and T-cell activity were assayed in 
116 patients treated surgically for invasive breast cancer. A lower NK cell 
cytotoxic activity and lower NK cell response to IFNy was observed. A lower 
proliferative response of peripheral blood lymphocytes to plant lectins and to a 
monoclonal antibody directed against the T-cell receptor, was also found 
(Andersen et aI., 1998). Furthermore, in another study in breast carcinoma 
patients, a post-operative decrease in Iymphoproliferation and NK cell function 
was shown (Stanojevit_Bakit et aI., 1999). 
35. In a study by Berguer and his colleagues the cytokine synthesis 
after open and laparoscopic surgery, were compared. Intracellular T-cell IFNy, 
IL-4, and IL-10, along with serum IL-6, were immediately measured before and 
one day after laparoscopic cholesystectomy. There was a slight increase of 
intracellular levels of IFNy in stimulated T-cell subsets after surgery. However, 
there were no post-operative changes in stimulated IL-4 or IL-10 levels. Post-
operative serum IL-6 levels were significantly elevated compared to pre-operative 
values. In total, major open surgery influences T-cell intracellular IFNy, IL-4, and 
IL-10 more than laparoscopic cholesystectomy (Berguer et a\., 2000). 
36. Surgical trauma is associated with decreased Th1 cytokine 
production. The in-vitro cytokine synthesis was measured immediately before 
and for 2 days after aortic surgery or carotid endarterectomy. The levels of IL-2 
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and I FNy were significantly depressed during the post-operative period in all T-
cell subsets. There was no post-operative increase in IL-4 or IL-10 synthesis 
(Berguer et aI., 1998; Berguer et aI., 1999). 
37. In a clinical study, significant suppression in NK cell function and IL-
2 production were observed after severe burning (Rodrick et aI., 1986a). 
38. In mice it was shown that IL-2 production in splenocytes stimulated 
by concanavalin-A was suppressed up to 21 days following burns. Increased IL-
2 production was observed after adding Indomethacin to the cell culture (Wood et 
aI., 1987). 
39. In a clinical study by Blazer the effect of burn injury on NK cell 
function was investigated. The more severely burned patients had significantly 
depressed NK cytotoxic function persisting for as long as 40 days following 
burning injury. By contrast patients with less burns showed a decreased NK cell 
cytotoxic function persisting for 10 days following burning injury (Blazar et aI., 
1986). 
40. Another clinical study showed that the alteration in neutrophil 
function after burn injury may be caused by LPS soon after injury and by C5a 
later after injury (Moore et aI., 1986; Davis et aI., 1987). 
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A technique was developed to measure the frequency of natural killer cell precursors (NKpf) in human peripheral blood 
mononuclear cell (PBMC) samples. Functional maturity of NK cells was reflected in their ability to lyse target cells from the 
K562 cell line. During the development of the technique, venous blood was taken from one healthy adult and assayed at 
different times to avoid individual variation. The technique was based on the principle of limiting dilution analysis. The NKpf 
assay was set up with a range of cell dilutions from 40,000 to 625 per 100 IJ.l/well in 96-well culture plates. At the end of the 
culture period, the K562 cell line labelled with europium (Eu-K562) was added and the Eu-release was measured in culture 
supernatants using time-resolved fluorometry. The NKpfvalue differed between individuals and was influenced by the length of 
time in culture, being maximal at day 5. Maturation ofNKp required the continuous presence ofrecombinant interleukin 2 (rIL-
2), or rIL-15, both being equally effective. In the absence of cytokines, the functional NK cells declined rapidly beyond 24 h in 
culture. Irradiated allogeneic cells appeared to substitute in part for cytokines, but the numbers of allo-activated NKpf were 
lower than those observed when allo-activated NKpf were cultured with rIL-2. This suggested selective activation by the 
allogeneic stimulus of subsets of NKp or rIL-2-rescue of NKp subsets destined for apoptotic cell death. Alternatively, the 
increased frequency could have been attributable to activation of precursors of natural killer-T cells (NK-Tp). This assay is 
suitable for estimating the total number of precursors of functional NK cells in the blood of patients. © 2002 Elsevier Science 
B. V. All rights reserved. 
Keywords: Natural killer cell precursor frequency; rIL-2; rIL-15; Europium release; Limiting dilution analysis 
1. Introduction 
Maturation pathways of human natural killer (NK) 
cells are complex and poorly understood. T cells and 
NK cells are both derived from haemopoietic stem 
-
• Corresponding author. Tel.: +44-117-959-5340; fax: +44-117-
950-5342. 
E-mail address: ben.bradley@bris.ac.uk (B.A. Bradley). 
cells, but NK cells develop primarily but not exclu-
sively along non-thymic pathways (Sivakumar et a!., 
1998; Punzel et aI., 1999; Raulet, 1999). Although 
qualitative assays have been widely applied, few quan-
titative assays have been developed to measure the 
precursors of functional human NK cells. Long-tenn 
bone marrow cultures showed that CD3 - CD56+ 
CD7+ NK cells developed from CD34+ HLA DR -
bone marrow cells in the presence of rIL-15 and tern 
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cell factor. They were cytotoxic against target cells 
from the KS62 cell line, a functional hallmark of 
mature NK cells that we have adopted in this assay. 
These cells express the characteristic CD3 - CDS6+ 
phenotype ofNK cells, but not the T cell (CD3+ CDS+ 
TeR), monocyte (CDI4+ CD1S+) or (CDI9+) B cell 
phenotypes. (Carayol et al., 1998; Yu et al., 1998; 
Miller et al., 1999; Sato et al., 1999). Others have 
demonstrated that the early human haemopoietic stem 
cell phenotype (CD34+ CD3 - CD8 - CDS6 - ) 
yielded NK cell clones in the presence of rIL-l5, 
suggesting an important role for this cytokine in the 
development and maturation (Mrozek et al., 1996; Yu 
et al., 1998; Liu et al., 2000). The distinction between 
NK cells and NK-T cells that have some of the hall-
marks of thymus processed cells is unclear, and we 
have not attempted to distinguish between these sub-
sets in this study (Sato et al., 1999). 
Functional assay systems other than lysis of the 
K562 target cell line have indicated that NK cells play 
a vital role in defence against bacterial infection, 
virus-infected cells and malignant cells. Patients with 
reduced or no NK activity have a high frequency of 
infections and cancer (Herberman, 1981; Pross and 
Lotzova, 1993; Kos, 1998; Gosselin et al., 1999). 
Normal mice infected with lymphocytic choriomenin-
gitis virus show peak NK cell activity on day 3 
following infection, whereas a peak of CD8+ T cell 
activity is seen on day 7. As they differentiate, human 
NK cells secrete inflammatory cytokines such as 
interferon gamma (IFN -1), tumour necrosis factor 
(TNF-~), IL-3, IL-8 and granulocyte/macrophage 
colony stimulation factor (GM-CSF) (Carson et al., 
1995; Kos, 1998; Nguyen et al., 1998; Biron et al., 
1999). In certain culture conditions, NK cells also 
produce the anti-inflammatory cytokines, IL-S, IL-IO 
and IL-13 (Warren et al., 1995; Mehrotra et al., 1998; 
Peritt et al., 1998; Hoshino et al., 1999). 
Activated T cells producing IL-2 are able to drive 
NK cell activation and proliferation through the <x, 0 
and "I sub-units of the IL-2 receptor (IL-2R) expressed 
on the surface of NK cells (Voss et al., 1992; Carson 
et al., 1994; Eicher and Waldmann, 1998; Waldmann 
et al., 1998). The IL-1SR has a unique <X chain but 
shares the 0 and 1 chains of the IL-2R, thus account-
ing for the shared signalling activity observed by these 
two cytokines (Carson et al., 1997; Waldmann and 
Tagaya, 1999). In the presence of excess IL-2, human 
NK cells become lymphokine-activated killer (LAK) 
cells that lyse fresh tumour target cells through a 
mechanism independent of MHC restriction. In 
vivo-activated NK cells are able to migrate through 
solid tissues, localise to the sites of metastases and 
kill tumour cells (Pavletic et al., 1993; Okada ~t aI., 
1996; Tomita et al., 1998). 
Recent reports suggest that IL-IS shares many of 
biological properties of IL-2 despite the absence of 
sequence homology. Activated monocyte/macro-
phage, bone marrow stromal cells and dendritic cells 
produce IL-1S (Carson et al., 1994; Seidel et al., 1998; 
Waldmann et al., 1998). Several reports have 
described how mice lacking the IL-2 gene develop 
NK cells, whereas mice and humans lacking the "/ 
sub-unit of the IL-2R have no NK cells. IL-IS uses its 
own IL-1SRQ chain when binding with high affinity 
to IL-ISR thereby signalling the NK cells to produce 
IFN-,,/, GM-CSF and TNF-Q (Noguchi et al., 1993; 
DiSanto et al., 1995; Carson et al., 1997). In vitro 
studies have demonstrated that IL-2 and IL-15 can 
activate human NK precursors cells and enhance the 
cytotoxicity of neonatal NK cells against K562 targets 
and virus-infected cells (Gaddy and Broxmeyer, 1997; 
Loubeau et al., 1997; Gosselin et al., 1999). In vivo 
IL-2 is only transiently produced by antigen-activated 
T cells, which in tum express high affinity IL-2R. IL-
lS is produced by activated monocyte/macrophages, 
bone marrow stromal cells, dendritic cells and kerati-
nocytes (Blauvelt et a1., 1996; 10nuleit et al., 1997; 
Waldmann and Tagaya, 1999). 
In this study, we have attempted to develop and 
standardise a non-radioactive europium (Eu)-release 
limiting dilution analysis (LDA) initially described in 
outline elsewhere (Blomberg et al., 1986a,b; Nagao et 
a1., 1996) and to quantitate the frequency of natural 
killer cell precursors (NKpt) present in human periph-
eral blood. 
2. Materials and methods 
2.1. Subjects studied 
The experiments described in this study were fully 
approved by the local hospital researc~ ethics com-
mittee and informed consent was obtamed from all 
volun;eers. Experiments designed to investigate the 
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factors influencing NKpf estimates were performed 
with blood from one healthy male adult. Other experi-
ments to investigate individual variation were per-
formed on samples obtained from 15 Caucasian 
patients aged between 45 and 83 who were awaiting 
surgery for osteoarthritis. Patients were excluded from 
the study if they had pre-existing infection, previous 
blood transfusion, malignancy, autoimmune disorders 
and diabetes. 
2.2. Collection and isolation of blood 
Twenty milliliters of whole blood was collected in a 
sterile tube containing preservative-free sodium hep-
arin (25 units/ml of blood). Peripheral blood mono-
nuclear cells (PBMC) were isolated within 12 h of 
collection by density gradient centrifugation (Lympho-
prep of specific gravity 1077, Nycomed). After iso-
lation of PBMC, they were cryopreserved in liquid 
nitrogen until required. To prevent ice crystal damage, 
PBMC were frozen in a 1: 1 mixture of complete 
culture medium (CCM) consisting of RPMI 1640 
(Sigma) supplemented with 50% heat-inactivated fetal 
calf serum (Sigma) and 3 mM L-glutamine (Sigma), 
and 20% dimethyl sulfoxide (DMSO) in RPMI 1640 
(Sigma). Penicillin (100 units/ml) plus streptomycin 
(100 j.1g/ml) (Sigma) were also added to the medium to 
prevent bacterial contamination. 
The cells were cooled in the nitrogen vapour at 
approximately - 1 uC/min, using a 'plug' inserted 
into the neck of the Dewer flask. After 2 h, cryovials 
(Nunc, Denmark) were transferred to racks stored in 
the vapour phase of a large liquid nitrogen freezer. For 
allo-stimulation experiments, a pool of PBMC taken 
from four HLA-disparate, healthy apheresis donors 
were irradiated (30 Gy) and added to the culture as 
described below. 
The HLA negative NK sensitive human erythro-
leukaemic K562 cell line (ECACC, UK) was used as 
target for quantification of functional NK cells. The 
cell line was grown in stationary cell suspension 
cultures consisting of RPMI 1640 supplemented with 
2% heat-inactivated AB serum and 3 mM L-glutamine 
(Sigma) in vented tissue culture flasks (25 cm2 , 
Falcon). Antibiotics were not added as this reduced 
assay sensitivity. To ensure optimal growth, culture 
media were replaced on the second day and harvested 
on days 4-5. The cell line was regularly screened for 
mycoplasma using a Mycloplasma Test Medium Kit 
(Sigma). 
2.3. NKpf assay 
The complete culture medium (CCM) used throug-
hout consisted of RPMI 1640 (Sigma) supplemented 
with 10% heat-inactivated human AB serum from 
normal healthy male donors (Sigma) and 3 mM L-
glutamine (Sigma). Antibiotics were not added to 
CCM as this reduced assay sensitivity. rIL-2 (Euro-
cetus, Amsterdam) diluted in CCM was added to 
cultures in a final concentration of 25-50 Cetus unit 
ml. The rIL-15 (R&D, UK) was similarly diluted to a 
final concentration of 10 or 20 ng/ml depending on the 
experimental conditions. Both rIL-2 and rIL-I5 were 
added on day 0 when setting up the assay and during 
feeding on day 5. 
PBMC were rapidly thawed in a 37 uC water bath 
and the viability of cells was checked by staining with 
trypan blue and counting them by phase-contrast 
microscopy. Although the yield of viable cells after 
thawing was not calculated in all instances, the gen-
eral experience was that approximately 90% of intact 
thawed PBMC identifiable by phase-contrast micro-
scopy were judged to be viable on the basis that they 
excluded trypan blue. Viable PBMC were titrated in 
seven two-fold dilutions using 24 replicates per dilu-
tion in CCM starting with a concentration of 4 x 104 
and finishing with 0.0625 x 104 PBMC per 100 ILI/ 
well in Falcon 3077 96-well round-bottomed culture 
plates. The baseline control consisted of 100 III of 
CCM alone without PBMC. Where specified, an 
irradiated allogeneic pool of PBMC was added in a 
single concentration of 50,000 cells per 100 j.1l/well to 
responders on day 0 and incubated. All cultures were 
assayed following 18 hand 5, 7 or 10 days incubation 
at 37 uC in 5% CO2 in a humidified atmosphere. The 
7- and 10-day assays were refreshed with CCM on 
day 5. 
2.4. Quantitation of cytotoxicity 
The K562 cell line was transferred from culture 
flasks into a 50-ml polypropylene tube (Falcon) and 
centrifuged at 400 x g for 10 min in the cold (4 C'C) 
then washed twice with phosphate buffer saline (PBS). 
Cell counts were performed after the first wash to cal-
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culate the amount of europium (Eu) to be added. One 
milliliter of labelling buffer was added for each 
5 x 106 K562 cells. Labelling buffer consisted of 1 
ml HEPES buffer (Sigma) plus 40 j.LI of a solution of 
100 ~M diethylene triamino pentacetate (DTPA, 
Sigma), plus 20 j.LI of 20 j.LM solution of europium 
chloride (EuCI3, Fluka). Then, 50 j.LI of a solution of 
500 ~ dextran sulphate (Fluka) was added. The 
suspension was incubated for 15 min at 4 vC with 
gentle and thorough mixing. Then, 30 j.Ll of 100 mM 
solution of CaCl2 was added to stop the labelling re-
action, and the suspension was incubated for a further 
JO min at 4 vc. The K562 cell suspension was then 
washed four times with wash buffer (RPMI 1640 plus 
3 mM L-glutamine plus 79 j.LI/50 ml of 1 M CaCh) and 
centrifuged at 300 x g for 6 min at 4 vc. Thereafter, 
cells were washed twice with CCM centrifuging at 
400 x g for 6 min at 4 vc. A cell count was performed 
to calculate the approximate number of Eu-DTPA 
labelled cells to be added, and Eu-DTPA labelled cells 
(Eu-K562) were re-suspended in CCM at 105 cells/ml. 
The last stage of the NKpf assay was performed by 
adding 10,000 Eu-K562 in 100 j.LI to each well of a 
96-well culture plate. Plates were briefly centrifuged 
at 200 x g at room temperature for 1 min to accelerate 
the reaction and incubated for 3 h at 37 vc in 5% CO2 
in a humidified atmosphere. Plates were centrifuged 
for 5 min at 600 x g at room temperature and 20-l-Ll 
aliquots of supernatant from each well were then 
transferred to a new 'reader plate' (Nunc) pre-filled 
with 200 j.LI of enhancement solution (Delfia, Finland). 
Finally, europium release was evaluated in a time-
resolved fluorometer (Delfia) and the results were 
expressed in counts per second (cps) as described in 
detail elsewhere (Blomberg et al., 1986a,b; Nagao et 
al., 1996). Spontaneous release was determined by 
incubating target cells with CCM only and maximum 
release was obtained by lysing the target cells with 2% 
Triton X-I00. 
The mean and standard deviations between repli-
cate wells of the baseline culture were calculated and 
any well that exceeded the mean cps plus three times 
the standard deviation was scored positive. The per-
centage of negative wells at each responder cell 
dilution was calculated and plotted against the res-
ponder cell concentration per well. The calculation of 
the mean NKpf values plus the standard error (SE) 
and the 95% confidence intervals (95% CI) was 
facilitated by a computer program (Strijbosch et aI., 
1987, 1988). Estimates were expressed as mean NKpf 
per 106 PBMC plus/minus the SE and plotted on a 
~OglO scale as mean NKpf with 95% confidence 
mtervals (CI). The significance of the difference in 
mean NKpf for each group was analysed with the 
two-tailed Student's t-test. 
3. Results 
3.1. Effect of culture duration and timing of r1L-} 
addition on NKpf estimates 
All initial experiments used to define the factors 
influencing NKpfwere performed with PBMC from a 
single individual, AG. The lower limit of detection in 
this assay was 1 NKp per 106 PBMC. The maximum 
NKpf detected in AG blood after 7 days of culture 
was 2450 NKp per 106 PBMC (0.25%), obtained 
from experiments with rIL-15 (see Fig. 3 below). 
Initially, we showed that in the absence of rIL-2, 
NKpf decreased rapidly from a mean ± SD of 63 ± 6 
to 3 ± 1 per 106 PBMC between days 1 and 10 (Fig. 
1 a). By contrast, when rIL-2 was added, NKpf 
increased rapidly from 105 ± 4 to 1272 ± 141 between 
days 1 and 10 (Fig. 1 b). The increment between days 
1 and 5 implied rapid maturation of non-functional 
precursor NKp. When no extra IL-2 was added on 
day 5, there was no significant increment in NKpf 
between days 5 (776 ± 151), 7 (816 ± 174) and 10 
(821 ± 198) per 106 PBMC (Fig. 1 c). However, after 
adding extra rIL-2 on day 5, a small but significant 
increment in NKp was observed between days 5 
(782 ± 160) and 10 (1172 ± 131), implying that cul-
tures contained NKp at different stages of maturation 
(p < 0.05 between days 5 and 7 and days 5 and 10) 
(Fig. 1 d) and that the late maturing NKp fraction 
became IL-2-sensitive only during the later period of 
culture. 
In most cases, NKpf reached a plateau between 
days 7 and 10, suggesting that all-available rIL-2-
sensitive precursors had been activated. These results 
confirmed that maturation and proliferation of NKp 
and maintenance in culture was dependent on the 
continued presence of rIL-2, and that the full potential 
NK function was reflected in assays cultured to 
maturity over 7 days. Notwithstanding this observa-
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F!g. 1. M~an NKpf with 95% confidence intervals (95% CI) plotted on a 10glO scale (1_104, figures a and b; 102 _104, figures c and d) at 
dIfferent h.mes of culture: (a) no added cytokines; (b) rIL-2 added on days I and 5 together with fresh medium; (c) rIL-2 added on day 0 but only 
fresh medIUm on day 5; (d) rIL-2 added on day 0, and day 5 in fresh medium. The values shown are results of three to seven experiments. 
tion, all ensuing assays were tenninated at day 5 
unless otherwise stated, the rationale being technical 
simplicity and greater sensitivity during the clonal 
expansion phase. 
3.2. Alia-activated NKp 
The effect of activating NKp with a pool of 
irradiated allogeneic cells on day 0 was investigated. 
When allogeneic cells were added, an estimate of 
190 ± 82 per 106 PBMC was obtained on day 7. 
However, when rIL-2 was added, this NKpf value 
rose to 1919 ± 307 per 106 PBMC (Fig. 2), suggest-
ing that rIL-2 rescued certain NK progeny destined for 
apoptotic cell death. Alternatively, allo-activation may 
have stimulated a separate subset ofNKp tenned NK-
T cell precursors (NK-Tp) having the hallmarks of 
both thymus processed T and non-thymically pro-
cessed NK cells (Godfrey et al., 2000). To explore 
this concept, allo-activation was estimated on days 1, 
5 and 7. A similar increment (p < 0.001 between rIL-2 
alone and rIL-2 plus allo-activation) was observed on 
days 1, 5 and 7, supporting the view that allo-
activation was associated with an additional subset 
of functional NK-Tp cells. These observations were 
con finned in a further five experiments. 
3.3. Effect alr/L-i5 an NKpl 
Recombinant interleukin 15 (rIL-15) was a candi-
date cytokine that may have accounted for some of the 
allo-activation effect. Therefore, the effect of adding 
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Fig. 2. Mean NKpf with 95% CI plotted on a IOglO scale (1-104) 
after: co-culturing with an irradiated pool of allogeneic cells; adding 
rIL·2 on day zero; and co-culturing with both irradiated pool of 
allogeneic cells and rIL-2. The panels contain results obtained after 
1,5 and 7 days of culture. In all cases, fresh medium with cytokines 
was added on day 5. 
rIL-IS to the culture was investigated in view of the 
knowledge that it played a pivotal role in the differ-
entiation of NK cells from their progenitors and 
shared many functions ascribed to IL-2. NKpf esti-
mates were highest when PBMC were cultured with 
rIL-iS at 10-20 ng/ml. (Fig. 3). Indeed, these levels 
were significantly higher than with rIL-2 at 50 IU/ml 
(p<O.05). Furthermore, there was no incremental 
effect on NKpf with the addition of rIL-2 to rIL-15. 
The rIL-15 alone appeared to be significantly 
(p<O.05) more effective than rIL-2 in driving the 
differentiation of NKp to maturity. This was con-
finned in a further four repeat experiments. 
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Fig. 3. Mean NKpfwith 95% CI plotted on a IOglO scale (102 _104) 
after adding different concentrations and combinations of rIL-2 and 
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Fig. 4. Mean NKpfwith 95% CI plotted on a IOglO scale (102 -104) 
in 15 individuals ranked from lowest to highest. PBMC were 
cultured with 25 Cetus unitlml rJL-2 plus 10 ng/ml rIL-15, and cells 
were assayed after 5 days. 
3.4. Individual variation in NKpf 
We next investigated the variation between 15 
individuals tested in a 5-day assay to which 25 IU/ 
ml rIL-2 and 10 ng/ml rIL-15 were added on day O. 
NKpf estimates ranged between 320 (95% CI 228-
430) and 1300 (95% CI 672-1746) per 106 PBMC. 
These were ranked from the lowest to the highest and 
were numbered I to 15 (Fig. 4). Technical variation 
was an unlikely explanation since five repetitions of 
the assay with one individual gave a median NKpf of 
1503 and a sampling error of ± 190 per 106 PBMC. 
4. Discussion 
In this report, we have described a novel method 
for quantifying the number of precursors of function-
ally active NK cells within a PBMC sample. We have 
shown that proliferation and maturation of function-
ally viable NK cells was absolutely dependent on the 
continued presence of rIL-2 and rIL-15 in the culture 
and that functional viability dwindled in their absence. 
Following allo-activation with an irradiated pool of 
PBMC, NKpf was lower than when cyto~ines were 
added. Individual differences in NKpf estImates bet-
ween 15 adults ranged from 300 (0.03%) to 1500 
(0.15%) per 106 PBMC. The observation.that rI~-2 
and rIL-15 were equally effective is consIstent WIth 
the view that they both share the same signalling path-
way. 
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The novelty of this assay lies in its ability to es-
timate the full potential NK function. Unlike short-
tenn qualitative assays used extensively elsewhere, 
this assay permits accurate estimates of the potential 
NK function within a blood sample. NKpf rose to a 
plateau by day 7 and the increment in NKpf between 
days 7 and 10 was insignificant, suggesting that all 
available precursors had matured into functionally 
viable NK cells. In vivo, the story may be different 
since these mature NK cells will be dependent on the 
prevailing cytokine microenvironment and may not 
be sustained. The observed variation in NKpf bet-
ween healthy individuals reflects variables that have 
yet to be fully explored, such as clone size and num-
ber. 
The present assay is based on a modification of the 
well established non-radioactive Eu-release assay. 
(Blomberg et al., 1986a,b; Nagao et al., 1996). It is 
relatively simple, sensitive and non-hazardous. The 
Eu-release method has been shown to be as sensitive 
as the 51 Cr-release method for measuring functional 
NK cells Furthermore, NKpf estimates are relatively 
insensitive to target cell concentration since the pres-
ence or absence of Eu-release over and above the 
background plus three times the SD is considered to 
be a qualitative indicator of a functional NK clone(s). 
We confirmed this assumption by showing that NKpf 
estimates obtained with 5000 or 10,000 target cells! 
well were not significantly different (unpublished 
data). 
Both rIL-2 and rIL-15 drove proliferation and 
maturation as evidenced by the plateau at day 7 of 
culture. When both cytokines were given together, 
there was no increment in NKpf, suggesting that the 
same signalling pathways were used to equal effect by 
both cytokines. However, in the absence of experi-
ments with purified subsets, it is impossible to know 
whether these cytokines were operating directly 
through receptors on NK cells and/or indirectly via 
helper T cells in the culture. Since receptors for both 
cytokines shared the same ~ and common "'{ chain, 
they were likely to have used the same signalling 
pathway (Carson et al., 1997; Waldmann et al., 1998; 
Waldmann and Tagaya, 1999). Human IL-15 has been 
shown to use the IL-2R and its protein sub-units for 
binding and signal transduction in NK cells, and it has 
a distinct effect on the CD56+ subset. Furthermore, 
cord blood cells treated with rIL-15 exhibited aug-
mented NK activity and an increased percentage of 
CD56 + 16+ cells (Mrozek et al., 1996; Gaddy and 
Broxmeyer, 1997; Nguyen et al., 1998). 
In vivo NK clonal expansion would be subject to 
regulatory mechanisms leading to clonal contraction. 
Similar processes might operate in vitro and explain 
why the NKpf with allo-activation alone was less than 
when cytokine was added. If, in a proportion of 
culture wells, clonal contraction through apoptosis 
occurred, this would result in lower NKpf estimates. 
NK cells destined for apoptosis could have been 
'rescued' by rIL-2 added to the allogeneic stimulus 
and this may explain the synergistic effect of the two 
stimuli. However, the increment associated with allo-
geneic stimulus plus rIL-2 observed as early as day 1 
(see Fig. 2) supported the view that two populations 
of cells were activated, namely the NKp and the NK-
Tp. 
For the future, we intend to apply this NKpf assay 
to monitor the effects of surgery, blood transfusion 
and transplantation. We have already shown that the 
early signalling pathways leading to proliferation and 
maturation of functional NK cells are highly resistant 
to immunosuppressive drugs such as cyclosporin, 
tacrolimus (Haque et aI., 1999) and rapamycin 
(unpublished). Furthermore, we have speculated that 
once armed with allo-antibody, NK cells may become 
vehicles of graft destruction and acute rejection. 
Peptide-specific T cell precursor frequencies meas-
ured by limiting dilution analysis (LDA) are reputedly 
lower than frequencies estimated by tetramer analysis 
without LDA. This may be a consequence of the need 
for interactions between several different cell popula-
tions during T cell maturation (e.g. T cells and 
dendritic cells). Maturation and proliferation of NKp 
requires only the presence of soluble growth factors 
and may be less susceptible to this artifact. Tetramer 
analysis using a range of HLA Class I peptides would 
complement this NK functional assay by offering an 
insight into the distribution of inhibitory receptors, but 
it would be wrong to assume that all cells carrying 
inhibitory receptors had the potential to lyse NK 
targets and vice versa. Hence, the shortcomings 
observed with estimates of T cell precursors are 
unlikely to be applicable in this case. We suggest that 
the method described here gives more accurate esti-
mates of the potential number of NKp than previous 
assays. 
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